<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Cell Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Cell Neurosci</journal-id>
<journal-id journal-id-type="publisher-id">Front. Cell. Neurosci.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Cellular Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="epub">1662-5102</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28326014</article-id>
<article-id pub-id-type="pmc">5339239</article-id>
<article-id pub-id-type="doi">10.3389/fncel.2017.00054</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>The GABAergic Hypothesis for Cognitive Disabilities in Down Syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Contestabile</surname>
<given-names>Andrea</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/419529/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Magara</surname>
<given-names>Salvatore</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/212961/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cancedda</surname>
<given-names>Laura</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/11244/overview" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia (IIT)</institution>
<country>Genova, Italy</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Dulbecco Telethon Institute</institution>
<country>Genova, Italy</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Daniela Tropea, Trinity College, Dublin, Ireland</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Enrico Cherubini, Scuola Internazionale di Studi Superiori Avanzati (SISSA), Italy; Nicola Berretta, Fondazione Santa Lucia (IRCCS), Italy</p>
</fn>
<corresp id="fn001">*Correspondence: Andrea Contestabile <email xlink:type="simple">andrea.contestabile@iit.it</email> Laura Cancedda <email xlink:type="simple">laura.cancedda@iit.it</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>07</day>
<month>3</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>11</volume>
<elocation-id>54</elocation-id>
<history>
<date date-type="received">
<day>21</day>
<month>12</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>2</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2017 Contestabile, Magara and Cancedda.</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>Contestabile, Magara and Cancedda</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution and reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Down syndrome (DS) is a genetic disorder caused by the presence of a third copy of chromosome 21. DS affects multiple organs, but it invariably results in altered brain development and diverse degrees of intellectual disability. A large body of evidence has shown that synaptic deficits and memory impairment are largely determined by altered GABAergic signaling in trisomic mouse models of DS. These alterations arise during brain development while extending into adulthood, and include genesis of GABAergic neurons, variation of the inhibitory drive and modifications in the control of neural-network excitability. Accordingly, different pharmacological interventions targeting GABAergic signaling have proven promising preclinical approaches to rescue cognitive impairment in DS mouse models. In this review, we will discuss recent data regarding the complex scenario of GABAergic dysfunctions in the trisomic brain of DS mice and patients, and we will evaluate the state of current clinical research targeting GABAergic signaling in individuals with DS.</p>
</abstract>
<kwd-group>
<kwd>GABA</kwd>
<kwd>down syndrome</kwd>
<kwd>cognitive impairment</kwd>
<kwd>gaba receptors</kwd>
<kwd>chloride homeostasis</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source id="cn001">Fondazione Telethon<named-content content-type="fundref-id">10.13039/100007353</named-content></funding-source>
<award-id rid="cn001">GGP15043</award-id>
<award-id rid="cn001">GGP13187</award-id>
<award-id rid="cn001"> TCP15021</award-id>
</award-group>
<award-group>
<funding-source id="cn002">Fondation Jérôme Lejeune<named-content content-type="fundref-id">10.13039/100007353</named-content></funding-source>
<award-id rid="cn002">254-CA2014A</award-id>
<award-id rid="cn002">1266_CL2014A</award-id>
</award-group>
</funding-group>
<counts>
<fig-count count="1"></fig-count>
<table-count count="0"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="288"></ref-count>
<page-count count="21"></page-count>
<word-count count="19726"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="introduction">
<title>Introduction</title>
<p>Down syndrome (DS) or trisomy 21 is the leading cause of genetically-defined intellectual disability and congenital birth defects. DS is characterized by many phenotypical features affecting almost all body systems, including developmental defects and growth delay (Nadel, <xref ref-type="bibr" rid="B174">2003</xref>; Antonarakis and Epstein, <xref ref-type="bibr" rid="B3">2006</xref>). In particular, brains of individuals with DS show decreased volume and reduced neuronal density in diverse brain areas (e.g., cortex, hippocampus and cerebellum; Sylvester, <xref ref-type="bibr" rid="B248">1983</xref>; Coyle et al., <xref ref-type="bibr" rid="B63">1986</xref>; Aylward et al., <xref ref-type="bibr" rid="B6">1997</xref>, <xref ref-type="bibr" rid="B7">1999</xref>; Shapiro, <xref ref-type="bibr" rid="B227">2001</xref>). These alterations originate early during development (Schmidt-Sidor et al., <xref ref-type="bibr" rid="B222">1990</xref>; Winter et al., <xref ref-type="bibr" rid="B275">2000</xref>; Pinter et al., <xref ref-type="bibr" rid="B188">2001</xref>; Larsen et al., <xref ref-type="bibr" rid="B135">2008</xref>) and are possibly due to defective neuronal precursor proliferation during gestation (Contestabile et al., <xref ref-type="bibr" rid="B54">2007</xref>; Guidi et al., <xref ref-type="bibr" rid="B96">2008</xref>). Accordingly, the development of individuals with DS is characterized by delayed cognitive progress in infancy and childhood, leading to mild-to-moderate mental retardation with an Intelligence Quotient (IQ) ranging from 30 to 70 (Vicari et al., <xref ref-type="bibr" rid="B259">2000</xref>, <xref ref-type="bibr" rid="B260">2005</xref>; Pennington et al., <xref ref-type="bibr" rid="B185">2003</xref>; Vicari, <xref ref-type="bibr" rid="B258">2004</xref>). This scenario is additionally worsened during adulthood by further loss of cognitive abilities and the development of Alzheimer’s disease (AD) by the fourth decade of life (Wisniewski et al., <xref ref-type="bibr" rid="B280">1985</xref>; Mann and Esiri, <xref ref-type="bibr" rid="B155">1989</xref>; Leverenz and Raskind, <xref ref-type="bibr" rid="B142">1998</xref>; Teipel and Hampel, <xref ref-type="bibr" rid="B252">2006</xref>).</p>
<p>Although cognitive impairment is the most common and severe feature of DS, other neurological and psychiatric manifestations of the disease highly impinge on the quality of life of individuals with DS and their families. In particular, the DS population shows increased frequency of anxiety (Vicari et al., <xref ref-type="bibr" rid="B261">2013</xref>), clinically relevant sleep disturbance (Carter et al., <xref ref-type="bibr" rid="B35">2009</xref>; Breslin et al., <xref ref-type="bibr" rid="B32">2011</xref>; Angriman et al., <xref ref-type="bibr" rid="B2">2015</xref>; Edgin et al., <xref ref-type="bibr" rid="B76">2015</xref>; Konstantinopoulou et al., <xref ref-type="bibr" rid="B129">2016</xref>; Maris et al., <xref ref-type="bibr" rid="B160">2016</xref>), and hyperactivity or movement disorders (Pueschel et al., <xref ref-type="bibr" rid="B195">1991</xref>; Haw et al., <xref ref-type="bibr" rid="B106">1996</xref>). Finally, DS patients demonstrate increased incidence of epileptic episodes with seizure onset mainly concentrated during early life and aging (Stafstrom et al., <xref ref-type="bibr" rid="B238">1991</xref>; Lott and Dierssen, <xref ref-type="bibr" rid="B149">2010</xref>; Robertson et al., <xref ref-type="bibr" rid="B205">2015</xref>).</p>
<p>The identification of possible mechanisms leading to cognitive impairment in DS has been largely conducted thanks to the analysis of different DS genetic mouse models (Dierssen, <xref ref-type="bibr" rid="B74">2012</xref>). Interestingly, compelling studies in these animals indicate that altered signaling of the neurotransmitter GABA is one of the main determinants in reducing cognitive and memory functions. In particular, GABAergic dysfunctions impair synaptic plasticity and learning and memory in DS by altering optimal excitatory/inhibitory synaptic balance (Kleschevnikov et al., <xref ref-type="bibr" rid="B124">2004</xref>, <xref ref-type="bibr" rid="B122">2012a</xref>,<xref ref-type="bibr" rid="B123">b</xref>; Costa and Grybko, <xref ref-type="bibr" rid="B60">2005</xref>; Fernandez et al., <xref ref-type="bibr" rid="B81">2007</xref>; Deidda et al., <xref ref-type="bibr" rid="B71">2014</xref>). In this review article, we will survey available data on the alteration of GABAergic signaling in DS trisomic animal models and individuals with DS. Additionally, since no effective pharmacological treatment for ameliorating cognitive deficits in DS has been found yet, we will also evaluate the current status of pre-clinical and clinical trials with GABAergic drugs in DS.</p>
</sec>
<sec id="s2">
<title>GABA Signaling in The Brain</title>
<p>GABA is the main inhibitory neurotransmitter in the adult and healthy brain and it acts through ionotropic and metabotropic receptors (GABA<sub>A</sub>Rs and GABA<sub>B</sub>Rs, respectively).</p>
<sec id="s2-1">
<title>GABA<sub>A</sub> Receptors</title>
<p>GABA<sub>A</sub>Rs are chloride-permeable ion channels. In the adult brain, the chloride gradient across the neuronal cell membrane is sustained by the exporter K-Cl cotransporter (KCC2), which maintains low intracellular chloride concentration ([Cl<sup>−</sup>]<sub>i</sub>). Thus, GABA<sub>A</sub>R opening generates an influx of negative chloride ions that hyperpolarizes the cell membrane potential and inhibits neuronal activity. Moreover, opening of GABA<sub>A</sub>R ion channels may also shunt concurrent excitatory currents (e.g., driven by the neurotransmitter glutamate), thus preventing them from bringing the membrane potential to the action potential threshold. Indeed, GABA<sub>A</sub>R opening short-circuits depolarizing synaptic currents by locally reducing the input resistance (Ben-Ari, <xref ref-type="bibr" rid="B19">2002</xref>; Jonas and Buzsaki, <xref ref-type="bibr" rid="B112">2007</xref>; Silver, <xref ref-type="bibr" rid="B232">2010</xref>; Khazipov et al., <xref ref-type="bibr" rid="B118">2015</xref>). Thus, adult GABA<sub>A</sub>-mediated transmission is physiologically hyperpolarizing and inhibitory. Conversely, in early neurodevelopment, KCC2 expression is low, and associated with high expression of the chloride importer Na-K-Cl cotransporter (NKCC1), which generates high [Cl<sup>−</sup>]<sub>i</sub>. In this condition, the chloride flux through GABA<sub>A</sub>Rs is outward and depolarizes the cell membrane potential (Cherubini et al., <xref ref-type="bibr" rid="B44">1990</xref>; Rivera et al., <xref ref-type="bibr" rid="B204">1999</xref>; Ben-Ari, <xref ref-type="bibr" rid="B19">2002</xref>; Fiumelli et al., <xref ref-type="bibr" rid="B83">2005</xref>). Although GABA<sub>A</sub>R-mediated depolarizing postsynaptic potentials (PSPs) will be in most cases not sufficient to reach the threshold for action-potential generation, they will be able to activate voltage-gated calcium channels (VGCCs), remove the voltage-dependent magnesium block from NMDA receptors (Leinekugel et al., <xref ref-type="bibr" rid="B139">1995</xref>, <xref ref-type="bibr" rid="B138">1997</xref>; Ben-Ari, <xref ref-type="bibr" rid="B19">2002</xref>), and possibly add up to concurrent excitatory inputs (Gulledge and Stuart, <xref ref-type="bibr" rid="B99">2003</xref>). Consequently, even an initially mild depolarizing effect of GABA can contribute to a more pronounced excitation and eventually reach the threshold for action potential firing. Thus, GABA<sub>A</sub>-mediated transmission is generally depolarizing and possibly excitatory in the immature brain, although depolarizing GABA<sub>A</sub> currents may still be inhibitory by shunting concurrent excitatory inputs. Notably, a depolarizing (rather than hyperpolarizing) GABA<sub>A</sub>R response may also occur in mature neurons depending on timing and location of GABA<sub>A</sub>Rs, upon relatively small difference in [Cl<sup>−</sup>]<sub>i</sub> at different cell compartments<sub>,</sub> more hyperpolarized resting membrane potentials, sustained activity or even pathological conditions (Lamsa and Taira, <xref ref-type="bibr" rid="B134">2003</xref>; Khirug et al., <xref ref-type="bibr" rid="B119">2008</xref>; Chiang et al., <xref ref-type="bibr" rid="B45">2012</xref>; Cellot and Cherubini, <xref ref-type="bibr" rid="B38">2014</xref>). Indeed, as the reversal potential for GABA<sub>A</sub>R-mediated chloride currents (<italic>E</italic><sub>Cl</sub>) sits very near to the resting membrane potential (<italic>V</italic><sub>REST</sub>), relatively small changes in [Cl<sup>−</sup>]<sub>i</sub> are sufficient to change the polarity of GABAergic responses. In particular, if <italic>E</italic><sub>Cl</sub> is more negative than <italic>V</italic><sub>REST</sub>, the chloride flow will be inward (hyperpolarizing). Instead, if <italic>E</italic><sub>Cl</sub> is less negative than <italic>V</italic><sub>REST</sub>, the chloride flow will be in the opposite direction, generating depolarizing PSPs.</p>
<p>GABA<sub>A</sub>Rs are composed of five subunits, and the many subunit variants identified in mammals (six α, three β, three γ, one δ, three ρ, one ε, one π and one θ) confer different pharmacological and kinetic properties to the receptor (Olsen and Sieghart, <xref ref-type="bibr" rid="B178">2008</xref>; Fritschy and Panzanelli, <xref ref-type="bibr" rid="B86">2014</xref>). In the CNS, the largest population of GABA<sub>A</sub>Rs is composed of 2 α, 2 β and 1 γ subunits, but isoform expression and receptor composition change with subcellular localization, brain area, and development, thus assuring receptor properties set to fulfil specific neuronal needs. For example, the α<sub>1–3</sub>, β<sub>2–3</sub> and γ<sub>2</sub> isoforms are the most represented in the adult brain, constituting synaptic GABA<sub>A</sub>Rs. In particular, thanks to their fast kinetics with rapid onset and desensitization, they generate phasic currents following GABA release from presynaptic vesicles with spatial and temporal accuracy. Conversely, α<sub>5</sub>- or δ-containing GABA<sub>A</sub>Rs are mainly extra-synaptic. The presence of the α<sub>5</sub> or δ subunits confers high GABA affinity and slow desensitization kinetics to GABA<sub>A</sub>Rs. Thus, α<sub>5</sub> or δ–containing receptors are able to detect ambient GABA spilled out of the synaptic cleft and generate long-lasting (tonic/extrasynaptic) currents (Böhme et al., <xref ref-type="bibr" rid="B28">2004</xref>; Caraiscos et al., <xref ref-type="bibr" rid="B34">2004</xref>; Farrant and Nusser, <xref ref-type="bibr" rid="B78">2005</xref>; Zheleznova et al., <xref ref-type="bibr" rid="B288">2009</xref>).</p>
<p>Phasic vs. tonic GABA<sub>A</sub>-mediated currents provide for different regulation of neuronal physiology. Phasic GABA transmission plays a relevant role in synaptic-input integration. Indeed, fast inhibition acts as coincidence detector of excitatory inputs by feed-forward inhibition: this mechanism ensures that a second input desynchronized with a first input is canceled out; thus, excitatory inputs sum up only when they are perfectly synchronized (Pouille and Scanziani, <xref ref-type="bibr" rid="B192">2001</xref>). A similar although opposite integration occurs when GABA is depolarizing. GABA<sub>A</sub>R opening may generate small excitatory potentials that last after the channel closure and sum up with concurrent excitatory inputs, thus facilitating the achievement of action potential threshold (Gulledge and Stuart, <xref ref-type="bibr" rid="B99">2003</xref>). While phasic inhibition participates in synaptic integration, tonic inhibition generates relatively persistent changes of input conductance, thus rightward shifting the input-output relationship. Therefore, tonic inhibition reduces the magnitude, duration and propagation length of excitatory PSPs, limiting their temporal/spatial summation possibilities and inhibiting neuronal excitability. Such effect is mainly mediated by shunting which is particularly relevant for the inhibitory action of tonic GABA transmission and less for the phasic inhibition, given the longer opening of tonic GABA<sub>A</sub>Rs (Ben-Ari, <xref ref-type="bibr" rid="B19">2002</xref>; Farrant and Nusser, <xref ref-type="bibr" rid="B78">2005</xref>; Jonas and Buzsaki, <xref ref-type="bibr" rid="B112">2007</xref>; Silver, <xref ref-type="bibr" rid="B232">2010</xref>; Khazipov et al., <xref ref-type="bibr" rid="B118">2015</xref>).</p>
<p>Integration processes of excitatory inputs depend from PSPs generated from GABA<sub>A</sub>Rs, shunting inhibition, and also from the localization of GABA<sub>A</sub>Rs. For example, on the dendrites of CA1 pyramidal neurons, GABAergic synapses are mostly located on the dendritic shaft and on spines (Megías et al., <xref ref-type="bibr" rid="B165">2001</xref>), thus participating to synaptic integration of two different sets of inputs: the ones already partially processed along the way from their synaptic origin to the dendritic shaft, and the ones originated in neighborhood synapses in the same spine, respectively. Notably, different cellular compartments show different [Cl<sup>−</sup>]<sub>i</sub> that critically determine GABA<sub>A</sub>R participation to input integration in a compartment-specific fashion. Indeed, [Cl<sup>−</sup>]<sub>i</sub> is maximum in the axon and axonal initial segment, lower in the soma, and it continues to decrease gradually along dendrites (Szabadics et al., <xref ref-type="bibr" rid="B249">2006</xref>; Khirug et al., <xref ref-type="bibr" rid="B119">2008</xref>; Waseem et al., <xref ref-type="bibr" rid="B268">2010</xref>). In summary, phasic inhibition plays as a coincidence detector and undergoes to tight spatial and temporal integration with excitatory inputs in a compartment-specific manner; tonic inhibition sets the neuronal excitability background, by affecting excitatory input-output relation.</p>
</sec>
<sec id="s2-2">
<title>GABA<sub>B</sub> Receptors</title>
<p>GABA<sub>B</sub>Rs are G<sub>i/o</sub>-protein-coupled receptors (GPCRs) mostly localized extra-synaptically. Their high affinity for GABA ensures that ambient GABA spilled out of synapses can activate GABA<sub>B</sub>Rs despite of their distance. In particular, the GABA<sub>B</sub>R Gα<sub>i/o</sub> subunit can lead to adenylate cyclase inhibition and consequent reduction of cAMP levels and PKA pathway activity (Bettler et al., <xref ref-type="bibr" rid="B23">2004</xref>; Padgett and Slesinger, <xref ref-type="bibr" rid="B181">2010</xref>); Gβγ<sub>i/o</sub> subunit, instead, inhibits voltage-gated calcium channels and opens G protein-coupled inwardly-rectifying potassium channels (GIRK/Kir3), tetramers formed by different compositions of GIRK1–4 subunits (Koyrakh et al., <xref ref-type="bibr" rid="B131">2005</xref>). In particular, presynaptic GABA<sub>B</sub>Rs reduce vesicle release by inhibition of the voltage-gated calcium channels and by a calcium independent mechanism (Rost et al., <xref ref-type="bibr" rid="B208">2011</xref>), whereas GABA<sub>B</sub>R subunits found on dendrite and spine necks regulate neuronal excitability by coupling to the GIRK channels (Nicoll, <xref ref-type="bibr" rid="B175">2004</xref>; Koyrakh et al., <xref ref-type="bibr" rid="B131">2005</xref>). Interestingly, all GIRK subunits virtually form protein complexes with GABA<sub>B</sub>R subunits in heterologous systems (David et al., <xref ref-type="bibr" rid="B66">2006</xref>; Fowler et al., <xref ref-type="bibr" rid="B84">2007</xref>; Ciruela et al., <xref ref-type="bibr" rid="B47">2010</xref>). Nevertheless, GABA<sub>B</sub>R-triggered potassium currents seem to be mostly mediated by GIRK2-containing homo- and hetero-tetramers (Koyrakh et al., <xref ref-type="bibr" rid="B131">2005</xref>). GIRK channel opening elicits an outward hyperpolarizing K<sup>+</sup> current and a decrease in the input resistance (Lüscher et al., <xref ref-type="bibr" rid="B152">1997</xref>; Koyrakh et al., <xref ref-type="bibr" rid="B131">2005</xref>). Thus, through GIRK channels, GABA<sub>B</sub>Rs inhibit neuronal excitability by shunting excitatory currents, hyperpolarizing the membrane with slow inhibitory PSPs, and contributing in maintaining <italic>V</italic><sub>REST</sub> (Lüscher et al., <xref ref-type="bibr" rid="B152">1997</xref>; Koyrakh et al., <xref ref-type="bibr" rid="B131">2005</xref>; Gassmann and Bettler, <xref ref-type="bibr" rid="B94">2012</xref>). These effects also prevent action potential back-propagation in dendrites (Leung and Peloquin, <xref ref-type="bibr" rid="B140">2006</xref>). Finally, through inhibition of postsynaptic voltage-gated calcium channels, GABA<sub>B</sub>R activation also prevents dendritic calcium spikes (Chalifoux and Carter, <xref ref-type="bibr" rid="B41">2011</xref>).</p>
</sec>
<sec id="s2-3">
<title>GABA<sub>A</sub> and GABA<sub>B</sub> Receptor Functions Across Neurodevelopment and Adulthood</title>
<p>Given the variety of potential signaling dynamics by GABA<sub>A</sub> and GABA<sub>B</sub> receptors, it is not surprising that GABA may play a relevant role in different processes during healthy neurodevelopment and adulthood, as well as under pathological conditions. In particular, depolarizing and possibly excitatory GABA<sub>A</sub>-mediated transmission in early life plays key roles in promoting neurodevelopment. α<sub>5</sub>- or δ-containing extrasynaptic GABA<sub>A</sub>Rs are predominant at this stage when synapses are not yet formed and ambient GABA released from growth cones and astrocytes is detected by high affinity subunits (Cellot and Cherubini, <xref ref-type="bibr" rid="B37">2013</xref>). Depolarizing tonic currents facilitate spiking, thus increasing the probability of firing coincidence from different cells and therefore of synaptic wiring important for synaptogenesis. Moreover, these tonic currents drive neuronal migration and maturation, axon growth, and synaptic plasticity (Ben-Ari et al., <xref ref-type="bibr" rid="B20">2007</xref>; Wang and Kriegstein, <xref ref-type="bibr" rid="B265">2009</xref>; Kilb et al., <xref ref-type="bibr" rid="B120">2013</xref>; Luhmann et al., <xref ref-type="bibr" rid="B151">2015</xref>). Also GABA<sub>B</sub>Rs regulate neuronal migration, maturation of pyramidal neurons, synapse formation and circuit development (Fiorentino et al., <xref ref-type="bibr" rid="B82">2009</xref>; Gaiarsa and Porcher, <xref ref-type="bibr" rid="B88">2013</xref>). Notably, GABA<sub>B</sub>R activation is not able to elicit GIRK-mediated (hyperpolarizing) currents in early neurodevelopment, although maintaining the pre-synaptic inhibitory function on neurotransmitter release. Indeed, coupling of postsynaptic GABA<sub>B</sub>Rs to Kir channels is delayed during development (Fukuda et al., <xref ref-type="bibr" rid="B87">1993</xref>; Gaiarsa et al., <xref ref-type="bibr" rid="B89">1995</xref>; McLean et al., <xref ref-type="bibr" rid="B164">1996</xref>).</p>
<p>Finally, in neurodevelopment, both GABA<sub>A</sub>- and GABA<sub>B</sub>-mediated transmission control synaptic plasticity. Indeed, GABA<sub>A</sub> receptors interfere both with the opening and the closure of the visual cortex critical period, i.e., the time window when brain plasticity can be evoked by environmental stimuli and experimental paradigms in slices and <italic>in vivo</italic> (i.e., long-term potentiation (LTP) and induction and monocular deprivation, respectively; Levelt and Hübener, <xref ref-type="bibr" rid="B141">2012</xref>). Eventually, in the adult brain, GABA<sub>A</sub>Rs usually exert a negative regulation on hippocampal plasticity and cognition. Indeed, GABA<sub>A</sub>R-mediated inhibition suppresses LTP both <italic>in vitro</italic> and <italic>in vivo</italic> (Wigström and Gustafsson, <xref ref-type="bibr" rid="B273">1986</xref>; Grover and Yan, <xref ref-type="bibr" rid="B95">1999</xref>; Matsuyama et al., <xref ref-type="bibr" rid="B162">2008</xref>), and benzodiazepines (positive regulators of GABA<sub>A</sub>Rs) or GABA<sub>A</sub>R activation impairs memory (Roth et al., <xref ref-type="bibr" rid="B209">1984</xref>; Zarrindast et al., <xref ref-type="bibr" rid="B285">2002</xref>; Raccuglia and Mueller, <xref ref-type="bibr" rid="B196">2013</xref>). While LTP is enhanced by GABA<sub>A</sub>R blockade (Wigström and Gustafsson, <xref ref-type="bibr" rid="B273">1986</xref>), long term depression (LTD) is facilitated by GABA<sub>A</sub>R activation <italic>in vitro</italic> (Steele and Mauk, <xref ref-type="bibr" rid="B243">1999</xref>), thus suggesting that GABA<sub>A</sub>-mediated inhibition balances the ratio between LTP and LTD. On the other hand, GABA<sub>B</sub>R-mediated membrane hyperpolarization, inhibition of voltage-gated calcium channels and of back-propagating spikes, as well as reduction of the cAMP/PKA generally contribute to prevent synaptic plasticity. Indeed, GABA<sub>B</sub>Rs generally suppress LTP and memory performance, however a dual role in plasticity regulation is mediated by auto- and hetero-GABA<sub>B</sub>Rs (Davies et al., <xref ref-type="bibr" rid="B67">1991</xref>; Stäubli et al., <xref ref-type="bibr" rid="B242">1999</xref>). Finally, GABAergic regulation of brain plasticity also involves adult neurogenesis. Indeed, tonic depolarizing GABA<sub>A</sub> responses by GABAergic Parvalbumin interneurons negatively regulate adult neurogenesis in the dentate gyrus (DG) of the hippocampus (Song et al., <xref ref-type="bibr" rid="B236">2012</xref>; Pontes et al., <xref ref-type="bibr" rid="B191">2013</xref>; Pallotto and Deprez, <xref ref-type="bibr" rid="B182">2014</xref>).</p>
<p>Phasic GABA<sub>A</sub>-mediated transmission also ensures simultaneous and temporally limited inhibition, able to synchronize network activity and generate network oscillations, according to both computational models and <italic>in vitro</italic> slice experiments from juvenile (P14–27) and adult mice (Wang and Buzsáki, <xref ref-type="bibr" rid="B267">1996</xref>; Mann and Mody, <xref ref-type="bibr" rid="B156">2010</xref>). Moreover, GABA<sub>B</sub>Rs synchronize hippocampal network activity at low oscillation frequency (Scanziani, <xref ref-type="bibr" rid="B221">2000</xref>; Kohl and Paulsen, <xref ref-type="bibr" rid="B128">2010</xref>) and are activated during cortical up-states, contributing to their termination (Mann et al., <xref ref-type="bibr" rid="B157">2009</xref>). Finally, GABA also exerts key roles in pathological conditions such as a number of neurodevelopmental disorders (Ramamoorthi and Lin, <xref ref-type="bibr" rid="B197">2011</xref>; Deidda et al., <xref ref-type="bibr" rid="B71">2014</xref>), epilepsy (Kaila et al., <xref ref-type="bibr" rid="B114">2014a</xref>), anxiety (Nuss, <xref ref-type="bibr" rid="B176">2015</xref>), and neurodegenerative diseases (e.g., AD; Li et al., <xref ref-type="bibr" rid="B143">2016</xref>).</p>
</sec>
</sec>
<sec id="s3">
<title>Mouse Models of DS</title>
<p>Most of the current knowledge regarding alterations of the GABAergic signaling in the DS brain has come from the study of mouse models of DS. According to a recent study utilizing the Vertebrate Genome Annotation (VEGA) database<xref ref-type="fn" rid="fn0001"><sup>1</sup></xref>, the human chromosome 21 (Hsa21) contains a total of 222 protein-coding genes (of which 218 map to the long arm 21q), including two large clusters of 49 keratin-associated proteins (KRTAPs; Gupta et al., <xref ref-type="bibr" rid="B100">2016</xref>). The mouse genes orthologue of those mapping to the long arm of Hsa21 are distributed on three syntenic regions present on mouse chromosomes 10, 16 and 17. In particular, the distal portion of mouse chromosome 16 (Mmu16) encompasses a large (~28 Mb) region that contains ~55% of Hsa21 orthologous protein-coding genes (Antonarakis et al., <xref ref-type="bibr" rid="B4">2004</xref>; Gupta et al., <xref ref-type="bibr" rid="B100">2016</xref>). Therefore, many of the available DS mouse models have been created by genetic manipulation of this Mmu16 region. Specifically, the Ts65Dn mouse (Reeves et al., <xref ref-type="bibr" rid="B200">1995</xref>) is the most widely used murine model of DS and carries an extra translocation chromosome composed of the Mmu16 syntenic region fused to the centromeric portion of Mmu17. This freely-segregating extra chromosome contains 90 non-KRTAP, Hsa21 protein-coding orthologues, plus 35 protein-coding genes (deriving from Mmu17) that are not triplicated in DS (Duchon et al., <xref ref-type="bibr" rid="B75">2011</xref>; Gupta et al., <xref ref-type="bibr" rid="B100">2016</xref>). Additional DS mouse models carrying a smaller triplication of the Mmu16 syntenic region are the Ts1Cje and the Ts1Rhr. Ts1Cje mice are characterized by the genomic duplication of a Mmu16 segment containing 71 Hsa21 protein-coding orthologues and translocated to the distal portion of Mmu12 (Sago et al., <xref ref-type="bibr" rid="B218">1998</xref>; Gupta et al., <xref ref-type="bibr" rid="B100">2016</xref>). However, the translocation resulted in the deletion of seven genes in the most telomeric segment of Mmu12 (Duchon et al., <xref ref-type="bibr" rid="B75">2011</xref>). Ts1Rhr mice (Olson et al., <xref ref-type="bibr" rid="B179">2004</xref>) were generated by Cre/lox chromosome engineering and carry a tandem duplication of an even smaller Mmu16 region comprising 29 Hsa21 protein-coding orthologues from the so-called “DS critical region” (DSCR; Delabar et al., <xref ref-type="bibr" rid="B73">1993</xref>; Korenberg et al., <xref ref-type="bibr" rid="B130">1994</xref>).</p>
<p>The vast majority of the studies on DS-related cognitive and electrophysiological abnormalities have been performed on the Ts65Dn mouse. Indeed, although the Ts65Dn model still presents issues from a genetic point of view (Gardiner et al., <xref ref-type="bibr" rid="B91">2003</xref>), it recapitulates many of the phenotypic features of the human syndrome (Dierssen, <xref ref-type="bibr" rid="B74">2012</xref>; Rueda et al., <xref ref-type="bibr" rid="B215">2012</xref>), and it is currently the only mouse model used for preclinical identification of pharmacological interventions targeting DS cognitive impairment (Gardiner, <xref ref-type="bibr" rid="B93">2014</xref>). Moreover, phenotypic comparison of different DS mouse models has suggested that the genes triplicated in the Ts65Dn mouse are major responsible for DS-related cognitive abnormalities (Rueda et al., <xref ref-type="bibr" rid="B215">2012</xref>). In particular, Ts65Dn mice show severe behavioral deficits in different learning and memory tasks, including fear conditioning, T-maze spontaneous alternation, Morris water maze and object recognition tests (Reeves et al., <xref ref-type="bibr" rid="B200">1995</xref>; Costa et al., <xref ref-type="bibr" rid="B62">2007</xref>; Fernandez et al., <xref ref-type="bibr" rid="B81">2007</xref>; Contestabile et al., <xref ref-type="bibr" rid="B55">2013</xref>), and electrophysiological alterations in both synaptic transmission (Kleschevnikov et al., <xref ref-type="bibr" rid="B124">2004</xref>, <xref ref-type="bibr" rid="B123">2012b</xref>; Best et al., <xref ref-type="bibr" rid="B22">2007</xref>, <xref ref-type="bibr" rid="B21">2012</xref>; Hanson et al., <xref ref-type="bibr" rid="B102">2007</xref>; Mitra et al., <xref ref-type="bibr" rid="B167">2012</xref>) and hippocampal synaptic plasticity (Siarey et al., <xref ref-type="bibr" rid="B230">1997</xref>, <xref ref-type="bibr" rid="B229">1999</xref>; Kleschevnikov et al., <xref ref-type="bibr" rid="B124">2004</xref>; Costa and Grybko, <xref ref-type="bibr" rid="B60">2005</xref>; Contestabile et al., <xref ref-type="bibr" rid="B55">2013</xref>). In addition, Ts65Dn mice display alterations in dendritic spine morphology (Belichenko et al., <xref ref-type="bibr" rid="B18">2004</xref>; Guidi et al., <xref ref-type="bibr" rid="B98">2013</xref>) and impaired neurogenesis both in the developing brain (Baxter et al., <xref ref-type="bibr" rid="B9">2000</xref>; Roper et al., <xref ref-type="bibr" rid="B206">2006</xref>; Chakrabarti et al., <xref ref-type="bibr" rid="B40">2007</xref>, <xref ref-type="bibr" rid="B39">2010</xref>; Contestabile et al., <xref ref-type="bibr" rid="B54">2007</xref>, <xref ref-type="bibr" rid="B53">2009</xref>) and in neurogenic niches of the adult brain (Clark et al., <xref ref-type="bibr" rid="B48">2006</xref>; Bianchi et al., <xref ref-type="bibr" rid="B25">2010a</xref>; Contestabile et al., <xref ref-type="bibr" rid="B55">2013</xref>). Additionally, Ts65Dn mice are not spontaneously epileptic, but show increased seizures incidence in some experimental epilepsy paradigms (Cortez et al., <xref ref-type="bibr" rid="B58">2009</xref>; Westmark et al., <xref ref-type="bibr" rid="B270">2010</xref>; Joshi et al., <xref ref-type="bibr" rid="B113">2016</xref>). Finally, similarly to DS patients, Ts65Dn mice also exhibit some sleep alterations and hyperactivity in locomotor behavior (Escorihuela et al., <xref ref-type="bibr" rid="B77">1995</xref>; Reeves et al., <xref ref-type="bibr" rid="B200">1995</xref>; Sago et al., <xref ref-type="bibr" rid="B219">2000</xref>; Colas et al., <xref ref-type="bibr" rid="B50">2008</xref>).</p>
<p>Although Ts1Cje and Ts1Rhr mice show some DS-related phenotypes, the extent of these features is somewhat milder and with some distinct characteristics (Rueda et al., <xref ref-type="bibr" rid="B215">2012</xref>). In particular, Ts1Cje mice displayed deficits in synaptic plasticity and behavior in the T-maze test comparable to Ts65Dn mice, whereas memory performances were less severely affected in the Morris water maze and substantially spared in the novel object recognition (Sago et al., <xref ref-type="bibr" rid="B218">1998</xref>; Siarey et al., <xref ref-type="bibr" rid="B231">2005</xref>; Belichenko et al., <xref ref-type="bibr" rid="B17">2007</xref>; Fernandez and Garner, <xref ref-type="bibr" rid="B80">2007</xref>). On the other hand, Ts1Rhr mice showed impaired synaptic plasticity in the hippocampal DG, but unaffected plasticity in the CA1 hippocampal region. At the behavior level, deficits were detected in the <italic>T</italic>-maze and novel object recognition tests, but not in the Morris water maze test (Olson et al., <xref ref-type="bibr" rid="B180">2007</xref>; Belichenko P. N. et al., <xref ref-type="bibr" rid="B14">2009</xref>). Finally, Ts1Cje mice were found hypoactive (Sago et al., <xref ref-type="bibr" rid="B218">1998</xref>), and Ts1Rhr mice mostly not different compared to WT animals for locomotor behavior (Belichenko P. N. et al., <xref ref-type="bibr" rid="B14">2009</xref>).</p>
<p>In more recent years, systematic application of Cre/lox-mediated chromosome engineering has permitted the creation of three new murine lines (Dp10, Dp16 and Dp17) individually trisomic (through a tandem duplication on the corresponding chromosome) for the three complete syntenic regions on Mmu10, 16 and 17, respectively (Li et al., <xref ref-type="bibr" rid="B144">2007</xref>; Yu et al., <xref ref-type="bibr" rid="B283">2010a</xref>, <xref ref-type="bibr" rid="B284">b</xref>). Nevertheless, although these mouse lines represent ideal models in terms of genetic triplication, they lack the extra freely-segregating chromosome that is found in most individuals with DS and in Ts65Dn mice. In fact, the presence of an extra unpaired chromosome could also have a role <italic>per se</italic> in the phenotypic consequences of trisomy by impacting on global gene expression and/or chromatin structure (Reinholdt et al., <xref ref-type="bibr" rid="B201">2009</xref>; Dierssen, <xref ref-type="bibr" rid="B74">2012</xref>). On the other hand, mice fully-trisomic for all Hsa21 orthologue genes can also be created by successively crossing the Dp10, Dp16 and Dp17 lines, although decreased viability and poor breading have limited the experimental studies on these triple trisomic mice (Yu et al., <xref ref-type="bibr" rid="B283">2010a</xref>; Belichenko et al., <xref ref-type="bibr" rid="B15">2015</xref>). Moreover, the Dp10, Dp16 and Dp17 mice have also permitted the dissection of the relative contribution of the different triplicated regions to the diverse disease phenotypes. Interestingly, while Dp16 and triple trisomic mice (Dp10/Dp16/Dp17) show behavioral and synaptic plasticity deficits comparable to the ones found in Ts65Dn mice (Yu et al., <xref ref-type="bibr" rid="B283">2010a</xref>,<xref ref-type="bibr" rid="B284">b</xref>; Belichenko et al., <xref ref-type="bibr" rid="B15">2015</xref>), and the single trisomic mice Dp10 as well as Dp17 show normal (or even enhanced) performances (Yu et al., <xref ref-type="bibr" rid="B284">2010b</xref>), highlighting the importance of the Mmu16 syntenic region in DS-related phenotype.</p>
</sec>
<sec id="s4">
<title>GABA Signaling in DS Mouse Models</title>
<sec id="s4-1">
<title>GABA<sub>A</sub> Signaling and Trisomy</title>
<p>A first main finding regarding GABA-related phenotypes in DS came from the observation that the number of GABAergic interneurons is increased in both the cortex and the hippocampus of Ts65Dn mice (Chakrabarti et al., <xref ref-type="bibr" rid="B39">2010</xref>; Pérez-Cremades et al., <xref ref-type="bibr" rid="B187">2010</xref>; Hernández et al., <xref ref-type="bibr" rid="B108">2012</xref>; Hernández-González et al., <xref ref-type="bibr" rid="B109">2015</xref>). Specifically, this increase arises from amplified neurogenesis during embryonic development of neural progenitor cells in the medial ganglionic eminence (MGE, where most interneurons originate during development; Marín and Müller, <xref ref-type="bibr" rid="B159">2014</xref>), and it is more prominent for Parvalbumin and Somatostatin-positive GABAergic interneurons (Chakrabarti et al., <xref ref-type="bibr" rid="B39">2010</xref>). In line with the increase in GABAergic interneurons, the same authors reported also an increase in spontaneous GABAergic postsynaptic events in CA1 pyramidal neurons. Nevertheless, further functional analysis of GABAergic transmission by electrophysiology did not find evidence for alterations in the frequency of miniature inhibitory postsynaptic currents (mIPSC, which represent activity-independent quantal release of GABA), release probability at GABAergic synapses and evoked GABA<sub>A</sub> transmission in the hippocampal CA1 region of adult Ts65Dn mice (Chakrabarti et al., <xref ref-type="bibr" rid="B39">2010</xref>; Best et al., <xref ref-type="bibr" rid="B21">2012</xref>). Therefore, the increase of spontaneous GABAergic events observed in Ts65Dn mice may be due to a general enhancement in interneuron excitability rather than a specific increase in the number of GABAergic synapses. Indeed, further electron microscopy studies in the temporal cortex and hippocampus of adult Ts65Dn mice found the density of symmetric synapses (putative GABAergic) to be unaffected (Kurt et al., <xref ref-type="bibr" rid="B133">2000</xref>, <xref ref-type="bibr" rid="B132">2004</xref>; Belichenko P. V. et al., <xref ref-type="bibr" rid="B16">2009</xref>). Similarly, immunohistochemical evaluation of GABAergic terminals confirmed comparable density between WT and Ts65Dn mice in the DG, even if the distribution of GABAergic synapses appeared altered, with a selective redistribution of GABAergic synapses from the dendrite shaft and the spine heads to the spine neck of trisomic neurons (Belichenko et al., <xref ref-type="bibr" rid="B18">2004</xref>; Belichenko P. V. et al., <xref ref-type="bibr" rid="B16">2009</xref>; Kleschevnikov et al., <xref ref-type="bibr" rid="B123">2012b</xref>). Such selective retribution of GABAergic synapses to the spine neck was later also confirmed in the DG of Ts1Cje mice (Belichenko et al., <xref ref-type="bibr" rid="B17">2007</xref>). The altered location of GABAergic synapses in DS mice may impair synaptic input integration. Indeed, GABAergic contacts on the spine neck may account for integration of spine-converging inputs, in replacement of contacts on the spine head and on the dendritic shaft that integrate inputs at local synaptic and dendritic levels, respectively. Anyhow, the increased number of GABAergic neurons seems not to be directly associated with increased synaptic contacts in the DS brain. The reason is not fully understood, but GABAergic synaptic density may normalize in adulthood for compensatory mechanisms, after defective brain development. Indeed, differently than in adult Ts65Dn mice, both mIPSC frequency and evoked GABA<sub>A</sub> transmission (but not release probability) were found larger in the CA1 region of 2 weeks old Ts65Dn mice (Mitra et al., <xref ref-type="bibr" rid="B167">2012</xref>). Further support to the compensation hypothesis is the observation that an increased GABAergic synaptic density was in fact found specifically in the inner molecular layer and granular layer of the hippocampal DG of adult Ts65Dn mice (Martínez-Cué et al., <xref ref-type="bibr" rid="B161">2013</xref>; García-Cerro et al., <xref ref-type="bibr" rid="B90">2014</xref>; Mojabi et al., <xref ref-type="bibr" rid="B169">2016</xref>). Indeed, this brain area is highly innervated by GABAergic fibers, and one could expect that developmental compensatory mechanisms may be more difficult to put in place. On the other hand, all these seemingly conflicting results may simply indicate that GABA<sub>A</sub>-mediated dysfunctions are not uniform in all areas of the trisomic brain and/or may also be simply due to age-related changes. Indeed, mIPSC frequency and evoked GABAergic transmission were found increased in the DG of adult Ts65Dn mice, but with this alteration primarily attributed to increased release probability at GABAergic terminals, rather than increased synapse number (Kleschevnikov et al., <xref ref-type="bibr" rid="B124">2004</xref>, <xref ref-type="bibr" rid="B123">2012b</xref>), indicating possible sub-regional differences in the density of GABAergic synapses and its functional consequences (see Figure <xref ref-type="fig" rid="F1">1</xref>). Additionally, mIPSC frequency was found decreased (rather than increased) in the hippocampal CA3 region of Ts65Dn mice (Hanson et al., <xref ref-type="bibr" rid="B102">2007</xref>; Stagni et al., <xref ref-type="bibr" rid="B239">2013</xref>). Finally, outside the hippocampus, increased excitability, enhanced release probability and decreased tonic GABA inhibition were found in cerebellar granule cells of Ts65Dn mice (Usowicz and Garden, <xref ref-type="bibr" rid="B255">2012</xref>; Das et al., <xref ref-type="bibr" rid="B65">2013</xref>; Szemes et al., <xref ref-type="bibr" rid="B250">2013</xref>).</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p><bold>Subregion-specific GABA-related dysfunctions in the hippocampus of the Ts65Dn mouse model.</bold> IPSC, inhibitory postsynaptic currents; sIPSC, spontaneous IPSC; mIPSC, miniature IPSC; eIPSC, evoked IPSC; freq, frequency; ampl, amplitude; mEPSC, miniature excitatory postsynaptic currents; [Cl]<sub>I</sub>, intracellular chloride concentration; <italic>E</italic><sub>Cl</sub>, reversal potential of GABA<sub>A</sub>R-mediated Cl currents; <italic>V</italic><sub>REST</sub>, resting membrane potential. Arrows indicate increases or decreases of the reported measures.</p>
</caption>
<graphic xlink:href="fncel-11-00054-g0001"></graphic>
</fig>
<p>Phasic and tonic GABA transmission is necessary to synchronize neuronal firing and maintain physiological network oscillation. Interestingly, gamma oscillation power is reduced in Ts65Dn hippocampal slices, while duration and frequency of up-states are reduced in Ts65Dn layer 4 of somatosensory cortex slices (Hanson et al., <xref ref-type="bibr" rid="B103">2013</xref>; Cramer et al., <xref ref-type="bibr" rid="B64">2015</xref>).</p>
<p>Regarding the expression of the different GABA receptors, no statistical difference was found in the hippocampus of Ts65Dn mice compared to WT for <italic>α</italic><sub>1</sub>, <italic>α</italic><sub>2</sub>, <italic>α</italic><sub>3</sub>, <italic>α</italic><sub>5</sub>, <italic>γ</italic><sub>2</sub> subunits of GABA<sub>A</sub>R (Belichenko P. V. et al., <xref ref-type="bibr" rid="B16">2009</xref>; Best et al., <xref ref-type="bibr" rid="B21">2012</xref>; Kleschevnikov et al., <xref ref-type="bibr" rid="B123">2012b</xref>). However, decreased immunostaining for β<sub>2/3</sub> subunits of GABA<sub>A</sub>R have been reported in the DG of 3 month-old Ts65Dn mice, but not at later time points, suggesting possible age-related changes (Belichenko P. V. et al., <xref ref-type="bibr" rid="B16">2009</xref>). Moreover, the binding of the selective α<sub>5</sub> subtype radio-ligand [<sup>3</sup>H]RO0154513 was unchanged <italic>in vivo</italic> in Ts65Dn mice compared to WT, suggesting similar expression of GABA<sub>A</sub>Rs containing the α<sub>5</sub> subunit (Martínez-Cué et al., <xref ref-type="bibr" rid="B161">2013</xref>).</p>
<p>As detailed above, GABA<sub>A</sub>R-mediated transmission undergoes a developmental switch from depolarizing (excitatory) to hyperpolarizing (inhibitory) during neuronal maturation and it can shift between inhibition and excitation under some circumstances and/or in particular cellular compartments (Andersen et al., <xref ref-type="bibr" rid="B1">1980</xref>; Staley et al., <xref ref-type="bibr" rid="B240">1995</xref>; Gulledge and Stuart, <xref ref-type="bibr" rid="B99">2003</xref>; Viitanen et al., <xref ref-type="bibr" rid="B263">2010</xref>; Ruusuvuori et al., <xref ref-type="bibr" rid="B217">2013</xref>). Consequently, the complex relationship of ionic movements determined by GABA<sub>A</sub>R signaling and chloride transporters must be highly regulated to avoid deleterious consequences on neuronal physiology (Deidda et al., <xref ref-type="bibr" rid="B71">2014</xref>). In this regard, we have recently found that NKCC1 is upregulated in the brain of both Ts65Dn mice and individuals with DS (Deidda et al., <xref ref-type="bibr" rid="B72">2015b</xref>). Accordingly, we found that [Cl<sup>−</sup>]<sub>i</sub> was increased in CA1 pyramidal neurons from Ts65Dn mice and <italic>E</italic><sub>Cl</sub> was depolarized by 7.7 mV compared to WT neurons (Deidda et al., <xref ref-type="bibr" rid="B72">2015b</xref>). As a result, <italic>E</italic><sub>Cl</sub> was less negative than <italic>V</italic><sub>REST</sub> in trisomic neurons, thus predictive of outward Cl<sup>−</sup> depolarizing currents upon GABA<sub>A</sub>R activation. Accordingly, the mean firing frequency of individual CA1 neurons was increased by exogenous application of GABA in trisomic hippocampal slices, whereas it was decreased by blockade of GABA<sub>A</sub>R-mediated transmission with bicuculline, the opposite of what physiologically observed in WT neurons (Deidda et al., <xref ref-type="bibr" rid="B72">2015b</xref>). Therefore, despite the complex dual excitatory and shunting/inhibitory effect of GABA following <italic>E</italic><sub>Cl</sub> depolarization, GABA<sub>A</sub> signaling was mainly excitatory in Ts65Dn neurons in our experimental conditions of prolonged bath-application of the drugs in acute brain slices. In this regard, the contribution of evoked, synaptically released or tonic GABA signaling to the depolarizing effect of GABA<sub>A</sub>Rs has not been studied yet in Ts65Dn slices. Similarly, experiments are needed to evaluate <italic>in vivo</italic> the strength and direction of GABA<sub>A</sub> transmission in DS. Moreover, little is known about the contribution of GABAergic signaling on network dynamics in trisomic neurons. However, one calcium imaging study on hippocampal cultures showed decreased response to bicuculline application on network burst-amplitude and duration in Ts65Dn mice, as well as decreased network bursts upon GABA application in both WT and Ts65Dn culture (Stern et al., <xref ref-type="bibr" rid="B244">2015</xref>).</p>
<p>Despite of whether GABA<sub>A</sub>R-induced depolarization may reach the threshold for neuronal excitation or not, GABA<sub>A</sub>R-driven depolarization may still work in favor of excitation more efficiently than GABA<sub>A</sub>R-driven shunting would work in favor of inhibition. Indeed, in Ts65Dn neurons the shunting effect of GABA<sub>A</sub> opening may be very mild on dendritic signal processing, since most synapses are located on the spine neck. Instead, GABA<sub>A</sub> depolarizing PSPs may generate in the spine neck for the depolarized <italic>E</italic><sub>Cl</sub> and propagate to spine heads and dendritic shaft, consequently affecting NMDA receptor and voltage-gated channel openings, and adding up to concurrent excitatory PSPs. Notably, the concomitant hyperpolarized shift of <italic>V</italic><sub>REST</sub> in Ts65Dn neurons, due to GIRK2 triplication (Best et al., <xref ref-type="bibr" rid="B21">2012</xref>), may also contribute to the depolarizing action of GABA. Anyhow, pharmacological inhibition of NKCC1 transport activity with the specific antagonist Bumetanide completely restored the hyperpolarizing and inhibitory action of GABA in Ts65Dn neurons (Deidda et al., <xref ref-type="bibr" rid="B72">2015b</xref>).</p>
</sec>
<sec id="s4-2">
<title>GABA<sub>B</sub> Signaling and Trisomy</title>
<p>Another direct link between DS genetic triplication and GABA signaling came from the discovery that the KCNJ6 gene, which encodes the subunit 2 of the GIRK channel (GIRK2/Kir3.2), maps to Hsa21 (Ohira et al., <xref ref-type="bibr" rid="B177">1997</xref>; Hattori et al., <xref ref-type="bibr" rid="B105">2000</xref>). The presence of an extra KCNJ6 copy in Ts65Dn mice leads to overexpression of GIRK2 mRNA and protein in hippocampus, cortex and midbrain (Harashima et al., <xref ref-type="bibr" rid="B104">2006</xref>). Interestingly, also the GIRK1 protein (which is not triplicated in DS) is overexpressed in Ts65Dn brains, with normal levels of mRNA. Thus, the increased GIRK1 protein expression is most likely due to enhanced hetero-dimerization with GIRK2 subunit (which drives GIRK subunit trafficking) and downstream decreased protein turnover (Harashima et al., <xref ref-type="bibr" rid="B104">2006</xref>). As a consequence, GABA<sub>B</sub>/GIRK currents are increased in cultured primary hippocampal neurons (Best et al., <xref ref-type="bibr" rid="B22">2007</xref>), as well as in CA1 pyramidal neurons and in DG granule cells from acute slices of the Ts65Dn hippocampus (Best et al., <xref ref-type="bibr" rid="B21">2012</xref>; Kleschevnikov et al., <xref ref-type="bibr" rid="B123">2012b</xref>). This increase of GABA<sub>B</sub>/GIRK signaling in Ts65Dn neurons could strongly affect neuronal excitability and plasticity by enhancement of GIRK-mediated shunting inhibition, reduction of excitatory PSPs, back-propagating action potentials, and change of neuronal passive properties (Lüscher et al., <xref ref-type="bibr" rid="B152">1997</xref>; Koyrakh et al., <xref ref-type="bibr" rid="B131">2005</xref>). Anyhow, genetically restoring GIRK2 gene dosage to disomy in Ts65Dn mice (by crossing to GIRK2<sup>+/−</sup> mice) rescued the observed increase in GABA<sub>B</sub>-triggered currents in CA1 pyramidal neurons (Joshi et al., <xref ref-type="bibr" rid="B113">2016</xref>). In agreement with triplication of KCNJ6 and the increase of GABA<sub>B</sub>/GIRK signaling, <italic>V</italic><sub>REST</sub> is hyperpolarized by 2.3 mV in CA1 pyramidal neurons and by 6.2 mV in DG granule cells (DGGC; Best et al., <xref ref-type="bibr" rid="B21">2012</xref>; Kleschevnikov et al., <xref ref-type="bibr" rid="B123">2012b</xref>). Of note, whereas no statistical difference was found in the hippocampus of Ts65Dn mice compared to WT for GABA<sub>B</sub>R subunit 1, GABA<sub>B</sub>R subunit 2 was slightly decreased, most likely due to a compensatory adaptation mechanism in response to the increase of GIRK2 levels (Best et al., <xref ref-type="bibr" rid="B21">2012</xref>; Kleschevnikov et al., <xref ref-type="bibr" rid="B123">2012b</xref>).</p>
<p>Apart from GABA<sub>B</sub>Rs, GIRKs channels may also mediate signaling from many other neurotransmitters including acetylcholine, dopamine, opioid, serotonin, somatostatin and adenosine through their metabotropic GPCRs (Lüscher et al., <xref ref-type="bibr" rid="B152">1997</xref>). Therefore, GIRK2 triplication in DS may account for a large plethora of different effects depending on the neurotransmitter system involved. For example, GIRK2 channels also mediate the hypothermic response induced by administration of the serotonin 5-HT<sub>1A</sub> and 5-HT<sub>7</sub> receptor agonist 8-OH-DPAT (Costa et al., <xref ref-type="bibr" rid="B61">2005</xref>). Indeed, 8-OH-DPAT hypothermic response is increased in Ts65Dn mice (Stasko et al., <xref ref-type="bibr" rid="B241">2006</xref>).</p>
</sec>
<sec id="s4-3">
<title>Synaptic Plasticity and GABA Signaling in DS</title>
<p>A large body of evidence linking altered GABA physiology to DS-related cognitive phenotypes came from the study of hippocampal synaptic plasticity in trisomic mice. LTP and LTD are widely accepted models of synaptic plasticity, characterized by the strengthening or weakening (respectively) of synaptic efficiency following specific stimulation protocols. In particular, LTP represents the cellular correlate of memory and it is necessary for different cognitive processes, including learning (Lynch, <xref ref-type="bibr" rid="B153">2004</xref>; Whitlock et al., <xref ref-type="bibr" rid="B271">2006</xref>; Nabavi et al., <xref ref-type="bibr" rid="B173">2014</xref>). In line with the impairment in cognitive abilities characteristic of persons with DS and of DS mouse models, synaptic plasticity paradigms (both LTP and LTD) were found altered in Ts65Dn hippocampal slices (Siarey et al., <xref ref-type="bibr" rid="B230">1997</xref>, <xref ref-type="bibr" rid="B229">1999</xref>, <xref ref-type="bibr" rid="B228">2006</xref>).</p>
<p>Given the already described pivotal role of GABAergic inhibition in regulating synaptic plasticity and given the defective GABAergic transmission in DS animals, researchers have evaluated the effect of GABAergic drugs on different forms of hippocampal LTP in DS mice. Interestingly, LTP occurring at Shaffer collateral-CA1 synapses (CA3-CA1 LTP) was rescued in Ts65Dn slices by acute application in the recording bath of the GABA<sub>A</sub>R antagonist picrotoxin (PTX). Similarly, potentiation at perforant path-DGGC synapses (DG-LTP) was restored by application of either PTX or the GABA<sub>B</sub>R antagonist CGP55845 (Kleschevnikov et al., <xref ref-type="bibr" rid="B124">2004</xref>, <xref ref-type="bibr" rid="B122">2012a</xref>; Costa and Grybko, <xref ref-type="bibr" rid="B60">2005</xref>), establishing a causal link between GABAergic transmission and plasticity deficits in DS. Remarkably, CA3-CA1 LTP was also rescued by application of the NKCC1 inhibitor Bumetanide, indicating the involvement of depolarizing GABAergic signaling in the impairment of synaptic plasticity in DS (Deidda et al., <xref ref-type="bibr" rid="B72">2015b</xref>). An even more striking evidence came about when it was shown that DG-LTP was rescued in acute slices from Ts65Dn mice that had been chronically treated with the GABA<sub>A</sub>R blocker pentylenetetrazole (PTZ). The effect was evident for up to 1–3 months after treatment cessation (Fernandez et al., <xref ref-type="bibr" rid="B81">2007</xref>). Accordingly, chronic <italic>in vivo</italic> treatment with RO4938581, a selective negative allosteric modulator of α<sub>5</sub>-containing GABA<sub>A</sub>Rs, rescued <italic>in vitro</italic> CA3-CA1 LTP in Ts65Dn mice, although it was not assessed after drug withdrawal (Martínez-Cué et al., <xref ref-type="bibr" rid="B161">2013</xref>).</p>
<p>Finally, comparative evaluation of synaptic plasticity deficits in the other DS mouse models has shown that DG-LTP was similarly impaired and rescued by PTX application in Ts1Cje, Ts1Rhr, and triple trisomic (Dp10/Dp16/Dp17) mice (Belichenko et al., <xref ref-type="bibr" rid="B17">2007</xref>; Belichenko P. N. et al., <xref ref-type="bibr" rid="B14">2009</xref>; Belichenko et al., <xref ref-type="bibr" rid="B15">2015</xref>). Conversely, CA3-CA1 LTP was decreased in Ts1Cje, Dp16 and triple trisomic mice, unchanged in Ts1Rhr and Dp10 mice, and even significantly increased in Dp17 mice, but none of these later studies evaluated the possible contribution of GABAergic signaling (Siarey et al., <xref ref-type="bibr" rid="B231">2005</xref>; Olson et al., <xref ref-type="bibr" rid="B180">2007</xref>; Yu et al., <xref ref-type="bibr" rid="B283">2010a</xref>,<xref ref-type="bibr" rid="B284">b</xref>).</p>
<p>Of note, beside the two studies performed in primary neuronal cultures (Best et al., <xref ref-type="bibr" rid="B22">2007</xref>; Stern et al., <xref ref-type="bibr" rid="B244">2015</xref>), all other electrophysiological investigations of GABAergic signaling alteration in DS mouse model have been performed on acute brain slices. Therefore, further studies are needed to assess whether GABAergic dysfunctions can be fully reproduced on <italic>in vitro</italic> neuronal cultures and, most importantly, if they are also occurring <italic>in vivo</italic> in the intact brain.</p>
</sec>
</sec>
<sec id="s5">
<title>Pharmacological Interventions Targeting GABA Transmission to Rescue Cognitive Deficits in DS Mouse Models</title>
<p>Given the large body of evidence showing the involvement of GABA signaling in neurophysiology, cognition and synaptic plasticity in DS, many studies have evaluated learning and memory processes in DS mice after pharmacological interventions targeting GABAergic transmission. Although therapy with GABA<sub>A</sub>R antagonists may be hampered by possible pro-epileptic and anxiogenic side effects in patients already at increased risk for these conditions, a first seminal study evaluated the efficacy of different GABA<sub>A</sub>R antagonists (PTX, PTZ and Bilobalide) at non-epileptic doses on long-term declarative memory in the novel object recognition test in Ts65Dn mice: chronic (but not acute) blockade of GABA<sub>A</sub> transmission rescued object recognition memory after 2-weeks of treatment (Fernandez et al., <xref ref-type="bibr" rid="B81">2007</xref>). Strikingly, the positive effect of PTZ (a drug previously used in the clinic) was maintained after an additional 2 months of drug withdrawal, indicating that the treatment likely induced long-term neuronal-circuit rearrangements able to sustain cognitive performance in trisomic mice. The positive effect of chronic PTZ treatment on learning and memory was further confirmed in the Morris water maze by a later study (Rueda et al., <xref ref-type="bibr" rid="B214">2008</xref>). However, the same study showed a worsening effect of PTZ in Ts65Dn mice in a test for equilibrium, indicating a possible side effect of the drug. Interestingly, a follow-up study found that the effective dose of PTZ could be reduced by 10 times without compromising its efficacy, thus defining a potential safer therapeutic window with respect to the possible pro-epileptic and anxiogenic side effects of the drug (Colas et al., <xref ref-type="bibr" rid="B49">2013</xref>).</p>
<p>Prompted by the effectiveness of PTZ treatment and by the observation that mice knock-out for the GABA<sub>A</sub>R α<sub>5</sub> subunit—which is highly expressed in the hippocampus (Wisden et al., <xref ref-type="bibr" rid="B276">1992</xref>)—show increased learning and memory performance (Collinson et al., <xref ref-type="bibr" rid="B51">2002</xref>), a second series of studies has evaluated the efficacy of two inverse agonists selective for the α<sub>5</sub> subunit of the GABA<sub>A</sub>R and acting as negative allosteric modulators. These two drugs had been developed by different pharmaceutical companies as cognitive enhancers: α<sub>5IA</sub> (Chambers et al., <xref ref-type="bibr" rid="B42">2003</xref>) and RO4938581 (Ballard et al., <xref ref-type="bibr" rid="B8">2009</xref>). Both acute and chronic treatments with these drugs were proven effective in ameliorating cognitive performance of Ts65Dn mice in both the novel object recognition and Morris water maze tests without showing pro-epileptic or anxiogenic side effects that may be associated with GABA<sub>A</sub>R antagonism (Braudeau et al., <xref ref-type="bibr" rid="B30">2011a</xref>,<xref ref-type="bibr" rid="B31">b</xref>; Martínez-Cué et al., <xref ref-type="bibr" rid="B161">2013</xref>).</p>
<p>Moreover, following the observation that the chloride importer NKCC1 is upregulated in DS and that GABA<sub>A</sub> transmission is depolarizing in adult Ts65Dn mice, we have recently assessed the efficacy of the NKCC1 inhibitor Bumetanide (a FDA-approved loop diuretic) on learning and memory in trisomic mice. We found that chronic NKCC1 inhibition in Ts65Dn mice was able to rescue discriminative memory in the object recognition test, spatial memory in the object location test and associative memory in the contextual fear conditioning task (Deidda et al., <xref ref-type="bibr" rid="B72">2015b</xref>). Interestingly, the effect of Bumetanide was evident also after acute treatment and quickly lost upon treatment cessation, indicating that the effect of Bumetanide relied on direct NKCC1 inhibition rather than on neuronal-circuit rearrangements. These findings are in line with previous studies on the positive effect of GABA<sub>A</sub>R antagonists on learning and memory in DS mice. Indeed, GABA<sub>A</sub>R antagonists will reduce aberrant depolarizing GABA<sub>A</sub> signaling in Ts65Dn mice regardless of whether GABA<sub>A</sub>R signaling is increased in DS. On the other hand, since modulation of [Cl<sup>−</sup>]<sub>i</sub> is predicted to have only little effect on shunting inhibition, Bumetanide would preserve the ability of GABA<sub>A</sub> currents to shunt concurrent excitatory inputs, hence possibly reducing potential pro-epileptic side effects. Conversely, GABA<sub>A</sub>R antagonists together with reducing receptor transmission will also reduce the shunting inhibition, thus possibly increasing the risk of seizures and profoundly altering neuronal input integration.</p>
<p>With respect to increased GABA<sub>B</sub>R signaling in DS, both acute and chronic treatment with the specific GABA<sub>B</sub>R antagonist CGP55845 restored cognitive performance in the novel object recognition test and associative memory in the contextual fear conditioning test in Ts65Dn mice (Kleschevnikov et al., <xref ref-type="bibr" rid="B122">2012a</xref>), indicating also the possible involvement of metabotropic GABA signaling in DS cognitive impairment.</p>
</sec>
<sec id="s6">
<title>GABA Signaling in DS Patients and Patient-Derived iPSC</title>
<p>Less detailed information is obviously available regarding the GABAergic system in individuals with DS. Reduced brain size and decreased density of neurons are hallmarks of DS and mainly arise from reduced neurogenesis during brain development (Colon, <xref ref-type="bibr" rid="B52">1972</xref>; Sylvester, <xref ref-type="bibr" rid="B248">1983</xref>; Wisniewski et al., <xref ref-type="bibr" rid="B281">1984</xref>; Wisniewski and Schmidt-Sidor, <xref ref-type="bibr" rid="B279">1989</xref>; Wisniewski, <xref ref-type="bibr" rid="B277">1990</xref>; Kesslak et al., <xref ref-type="bibr" rid="B117">1994</xref>; Wisniewski and Kida, <xref ref-type="bibr" rid="B278">1994</xref>; Raz et al., <xref ref-type="bibr" rid="B198">1995</xref>; Aylward et al., <xref ref-type="bibr" rid="B6">1997</xref>, <xref ref-type="bibr" rid="B7">1999</xref>; Teipel et al., <xref ref-type="bibr" rid="B253">2003</xref>; Teipel and Hampel, <xref ref-type="bibr" rid="B252">2006</xref>; Contestabile et al., <xref ref-type="bibr" rid="B54">2007</xref>; Guidi et al., <xref ref-type="bibr" rid="B96">2008</xref>). Nevertheless, only two histological studies on DS autoptic brain samples have selectively evaluated cell counts of <italic>bona fide</italic> GABAergic interneurons. One first study found decreased number of Golgi-stained aspinous stellate (putative GABAergic) cells in the somatosensory, visual and auditory cortices (Ross et al., <xref ref-type="bibr" rid="B207">1984</xref>). Accordingly, the number of Parvalbumin and Calbindin-positive non-pyramidal neurons was also reduced in the frontal and temporal cortices of DS patients (Kobayashi et al., <xref ref-type="bibr" rid="B126">1990</xref>). Although such decrease of GABAergic neurons may come from a secondary effect due to Alzheimer-like degeneration in DS, brain GABA concentration has been shown to be specifically decreased in AD, but not in aging DS patients (Seidl et al., <xref ref-type="bibr" rid="B226">2001</xref>). Moreover, microarray studies to evaluate changes in gene expression on human DS cortical neuronal progenitor cells (hNPCs) in culture have shown gene changes indicative of decreased GABAergic interneuron genesis (Bhattacharyya et al., <xref ref-type="bibr" rid="B24">2009</xref>). Moreover, the same study showed increased expression of the α<sub>2</sub> subunit of the GABA<sub>A</sub>R<sub>,</sub> and downregulation of the α<sub>3</sub> and α<sub>5</sub> subunits in trisomic cells compared to controls (Bhattacharyya et al., <xref ref-type="bibr" rid="B24">2009</xref>). This GABA<sub>A</sub>R composition favoring the α<sub>2</sub> over the α<sub>5</sub> subunits may be indicative that GABA<sub>A</sub>R opening is fastened, possibly reducing the opportunity of shunting inhibition and generating quick PSPs, a condition that may be of particular relevance if GABA<sub>A</sub>-mediated transmission is depolarizing in humans. Indeed, we have shown that NKCC1 is overexpressed also in the brains of DS patients, establishing a direct parallel with the Ts65Dn model (Deidda et al., <xref ref-type="bibr" rid="B72">2015b</xref>), and possibly suggesting depolarized <italic>E</italic><sub>Cl</sub> in humans as in animal models. Finally, GABA levels were found decreased or unchanged in neurochemical (Reynolds and Warner, <xref ref-type="bibr" rid="B202">1988</xref>; Seidl et al., <xref ref-type="bibr" rid="B226">2001</xref>; Whittle et al., <xref ref-type="bibr" rid="B272">2007</xref>) and <sup>1</sup>H MRS studies (Śmigielska-Kuzia and Sobaniec, <xref ref-type="bibr" rid="B234">2007</xref>; Śmigielska-Kuzia et al., <xref ref-type="bibr" rid="B235">2010</xref>) on human trisomic brains.</p>
<p>The recently developed technique for reprogramming somatic cells has opened the possibility of studying patient-derived neurons as a valuable tool for modeling neurological diseases (Takahashi et al., <xref ref-type="bibr" rid="B251">2007</xref>; Park et al., <xref ref-type="bibr" rid="B183">2008</xref>). This approach has been also applied to DS and has permitted the generation of different induced pluripotent stem cells (iPSCs) lines. In particular, two studies have used trisomic iPSCs to assess GABAergic neurogenesis and synaptogenesis upon induction of neuronal differentiation. The results from these studies have highlighted a general impairment in synaptogenesis of DS iPSC-derived neurons that was mirrored by a decrease in the frequency of both inhibitory and excitatory spontaneous postsynaptic currents (sPSCs). However, the percentage of neurons expressing GABAergic markers, the fraction of GABAergic synapses, or the ratio of glutamatergic to GABAergic sPSCs were substantially unaffected (Weick et al., <xref ref-type="bibr" rid="B269">2013</xref>; Hibaoui et al., <xref ref-type="bibr" rid="B110">2014</xref>).</p>
<p>Overall, although the available data from human studies—while limited—seem not to support the data derived from animal research of increased GABA-mediated transmission due to the overproduction of GABAergic interneurons, further electrophysiological studies on iPSCs-derived neurons are needed. On the other hand, no study has yet assessed the occurrence of depolarizing GABA<sub>A</sub> signaling or increased GABA<sub>B</sub>-mediated transmission in human DS neurons.</p>
</sec>
<sec id="s7">
<title>GABAergic Drugs in DS Clinical Trials</title>
<p>Due to the encouraging preclinical data highlighting a strong link between GABA signaling and DS cognitive impairment, some of the pharmacological interventions effective in DS mouse models have been translated into clinical trials on individuals with DS. In particular, although the use of PTZ on DS patients has been questioned due to the potential pro-epileptic side effects, the dosage effective in rescuing learning and memory in Ts65Dn mice is well below the epileptic dose (Colas et al., <xref ref-type="bibr" rid="B49">2013</xref>). Indeed, Balance Therapeutics is conducting a clinical trial in Australia to evaluate the efficacy of PTZ (BTD-001) on individuals with DS. This COMPOSE trial (Cognition and Memory in People with DS, registered in the Australian-New Zealand clinical trial registry as ACTRN12612000652875) is a phase IB study aimed at evaluating safety, tolerability, preliminary efficacy and pharmacodynamics of BTD-001 at two different doses in adults and adolescents with DS. Recruitment for this study has been completed<xref ref-type="fn" rid="fn0002"><sup>2</sup></xref> and the results are eagerly awaited.</p>
<p>Moreover, Hoffmann-La Roche has conducted two clinical trials for assessing the efficacy of the selective negative allosteric modulator of the α<sub>5</sub>-containig GABA<sub>A</sub>R Basmisanil (RG1662/RO5186582), a derivative of RO4938581, previously shown to rescue learning and memory in Ts65Dn mice (Martínez-Cué et al., <xref ref-type="bibr" rid="B161">2013</xref>). The first trial (CLEMATIS) was designed as a phase II placebo-controlled study (NCT02024789) aimed at evaluating the efficacy and safety of RG1662 at two different doses in adults and adolescents with DS. Disappointingly, although the complete results of the CLEMATIS trial have not been disclosed yet, a media release from Roche later this June has announced that the study did not meet its primary and secondary endpoints on improving cognitive functions in DS patients, and that there was no significant difference between the placebo and the treated groups<xref ref-type="fn" rid="fn0003"><sup>3</sup></xref>. The lack of efficacy seen in the CLEMATIS trial induced the discontinuation of the second ongoing placebo-controlled dose-investigating pediatric study (NCT02484703), aimed at evaluating pharmacokinetics, pharmacodynamics, efficacy, and safety of RG1662 in children with DS. The interruption was not decided for safety reasons, as the drug appeared to be well-tolerated and no relevant side effects were observed.</p>
</sec>
<sec id="s8">
<title>Speculation for Future Directions in The Research on DS and GABAergic Transmission</title>
<sec id="s8-1">
<title>Possible Convergence of Different Drug Treatments on GABAergic Signaling in DS</title>
<p>Alternative mechanisms, apart from GABA signaling, have been shown to underline LTP and/or cognitive deficits in Ts65Dn mice. Indeed, CA3-CA1 LTP and/or behavioral performances were rescued in Ts65Dn mice by a variety of manipulations including: acute application of the GluN2B-selective antagonist Ro25–6981 (Hanson et al., <xref ref-type="bibr" rid="B103">2013</xref>) or of the green tea polyphenolic compound epigallocatechin-3-gallate (EGCG, an inhibitor of the DS triplicated kinase Dyrk1A; Xie et al., <xref ref-type="bibr" rid="B282">2008</xref>), chronic treatments with polyphenolic green tea extracts enriched in EGCG (De la Torre et al., <xref ref-type="bibr" rid="B68">2014</xref>; Catuara-Solarz et al., <xref ref-type="bibr" rid="B36">2015</xref>), the monoacylglycerol lipase inhibitor JZL184 (Lysenko et al., <xref ref-type="bibr" rid="B154">2014</xref>), the neuro-hormone Melatonin (Corrales et al., <xref ref-type="bibr" rid="B57">2013</xref>), the Sonic Hedgehog agonist SAG1.1 (Das et al., <xref ref-type="bibr" rid="B65">2013</xref>), the serotonin reuptake inhibitor Fluoxetine (Bianchi et al., <xref ref-type="bibr" rid="B26">2010b</xref>; Begenisic et al., <xref ref-type="bibr" rid="B11">2014</xref>; Guidi et al., <xref ref-type="bibr" rid="B97">2014</xref>), or also exposure to an enriched environment (EE; Begenisic et al., <xref ref-type="bibr" rid="B13">2011</xref>, <xref ref-type="bibr" rid="B12">2015</xref>). Nevertheless, most of these treatments are also known to directly or indirectly modulate the GABAergic system, while for others such link has not been established yet. For example, Ro25–6981 selectively reduced the activation of GABAergic interneurons in the Stratum Radiatum of the hippocampus (Hanson et al., <xref ref-type="bibr" rid="B103">2013</xref>), whereas JZL184 decreased GABAergic transmission by likely modulating presynaptic cannabinoid receptors (Katona et al., <xref ref-type="bibr" rid="B116">1999</xref>; Zhang et al., <xref ref-type="bibr" rid="B286">2009</xref>; Lee et al., <xref ref-type="bibr" rid="B137">2015</xref>). Instead, both treatment with Fluoxetine and exposure of Ts65Dn mice to EE showed beneficial effects on LTP and memory in Ts65Dn mice, possibly by reducing release from GABAergic terminals (Begenisic et al., <xref ref-type="bibr" rid="B13">2011</xref>, <xref ref-type="bibr" rid="B11">2014</xref>, <xref ref-type="bibr" rid="B12">2015</xref>). Indeed, Fluoxetine has been previously found to reduce GABAergic neurotransmission in the hippocampus independently from the inhibition of serotonin reuptake (Méndez et al., <xref ref-type="bibr" rid="B166">2012</xref>; Caiati and Cherubini, <xref ref-type="bibr" rid="B33">2013</xref>), and to decrease the levels of extracellular GABA <italic>in vivo</italic> (Maya Vetencourt et al., <xref ref-type="bibr" rid="B163">2008</xref>). Additionally, Fluoxetine may also inhibit GIRK channels (Kobayashi et al., <xref ref-type="bibr" rid="B127">2003</xref>; Cornelisse et al., <xref ref-type="bibr" rid="B56">2007</xref>), therefore possibly normalizing enhanced GABA<sub>B</sub>R signaling in Ts65Dn mice. In this regard, it is important to note that GIRK channels are also coupled to serotonin receptors 5-HT<sub>1A</sub> (Williams et al., <xref ref-type="bibr" rid="B274">1988</xref>; Llamosas et al., <xref ref-type="bibr" rid="B145">2015</xref>; Montalbano et al., <xref ref-type="bibr" rid="B171">2015</xref>) and GIRK2 triplication can therefore impact on serotoninergic signaling in DS. Indeed, stimulation of 5-HT<sub>1A</sub> receptors in the hippocampus can reduce neuronal firing frequency and gamma oscillations through GIRK channels activation (Johnston et al., <xref ref-type="bibr" rid="B111">2014</xref>). Since fluoxetine treatment reduces GIRK-mediated 5-HT<sub>1A</sub> and GABA<sub>B</sub> receptor signaling in the dorsal Raphe (Cornelisse et al., <xref ref-type="bibr" rid="B56">2007</xref>), this mechanism may be involved in the therapeutic effect of fluoxetine in Ts65Dn mice. However, a possible link between changes in serotonin signaling due to GIRK2 overexpression and the effects of fluoxetine on learning and memory has not been assessed in DS mice. On the other hand, chronic treatment with polyphenolic green tea extracts enriched in EGCG decreased the expression of the GABAergic synaptic markers GAD67 and VGAT in the cortex of Ts65Dn mice (Souchet et al., <xref ref-type="bibr" rid="B237">2015</xref>). Conversely, EGCG positively modulated GABA<sub>A</sub>-mediated transmission when administered acutely (Vignes et al., <xref ref-type="bibr" rid="B262">2006</xref>; Park et al., <xref ref-type="bibr" rid="B184">2011</xref>). Of note, a recently concluded clinical trial (TESDAD, NCT01699711) evaluating the efficacy of long-term green tea extract treatment on DS patients showed some behavioral improvements, although—as stated by the authors—below the threshold for clinical relevance in 2 out of 15 measured tests (de la Torre et al., <xref ref-type="bibr" rid="B69">2016</xref>). Finally, the positive effect of Melatonin is unlikely to depend on decreased GABAergic signaling because it acts as a <italic>positive</italic> allosteric modulator of GABA<sub>A</sub> receptors (Wang et al., <xref ref-type="bibr" rid="B266">2003</xref>; Scott et al., <xref ref-type="bibr" rid="B223">2010</xref>; Cheng et al., <xref ref-type="bibr" rid="B43">2012</xref>). Altogether, these data indicate that a number of the large plethora of effective drug treatments able to restore LTP and/or memory in Ts65Dn mice may rely on a common ground of action through the modulation of the GABAergic system.</p>
</sec>
<sec id="s8-2">
<title>Excitatory Deficits in DS</title>
<p>Altogether, the literature reported above indicates a key role for GABAergic signaling in neuronal network deficits in trisomic mice. However, deficits in excitatory inputs and glutamatergic transmission could also contribute to the imbalance in excitatory/inhibitory transmission in the trisomic brain. Indeed, several lines of evidence indicate delayed development and decreased production of excitatory glutamatergic neurons in the cortex (Chakrabarti et al., <xref ref-type="bibr" rid="B40">2007</xref>, <xref ref-type="bibr" rid="B39">2010</xref>; Tyler and Haydar, <xref ref-type="bibr" rid="B254">2013</xref>; Guidi et al., <xref ref-type="bibr" rid="B97">2014</xref>), DG (Lorenzi and Reeves, <xref ref-type="bibr" rid="B148">2006</xref>; Contestabile et al., <xref ref-type="bibr" rid="B54">2007</xref>; Bianchi et al., <xref ref-type="bibr" rid="B26">2010b</xref>) and cerebellum (Baxter et al., <xref ref-type="bibr" rid="B9">2000</xref>; Roper et al., <xref ref-type="bibr" rid="B206">2006</xref>; Contestabile et al., <xref ref-type="bibr" rid="B53">2009</xref>) of Ts65Dn mice. Accordingly, a decreased density of glutamatergic synapses was found in the cortex and hippocampus of Ts65Dn mice by electron microscopy and immunohistochemistry (Kurt et al., <xref ref-type="bibr" rid="B133">2000</xref>, <xref ref-type="bibr" rid="B132">2004</xref>; Chakrabarti et al., <xref ref-type="bibr" rid="B40">2007</xref>; Rueda et al., <xref ref-type="bibr" rid="B216">2010</xref>; Guidi et al., <xref ref-type="bibr" rid="B98">2013</xref>; Stagni et al., <xref ref-type="bibr" rid="B239">2013</xref>; García-Cerro et al., <xref ref-type="bibr" rid="B90">2014</xref>), as well as in human DS iPSCs-derived neurons (Weick et al., <xref ref-type="bibr" rid="B269">2013</xref>; Hibaoui et al., <xref ref-type="bibr" rid="B110">2014</xref>). However, <italic>in vivo</italic>
<sup>1</sup>H MRS evaluation of different metabolites and neurotransmitters in the Ts65Dn hippocampus showed no difference in the concentration of either GABA or glutamate (Santin et al., <xref ref-type="bibr" rid="B220">2015</xref>). Despite of the evidence supporting a possible decrease of excitatory inputs, few electrophysiological studies have functionally evaluated glutamatergic signaling in trisomic mice. Decreased frequency of miniature excitatory postsynaptic currents (mEPSC) was found in the CA3 hippocampal region (Hanson et al., <xref ref-type="bibr" rid="B102">2007</xref>; Stagni et al., <xref ref-type="bibr" rid="B239">2013</xref>), whereas a decreased ratio of postsynaptic NMDA/AMPA-evoked responses was found in the CA1 region of Ts65Dn mice (Das et al., <xref ref-type="bibr" rid="B65">2013</xref>). Interestingly, Ts65Dn mice show increased electrophysiological and behavioral response to pharmacological manipulations of NMDA receptors (Costa et al., <xref ref-type="bibr" rid="B62">2007</xref>; Scott-McKean and Costa, <xref ref-type="bibr" rid="B224">2011</xref>). Although a complete mechanistic explanation behind such effect will need further investigations (Costa, <xref ref-type="bibr" rid="B59">2014</xref>), inhibition of NMDA transmission with the noncompetitive antagonist Memantine rescued learning and memory performance in different behavioral tests both after acute and chronic administration in Ts65Dn mice (Costa et al., <xref ref-type="bibr" rid="B62">2007</xref>; Rueda et al., <xref ref-type="bibr" rid="B216">2010</xref>; Lockrow et al., <xref ref-type="bibr" rid="B146">2011</xref>). Following these studies, two clinical trials evaluated the efficacy of Memantine on improving cognitive functions in DS patients. Although the drug was well-tolerated, the results of the first study (NCT00240760) did not show any improvement on cognitive functions (Hanney et al., <xref ref-type="bibr" rid="B101">2012</xref>). However, a pitfall of this study may be represented by the advanced age of participants. Indeed, since DS patients are at increased risk of developing Alzheimer degeneration early in life, irreversible pathological and/or degenerative changes may have been already in place by the time of treatment (Costa, <xref ref-type="bibr" rid="B59">2014</xref>). A second trial (NCT01112683) on a relatively small number of young-adults with DS showed no significant difference in the primary outcome. However, some encouraging improvements were detected in a secondary measure of verbal memory (Boada et al., <xref ref-type="bibr" rid="B27">2012</xref>). Overall, the lack of a comprehensive assessment of glutamatergic functions in DS mouse models will require a more detailed investigation to clearly evaluate the involvement of glutamatergic signaling in excitatory/inhibitory imbalance in the trisomic brain.</p>
</sec>
<sec id="s8-3">
<title>GABA in Neurodevelopment and Critical Period Plasticity in DS</title>
<p>DS is widely recognized as a neurodevelopmental disorder since many (but not all) brain deficits originate during the embryonic and early life. Since activation of both GABA<sub>A</sub>R and GABA<sub>B</sub>R plays a key role in brain development (Gaiarsa and Porcher, <xref ref-type="bibr" rid="B88">2013</xref>; Le Magueresse and Monyer, <xref ref-type="bibr" rid="B136">2013</xref>), changes in ambient GABA (also due to increased number of GABAergic interneurons) may underline at least some of the brain alterations that originate during DS fetal life and persist into adulthood. Nevertheless, no study has so far addressed the role of aberrant GABAergic signaling in neural circuit formation in DS. In particular, it would be interesting to evaluate the timing of the depolarizing/hyperpolarizing GABA switch (Ben-Ari, <xref ref-type="bibr" rid="B19">2002</xref>) and related developmental changes in GABA<sub>A</sub>R-subunit expression (Succol et al., <xref ref-type="bibr" rid="B246">2012</xref>) in trisomic mice. On the other hand, GABA<sub>B</sub>R signaling may affect DS brain development by modulating adenylate cyclase and calcium channels. Triplication of GIRK2 is instead unlikely to directly contribute to GABA<sub>B</sub>-mediated early developmental DS brain alterations, as coupling of GABA<sub>B</sub>Rs with GIRK channels does not occur until the second postnatal week of life in rats (Fukuda et al., <xref ref-type="bibr" rid="B87">1993</xref>; López-Bendito et al., <xref ref-type="bibr" rid="B147">2003</xref>; Bony et al., <xref ref-type="bibr" rid="B29">2013</xref>). Nevertheless, the possibility of premature coupling of GABA<sub>B</sub>Rs to GIRK2 due its overexpression in DS may still exist.</p>
<p>Anyhow, future studies are also needed to investigate whether modulating GABAergic signaling and/or intracellular Cl<sup>−</sup> accumulation during specific developmental periods, when brain circuits are possibly more prone to plastic changes, may result in beneficial effects in learning and memory that persist into adulthood. In this regard, it would be interesting to test the long-term effects of GABA<sub>A</sub>R inhibition (i.e., PTZ or α5 negative allosteric modulator treatments) or of lowering [Cl<sup>−</sup>]<sub>i</sub> with Bumetanide during brain development. The importance of an early intervention during a likely essential period of brain development in DS is highlighted by the observation that different treatments (e.g., Fluoxetine, SAG1.1 and Choline) administered during gestation or in the early postnatal period rescued memory performances in Ts65Dn mice later in life (Bianchi et al., <xref ref-type="bibr" rid="B26">2010b</xref>; Moon et al., <xref ref-type="bibr" rid="B172">2010</xref>; Das et al., <xref ref-type="bibr" rid="B65">2013</xref>; Guidi et al., <xref ref-type="bibr" rid="B98">2013</xref>; Velazquez et al., <xref ref-type="bibr" rid="B256">2013</xref>; Ash et al., <xref ref-type="bibr" rid="B5">2014</xref>). Nevertheless, one important and apparently neglected aspect of early pharmacological interventions is related to possible side effects of drug treatment during development, which should in fact be carefully considered. Indeed, similarly to the beneficial effect of the drugs, adverse effects may persist into adulthood and may impact on the functionality of different organs or systems. A recent example came from the NEMO trail (NCT01434225) regarding the use of Bumetanide on newborns with hypoxic ischemic encephalopathy. Indeed, the trial was interrupted because of hearing loss adverse effect (Pressler et al., <xref ref-type="bibr" rid="B194">2015</xref>). Moreover, in light of the encouraging results obtained on Ts65Dn offsprings prenatally and perinatally treated with Fluoxetine (Bianchi et al., <xref ref-type="bibr" rid="B26">2010b</xref>; Guidi et al., <xref ref-type="bibr" rid="B97">2014</xref>), a clinical trial has been recently announced<xref ref-type="fn" rid="fn0004"><sup>4</sup></xref>, aimed at assessing the efficacy of Fluoxetine administration during the prenatal (2nd trimester) and postnatal (up to 2 years of age) periods in ameliorating the developmental abilities of children with DS. However, the dosage and timing of administration should be carefully considered in the light of the fact that Fluoxetine administration during pregnancy has been associated to birth defects (Reefhuis et al., <xref ref-type="bibr" rid="B199">2015</xref>), and treatment in adult patients increased seizure susceptibility (Pisani et al., <xref ref-type="bibr" rid="B189">1999</xref>). Moreover, Fluoxetine treatment in rodents during embryonic and early postnatal life modifies the migration of cortical GABAergic interneurons, and—later in life—increases aggression in males as well as changes emotional and social behaviors (Kiryanova et al., <xref ref-type="bibr" rid="B121">2013</xref>; Ko et al., <xref ref-type="bibr" rid="B125">2014</xref>; Frazer et al., <xref ref-type="bibr" rid="B85">2015</xref>; Svirsky et al., <xref ref-type="bibr" rid="B247">2016</xref>).</p>
<p>Aberrant GABAergic transmission may also affect the critical-period plasticity in the visual cortex. Interestingly, this critical-period plasticity depends on the depolarizing action of GABA during early development and its length can be extended by reducing depolarizing GABA<sub>A</sub> signaling by treatment with Bumetanide (Deidda et al., <xref ref-type="bibr" rid="B70">2015a</xref>). Therefore, an early intervention with Bumetanide may provide an extended window for neuronal plasticity in DS. Although no study has assessed critical-period plasticity in visual cortical circuits of trisomic animals, Ts65Dn mice show deficits in cortical visual evoked potentials (VEPs; Scott-McKean et al., <xref ref-type="bibr" rid="B225">2010</xref>). Interestingly, exposure to EE either during development or adulthood restored cortical VEP responses in Ts65Dn mice, possibly through modulation of GABAergic transmission (Begenisic et al., <xref ref-type="bibr" rid="B13">2011</xref>, <xref ref-type="bibr" rid="B12">2015</xref>).</p>
</sec>
<sec id="s8-4">
<title>GABA in Other DS Symptoms, Possibly Affecting Cognition</title>
<p>Besides cognitive impairments, individuals with DS present a number of other symptoms (i.e., epilepsy, sleep disorders and anxiety) that affect the quality of their lives and may in turn also impinge on their cognitive abilities (Pueschel et al., <xref ref-type="bibr" rid="B195">1991</xref>; Stafstrom et al., <xref ref-type="bibr" rid="B238">1991</xref>; Haw et al., <xref ref-type="bibr" rid="B106">1996</xref>; Carter et al., <xref ref-type="bibr" rid="B35">2009</xref>; Lott and Dierssen, <xref ref-type="bibr" rid="B149">2010</xref>; Breslin et al., <xref ref-type="bibr" rid="B32">2011</xref>; Rissman and Mobley, <xref ref-type="bibr" rid="B203">2011</xref>; Vicari et al., <xref ref-type="bibr" rid="B261">2013</xref>; Angriman et al., <xref ref-type="bibr" rid="B2">2015</xref>; Edgin et al., <xref ref-type="bibr" rid="B76">2015</xref>; Robertson et al., <xref ref-type="bibr" rid="B205">2015</xref>; Konstantinopoulou et al., <xref ref-type="bibr" rid="B129">2016</xref>; Maris et al., <xref ref-type="bibr" rid="B160">2016</xref>). Interestingly, epilepsy, sleep disorders and anxiety have all been associated to defective GABAergic transmission (Wagner et al., <xref ref-type="bibr" rid="B264">1997</xref>; Choi et al., <xref ref-type="bibr" rid="B46">2008</xref>; Rudolph and Knoflach, <xref ref-type="bibr" rid="B213">2011</xref>; Möhler, <xref ref-type="bibr" rid="B168">2012</xref>; Kaila et al., <xref ref-type="bibr" rid="B115">2014b</xref>).</p>
<p>DS patients and Ts65Dn mice demonstrate increased incidence of epileptic seizures (Stafstrom et al., <xref ref-type="bibr" rid="B238">1991</xref>; Westmark et al., <xref ref-type="bibr" rid="B270">2010</xref>; Rissman and Mobley, <xref ref-type="bibr" rid="B203">2011</xref>; Lott, <xref ref-type="bibr" rid="B150">2012</xref>; Robertson et al., <xref ref-type="bibr" rid="B205">2015</xref>). These observations appeared contradictory when considering that increased GABA signaling in Ts65Dn mice was expected to overall decrease neuronal network activity, and therefore reduce incidence of seizures. However, the increased incidence of seizures is in line with depolarizing GABA<sub>A</sub> signaling in DS, because the shift in GABA<sub>A</sub>R-mediated responses will also clearly impact on the excitatory/inhibitory balance and promote brain neuronal circuit hyperexcitability. Interestingly, administration of γ-butyrolactone (GBL, a prodrug for the GABA<sub>B</sub>R agonist γ-hydroxybutyrate: GHB) induced epileptiform activity in Ts65Dn mice that was rescued by genetically restoring GIRK2 gene dosage to disomy (Cortez et al., <xref ref-type="bibr" rid="B58">2009</xref>; Joshi et al., <xref ref-type="bibr" rid="B113">2016</xref>). Although the general molecular mechanism of GHB action is still matter of debate (Bay et al., <xref ref-type="bibr" rid="B10">2014</xref>; Venzi et al., <xref ref-type="bibr" rid="B257">2015</xref>), it is intriguing to speculate that, in the scenario of GABA dysregulation in DS, both the GABA<sub>B</sub>R-GIRK2 signaling and depolarizing GABA<sub>A</sub> signaling may play a role in GBL-induced epileptic phenotype seen in Ts65Dn mice. Indeed, GHB would further increase the already enhanced GIRK2-mediated signaling, thus abnormally drifting <italic>V</italic><sub>REST</sub> towards hyperpolarization. This condition would emphasize the depolarizing GABA<sub>A</sub> signaling, with amplification of all depolarizing inputs and consequent trigger of epileptic activity. On the other hand, Ts65Dn mice also show increased incidence of audiogenic seizure that can be reduced by treatment with the metabotropic glutamate receptor subtype mGluR<sub>5</sub> antagonist Fenobam (Westmark et al., <xref ref-type="bibr" rid="B270">2010</xref>), but not by inhibition of NKCC1 with Bumetanide (Deidda et al., <xref ref-type="bibr" rid="B72">2015b</xref>). Moreover, also the characteristic hyperactivity of Ts65Dn mice (Escorihuela et al., <xref ref-type="bibr" rid="B77">1995</xref>; Reeves et al., <xref ref-type="bibr" rid="B200">1995</xref>; Sago et al., <xref ref-type="bibr" rid="B219">2000</xref>) was reduced by the α<sub>5</sub>-containing GABA<sub>A</sub>R negative modulator RO4938581 (Martínez-Cué et al., <xref ref-type="bibr" rid="B161">2013</xref>), but not by Bumetanide treatment (Deidda et al., <xref ref-type="bibr" rid="B72">2015b</xref>). These observations indicate that more complex mechanisms in addition to altered GABA signaling may underline these increased seizure susceptibility and hyperactive phenotypes in Ts65Dn mice.</p>
<p>DS patients have also higher incidence of sleep disturbance in relation to the general population (Carter et al., <xref ref-type="bibr" rid="B35">2009</xref>; Breslin et al., <xref ref-type="bibr" rid="B32">2011</xref>; Edgin et al., <xref ref-type="bibr" rid="B76">2015</xref>; Konstantinopoulou et al., <xref ref-type="bibr" rid="B129">2016</xref>; Maris et al., <xref ref-type="bibr" rid="B160">2016</xref>), and Ts65Dn mice show some sleep alterations mainly consisting in increased awaking and higher theta power in sleep EEG (Colas et al., <xref ref-type="bibr" rid="B50">2008</xref>). On the other hand, Ts65Dn mice show little or no differences in circadian rhythms, which are not altered by PTZ treatment (Stewart et al., <xref ref-type="bibr" rid="B245">2007</xref>; Ruby et al., <xref ref-type="bibr" rid="B211">2010</xref>). Nevertheless, it is striking the observation that PTZ was effective in restoring memory performances in Ts65Dn mice only when it was administrated during the light phase of the day, but not during the dark phase, indicating a possible different circadian contribution of the GABAergic system on learning and memory in DS (Colas et al., <xref ref-type="bibr" rid="B49">2013</xref>). Given the recently identified connection between GABA signaling and memory in circadian arrhythmic animals (Ruby et al., <xref ref-type="bibr" rid="B212">2008</xref>, <xref ref-type="bibr" rid="B210">2013</xref>), more studies are needed to uncover this possible relationship in DS. Since GABA<sub>A</sub> signaling (and possibly Cl<sup>−</sup> homeostasis) has been repeatedly described as a key regulator of sleep and circadian rhythms (Wagner et al., <xref ref-type="bibr" rid="B264">1997</xref>; Choi et al., <xref ref-type="bibr" rid="B46">2008</xref>), it is possible that alterations of GABA signaling and/or expression of NKCC1 may play a role in sleep disorders in DS.</p>
<p>Finally, the strong involvement of GABA<sub>A</sub> signaling in anxiety disorders (Rudolph and Knoflach, <xref ref-type="bibr" rid="B213">2011</xref>; Möhler, <xref ref-type="bibr" rid="B168">2012</xref>) and the observation that DS patients show increased anxiety (Vicari et al., <xref ref-type="bibr" rid="B261">2013</xref>) may indicate that also this aspect possibly originates, at least in part, from the alteration of GABA<sub>A</sub> signaling. However, this issue has not been addressed yet in DS mice. On the other hand, since GIRK2 knockout mice show reduced anxiety-related behavior (Pravetoni and Wickman, <xref ref-type="bibr" rid="B193">2008</xref>) but GABA<sub>B</sub>R knockout mice show an anxious phenotype (Mombereau et al., <xref ref-type="bibr" rid="B170">2005</xref>), coupling of GIRK channels to metabotropic neurotransmitter receptor systems other than GABA<sub>B</sub>Rs may play a role in regulating anxiety-related behaviors in DS. For example the overexpression of GIRK2 in the midbrain of Ts65Dn mice (Harashima et al., <xref ref-type="bibr" rid="B104">2006</xref>) may modulate signal transduction of dopamine receptors (Perez et al., <xref ref-type="bibr" rid="B186">2006</xref>; Podda et al., <xref ref-type="bibr" rid="B190">2010</xref>; Marcott et al., <xref ref-type="bibr" rid="B158">2014</xref>; Zhao et al., <xref ref-type="bibr" rid="B287">2016</xref>) and impact on different DS phenotypes including anxiety-related symptoms (Sim et al., <xref ref-type="bibr" rid="B233">2013</xref>). Finally, a possible role for altered GABAergic transmission in impaired adult neurogenesis (Song et al., <xref ref-type="bibr" rid="B236">2012</xref>; Pallotto and Deprez, <xref ref-type="bibr" rid="B182">2014</xref>) and AD (Li et al., <xref ref-type="bibr" rid="B143">2016</xref>)-which both eventually result in impaired cognition- is still an unexplored field of research in DS (Rissman and Mobley, <xref ref-type="bibr" rid="B203">2011</xref>).</p>
</sec>
</sec>
<sec id="s9">
<title>Concluding Remarks</title>
<p>The genetic cause of DS has been unequivocally identified in the triplication of genes located on the human chromosome 21, although the exact group of genes and the pathological mechanisms underlying DS intellectual disability are still unclear. Despite of the limitations in reproducing in mice the exact genetic condition characterizing DS human pathology, the creation of DS mouse models with construct and face validity has been giving nevertheless a wide contribution in understanding gene-phenotype association, DS pathological processes, and in extending therapeutic prospects. Here, we evaluated the evidence pointing at a role for abnormal signaling from GABA<sub>A</sub> and GABA<sub>B</sub> receptors in the neuronal defects associated with DS, and we considered particularly the Ts65Dn mouse model of DS, one of the most largely used. The origin of defective GABAergic transmission tracks back into early neurodevelopment, with possible excitatory/inhibitory unbalance and neuronal and plasticity impairments that persist into adulthood. However, the weight of the GABAergic inhibitory vs. the glutamatergic excitatory transmission in this unbalance is still unclear. Indeed, depolarizing GABA<sub>A</sub> signaling coexists with glutamatergic excitatory alterations in Ts65Dn mice, and excitatory/inhibitory unbalance appears to be brain-region specific in DS mouse models. Moreover, possible decreased GABAergic transmission in human DS patients may seem to be discordant with the increased GABAergic transmission in Ts65Dn mice, although to date, human data are still scarce and inconclusive. Fortunately, the recent advances in the use of human-derived iPSCs may give a large contribution in the future understanding of DS neuropathology, with higher translational viability. Indeed, whether the failure of the CLEMATIS trial and limited positive results from other clinical studies can be ascribed to inefficacy of the drugs (despite the strong preclinical data), a low predictive potential of the Ts65Dn mouse model may also have played a role. For example, changes in GABA<sub>A</sub>R subunit composition specific for human DS (Bhattacharyya et al., <xref ref-type="bibr" rid="B24">2009</xref>), but lacking in Ts65Dn mice, could account for the failure of pharmacological treatments with a α<sub>5</sub> selective antagonist in individuals with DS. Since the “perfect” mouse model does not exist yet, it will be worth for the future to assess the efficacy of each new pharmacological treatment in more than one DS mouse model, and promote parallel human and animal studies. On the other hand, the failures of clinical trials may also rest in the inadequacy of current neuropsychological tests in measuring cognitive improvements in DS (Gardiner, <xref ref-type="bibr" rid="B92">2010</xref>, <xref ref-type="bibr" rid="B93">2014</xref>; Fernandez and Edgin, <xref ref-type="bibr" rid="B79">2016</xref>). Indeed, cognitive performance measured by tests are mostly dependent by the integration of different cognitive domains, thus the selective improvement of one of them may not be detected; on the other hand, an improvement in neuropsychological tests may not imply a perceived substantial improvement in the daily life.</p>
<p>In conclusion, the data reported above clearly highlight the multifaceted nature of DS brain abnormalities. These alterations represent the sum of different molecular mechanisms that most likely include impaired GABAergic transmission. Possibly, these abnormalities originate (at least in part) during development and lead to complex synaptic, physiological and circuit changes, ultimately causing cognitive deficits and other neurological manifestations. As a consequence, the still unmet need of identifying effective pharmacological interventions to alleviate DS-related cognitive impairment represents an incredible complex challenge for the future. Surely, the insights about GABA-related impairments in DS models may be of great relevance also for other neurodevelopmental disorders where defective GABAergic transmission (including depolarizing GABA<sub>A</sub> signaling) may play a pathological role (e.g., Autism, Fragile X syndrome, epilepsy, and possibly Rett syndrome; Cellot and Cherubini, <xref ref-type="bibr" rid="B38">2014</xref>; Deidda et al., <xref ref-type="bibr" rid="B71">2014</xref>; He et al., <xref ref-type="bibr" rid="B107">2014</xref>; Khazipov et al., <xref ref-type="bibr" rid="B118">2015</xref>).</p>
</sec>
<sec id="s10">
<title>Author Contributions</title>
<p>AC, SM and LC contributed to the conception and writing of the manuscript.</p>
</sec>
<sec id="s11">
<title>Funding</title>
<p>This work was supported by Jérôme Lejeune Foundation (grants 254-CA2014A to AC, and 1266_CL2014A to LC) and Telethon Foundation (grants GGP15043 to AC and GGP13187, TCP15021 to LC).</p>
</sec>
<sec id="s12">
<title>Conflict of Interest Statement</title>
<p>AC and LC are named as co-inventors on International Patent Application PCT/EP2014/078561, filed on December 18, 2014, and connected US, EP, JP National Phase Applications, claiming priority to US Provisional Application US 61/919,195, priority date December 20, 2013. The other author SM declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<fn-group>
<fn id="fn0001">
<p>
<sup>1</sup>
<ext-link ext-link-type="uri" xlink:href="http://vega.sanger.ac.uk">http://vega.sanger.ac.uk</ext-link>
</p>
</fn>
<fn id="fn0002">
<p>
<sup>2</sup>
<ext-link ext-link-type="uri" xlink:href="http://www.anzctr.org.au">http://www.anzctr.org.au</ext-link>
</p>
</fn>
<fn id="fn0003">
<p>
<sup>3</sup>
<ext-link ext-link-type="uri" xlink:href="http://www.roche.com/media/store/statements.htm">http://www.roche.com/media/store/statements.htm</ext-link>
</p>
</fn>
<fn id="fn0004">
<p>
<sup>4</sup>
<ext-link ext-link-type="uri" xlink:href="http://www.utsouthwestern.edu/research/fact/detail.html?studyid=STU%20032014-006">http://www.utsouthwestern.edu/research/fact/detail.html?studyid=STU%20032014-006</ext-link>
</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>P.</given-names></name><name><surname>Dingledine</surname><given-names>R.</given-names></name><name><surname>Gjerstad</surname><given-names>L.</given-names></name><name><surname>Langmoen</surname><given-names>I. A.</given-names></name><name><surname>Laursen</surname><given-names>A. M.</given-names></name></person-group> (<year>1980</year>). <article-title>Two different responses of hippocampal pyramidal cells to application of gamma-amino butyric acid</article-title>. <source/>J. Physiol.
<volume>305</volume>, <fpage>279</fpage>–<lpage>296</lpage>. <pub-id pub-id-type="doi">10.1113/jphysiol.1980.sp013363</pub-id><pub-id pub-id-type="pmid">7441554</pub-id></mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angriman</surname><given-names>M.</given-names></name><name><surname>Caravale</surname><given-names>B.</given-names></name><name><surname>Novelli</surname><given-names>L.</given-names></name><name><surname>Ferri</surname><given-names>R.</given-names></name><name><surname>Bruni</surname><given-names>O.</given-names></name></person-group> (<year>2015</year>). <article-title>Sleep in children with neurodevelopmental disabilities</article-title>. <source/>Neuropediatrics
<volume>46</volume>, <fpage>199</fpage>–<lpage>210</lpage>. <pub-id pub-id-type="doi">10.1055/s-0035-1550151</pub-id><pub-id pub-id-type="pmid">25918987</pub-id></mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonarakis</surname><given-names>E. S.</given-names></name><name><surname>Epstein</surname><given-names>C. J.</given-names></name></person-group> (<year>2006</year>). <article-title>The challenge of Down syndrome</article-title>. <source/>Trends Mol. Med.
<volume>12</volume>, <fpage>473</fpage>–<lpage>479</lpage>. <pub-id pub-id-type="doi">10.1016/j.molmed.2006.08.005</pub-id><pub-id pub-id-type="pmid">16935027</pub-id></mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonarakis</surname><given-names>S. E.</given-names></name><name><surname>Lyle</surname><given-names>R.</given-names></name><name><surname>Dermitzakis</surname><given-names>E. T.</given-names></name><name><surname>Reymond</surname><given-names>A.</given-names></name><name><surname>Deutsch</surname><given-names>S.</given-names></name></person-group> (<year>2004</year>). <article-title>Chromosome 21 and Down syndrome: from genomics to pathophysiology</article-title>. <source/>Nat. Rev. Genet.
<volume>5</volume>, <fpage>725</fpage>–<lpage>738</lpage>. <pub-id pub-id-type="doi">10.1038/nrg1448</pub-id><pub-id pub-id-type="pmid">15510164</pub-id></mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ash</surname><given-names>J. A.</given-names></name><name><surname>Velazquez</surname><given-names>R.</given-names></name><name><surname>Kelley</surname><given-names>C. M.</given-names></name><name><surname>Powers</surname><given-names>B. E.</given-names></name><name><surname>Ginsberg</surname><given-names>S. D.</given-names></name><name><surname>Mufson</surname><given-names>E. J.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Maternal choline supplementation improves spatial mapping and increases basal forebrain cholinergic neuron number and size in aged Ts65Dn mice</article-title>. <source/>Neurobiol. Dis.
<volume>70</volume>, <fpage>32</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2014.06.001</pub-id><pub-id pub-id-type="pmid">24932939</pub-id></mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aylward</surname><given-names>E. H.</given-names></name><name><surname>Habbak</surname><given-names>R.</given-names></name><name><surname>Warren</surname><given-names>A. C.</given-names></name><name><surname>Pulsifer</surname><given-names>M. B.</given-names></name><name><surname>Barta</surname><given-names>P. E.</given-names></name><name><surname>Jerram</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>1997</year>). <article-title>Cerebellar volume in adults with Down syndrome</article-title>. <source/>Arch. Neurol.
<volume>54</volume>, <fpage>209</fpage>–<lpage>212</lpage>. <pub-id pub-id-type="doi">10.1001/archneur.1997.00550140077016</pub-id><pub-id pub-id-type="pmid">9041863</pub-id></mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aylward</surname><given-names>E. H.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Honeycutt</surname><given-names>N. A.</given-names></name><name><surname>Warren</surname><given-names>A. C.</given-names></name><name><surname>Pulsifer</surname><given-names>M. B.</given-names></name><name><surname>Barta</surname><given-names>P. E.</given-names></name><etal></etal></person-group>. (<year>1999</year>). <article-title>MRI volumes of the hippocampus and amygdala in adults with Down’s syndrome with and without dementia</article-title>. <source/>Am. J. Psychiatry
<volume>156</volume>, <fpage>564</fpage>–<lpage>568</lpage>. <pub-id pub-id-type="doi">10.1176/ajp.156.4.564</pub-id><pub-id pub-id-type="pmid">10200735</pub-id></mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballard</surname><given-names>T. M.</given-names></name><name><surname>Knoflach</surname><given-names>F.</given-names></name><name><surname>Prinssen</surname><given-names>E.</given-names></name><name><surname>Borroni</surname><given-names>E.</given-names></name><name><surname>Vivian</surname><given-names>J. A.</given-names></name><name><surname>Basile</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>RO4938581, a novel cognitive enhancer acting at GABA<sub>A</sub> α5 subunit-containing receptors</article-title>. <source/>Psychopharmacology
<volume>202</volume>, <fpage>207</fpage>–<lpage>223</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-008-1357-7</pub-id><pub-id pub-id-type="pmid">18936916</pub-id></mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baxter</surname><given-names>L. L.</given-names></name><name><surname>Moran</surname><given-names>T. H.</given-names></name><name><surname>Richtsmeier</surname><given-names>J. T.</given-names></name><name><surname>Troncoso</surname><given-names>J.</given-names></name><name><surname>Reeves</surname><given-names>R. H.</given-names></name></person-group> (<year>2000</year>). <article-title>Discovery and genetic localization of Down syndrome cerebellar phenotypes using the Ts65Dn mouse</article-title>. <source/>Hum. Mol. Genet.
<volume>9</volume>, <fpage>195</fpage>–<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/9.2.195</pub-id><pub-id pub-id-type="pmid">10607830</pub-id></mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bay</surname><given-names>T.</given-names></name><name><surname>Eghorn</surname><given-names>L. F.</given-names></name><name><surname>Klein</surname><given-names>A. B.</given-names></name><name><surname>Wellendorph</surname><given-names>P.</given-names></name></person-group> (<year>2014</year>). <article-title>GHB receptor targets in the CNS: focus on high-affinity binding sites</article-title>. <source/>Biochem. Pharmacol.
<volume>87</volume>, <fpage>220</fpage>–<lpage>228</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2013.10.028</pub-id><pub-id pub-id-type="pmid">24269284</pub-id></mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Begenisic</surname><given-names>T.</given-names></name><name><surname>Baroncelli</surname><given-names>L.</given-names></name><name><surname>Sansevero</surname><given-names>G.</given-names></name><name><surname>Milanese</surname><given-names>M.</given-names></name><name><surname>Bonifacino</surname><given-names>T.</given-names></name><name><surname>Bonanno</surname><given-names>G.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Fluoxetine in adulthood normalizes GABA release and rescues hippocampal synaptic plasticity and spatial memory in a mouse model of Down syndrome</article-title>. <source/>Neurobiol. Dis.
<volume>63</volume>, <fpage>12</fpage>–<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2013.11.010</pub-id><pub-id pub-id-type="pmid">24269730</pub-id></mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Begenisic</surname><given-names>T.</given-names></name><name><surname>Sansevero</surname><given-names>G.</given-names></name><name><surname>Baroncelli</surname><given-names>L.</given-names></name><name><surname>Cioni</surname><given-names>G.</given-names></name><name><surname>Sale</surname><given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>Early environmental therapy rescues brain development in a mouse model of Down syndrome</article-title>. <source/>Neurobiol. Dis.
<volume>82</volume>, <fpage>409</fpage>–<lpage>419</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2015.07.014</pub-id><pub-id pub-id-type="pmid">26244989</pub-id></mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Begenisic</surname><given-names>T.</given-names></name><name><surname>Spolidoro</surname><given-names>M.</given-names></name><name><surname>Braschi</surname><given-names>C.</given-names></name><name><surname>Baroncelli</surname><given-names>L.</given-names></name><name><surname>Milanese</surname><given-names>M.</given-names></name><name><surname>Pietra</surname><given-names>G.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Environmental enrichment decreases GABAergic inhibition and improves cognitive abilities, synaptic plasticity, and visual functions in a mouse model of Down syndrome</article-title>. <source/>Front. Cell. Neurosci.
<volume>5</volume>:<fpage>29</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2011.00029</pub-id><pub-id pub-id-type="pmid">22207837</pub-id></mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belichenko</surname><given-names>N. P.</given-names></name><name><surname>Belichenko</surname><given-names>P. V.</given-names></name><name><surname>Kleschevnikov</surname><given-names>A. M.</given-names></name><name><surname>Salehi</surname><given-names>A.</given-names></name><name><surname>Reeves</surname><given-names>R. H.</given-names></name><name><surname>Mobley</surname><given-names>W. C.</given-names></name></person-group> (<year>2009</year>). <article-title>The “Down syndrome critical region” is sufficient in the mouse model to confer behavioral, neurophysiological and synaptic phenotypes characteristic of down syndrome</article-title>. <source/>J. Neurosci.
<volume>29</volume>, <fpage>5938</fpage>–<lpage>5948</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1547-09.2009</pub-id><pub-id pub-id-type="pmid">19420260</pub-id></mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belichenko</surname><given-names>P. V.</given-names></name><name><surname>Kleschevnikov</surname><given-names>A. M.</given-names></name><name><surname>Becker</surname><given-names>A.</given-names></name><name><surname>Wagner</surname><given-names>G. E.</given-names></name><name><surname>Lysenko</surname><given-names>L. V.</given-names></name><name><surname>Yu</surname><given-names>E. Y.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Down syndrome cognitive phenotypes modeled in mice trisomic for all HSA 21 homologues</article-title>. <source/>PLoS One
<volume>10</volume>:<fpage>e0134861</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0134861</pub-id><pub-id pub-id-type="pmid">26230397</pub-id></mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belichenko</surname><given-names>P. V.</given-names></name><name><surname>Kleschevnikov</surname><given-names>A. M.</given-names></name><name><surname>Masliah</surname><given-names>E.</given-names></name><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Takimoto-Kimura</surname><given-names>R.</given-names></name><name><surname>Salehi</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of Down syndrome</article-title>. <source/>J. Comp. Neurol.
<volume>512</volume>, <fpage>453</fpage>–<lpage>466</lpage>. <pub-id pub-id-type="doi">10.1002/cne.21895</pub-id><pub-id pub-id-type="pmid">19034952</pub-id></mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belichenko</surname><given-names>P. V.</given-names></name><name><surname>Kleschevnikov</surname><given-names>A. M.</given-names></name><name><surname>Salehi</surname><given-names>A.</given-names></name><name><surname>Epstein</surname><given-names>C. J.</given-names></name><name><surname>Mobley</surname><given-names>W. C.</given-names></name></person-group> (<year>2007</year>). <article-title>Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotype-phenotype relationships</article-title>. <source/>J. Comp. Neurol.
<volume>504</volume>, <fpage>329</fpage>–<lpage>345</lpage>. <pub-id pub-id-type="doi">10.1002/cne.21433</pub-id><pub-id pub-id-type="pmid">17663443</pub-id></mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belichenko</surname><given-names>P. V.</given-names></name><name><surname>Masliah</surname><given-names>E.</given-names></name><name><surname>Kleschevnikov</surname><given-names>A. M.</given-names></name><name><surname>Villar</surname><given-names>A. J.</given-names></name><name><surname>Epstein</surname><given-names>C. J.</given-names></name><name><surname>Salehi</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2004</year>). <article-title>Synaptic structural abnormalities in the Ts65Dn mouse model of Down syndrome</article-title>. <source/>J. Comp. Neurol.
<volume>480</volume>, <fpage>281</fpage>–<lpage>298</lpage>. <pub-id pub-id-type="doi">10.1002/cne.20337</pub-id><pub-id pub-id-type="pmid">15515178</pub-id></mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben-Ari</surname><given-names>Y.</given-names></name></person-group> (<year>2002</year>). <article-title>Excitatory actions of gaba during development: the nature of the nurture</article-title>. <source/>Nat. Rev. Neurosci.
<volume>3</volume>, <fpage>728</fpage>–<lpage>739</lpage>. <pub-id pub-id-type="doi">10.1038/nrn920</pub-id><pub-id pub-id-type="pmid">12209121</pub-id></mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben-Ari</surname><given-names>Y.</given-names></name><name><surname>Gaiarsa</surname><given-names>J. L.</given-names></name><name><surname>Tyzio</surname><given-names>R.</given-names></name><name><surname>Khazipov</surname><given-names>R.</given-names></name></person-group> (<year>2007</year>). <article-title>GABA: a pioneer transmitter that excites immature neurons and generates primitive oscillations</article-title>. <source/>Physiol. Rev.
<volume>87</volume>, <fpage>1215</fpage>–<lpage>1284</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00017.2006</pub-id><pub-id pub-id-type="pmid">17928584</pub-id></mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Best</surname><given-names>T. K.</given-names></name><name><surname>Cramer</surname><given-names>N. P.</given-names></name><name><surname>Chakrabarti</surname><given-names>L.</given-names></name><name><surname>Haydar</surname><given-names>T. F.</given-names></name><name><surname>Galdzicki</surname><given-names>Z.</given-names></name></person-group> (<year>2012</year>). <article-title>Dysfunctional hippocampal inhibition in the Ts65Dn mouse model of Down syndrome</article-title>. <source/>Exp. Neurol.
<volume>233</volume>, <fpage>749</fpage>–<lpage>757</lpage>. <pub-id pub-id-type="doi">10.1016/j.expneurol.2011.11.033</pub-id><pub-id pub-id-type="pmid">22178330</pub-id></mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Best</surname><given-names>T. K.</given-names></name><name><surname>Siarey</surname><given-names>R. J.</given-names></name><name><surname>Galdzicki</surname><given-names>Z.</given-names></name></person-group> (<year>2007</year>). <article-title>Ts65Dn, a mouse model of Down syndrome, exhibits increased GABA<sub>B</sub>-induced potassium current</article-title>. <source/>J. Neurophysiol.
<volume>97</volume>, <fpage>892</fpage>–<lpage>900</lpage>. <pub-id pub-id-type="doi">10.1152/jn.00626.2006</pub-id><pub-id pub-id-type="pmid">17093127</pub-id></mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bettler</surname><given-names>B.</given-names></name><name><surname>Kaupmann</surname><given-names>K.</given-names></name><name><surname>Mosbacher</surname><given-names>J.</given-names></name><name><surname>Gassmann</surname><given-names>M.</given-names></name></person-group> (<year>2004</year>). <article-title>Molecular structure and physiological functions of GABA<sub>B</sub>receptors</article-title>. <source/>Physiol. Rev.
<volume>84</volume>, <fpage>835</fpage>–<lpage>867</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00036.2003</pub-id><pub-id pub-id-type="pmid">15269338</pub-id></mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharyya</surname><given-names>A.</given-names></name><name><surname>McMillan</surname><given-names>E.</given-names></name><name><surname>Chen</surname><given-names>S. I.</given-names></name><name><surname>Wallace</surname><given-names>K.</given-names></name><name><surname>Svendsen</surname><given-names>C. N.</given-names></name></person-group> (<year>2009</year>). <article-title>A critical period in cortical interneuron neurogenesis in down syndrome revealed by human neural progenitor cells</article-title>. <source/>Dev. Neurosci.
<volume>31</volume>, <fpage>497</fpage>–<lpage>510</lpage>. <pub-id pub-id-type="doi">10.1159/000236899</pub-id><pub-id pub-id-type="pmid">19738365</pub-id></mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bianchi</surname><given-names>P.</given-names></name><name><surname>Ciani</surname><given-names>E.</given-names></name><name><surname>Contestabile</surname><given-names>A.</given-names></name><name><surname>Guidi</surname><given-names>S.</given-names></name><name><surname>Bartesaghi</surname><given-names>R.</given-names></name></person-group> (<year>2010a</year>). <article-title>Lithium restores neurogenesis in the subventricular zone of the Ts65Dn mouse, a model for Down syndrome</article-title>. <source/>Brain Pathol.
<volume>20</volume>, <fpage>106</fpage>–<lpage>118</lpage>. <pub-id pub-id-type="doi">10.1111/j.1750-3639.2008.00246.x</pub-id><pub-id pub-id-type="pmid">19298631</pub-id></mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bianchi</surname><given-names>P.</given-names></name><name><surname>Ciani</surname><given-names>E.</given-names></name><name><surname>Guidi</surname><given-names>S.</given-names></name><name><surname>Trazzi</surname><given-names>S.</given-names></name><name><surname>Felice</surname><given-names>D.</given-names></name><name><surname>Grossi</surname><given-names>G.</given-names></name><etal></etal></person-group>. (<year>2010b</year>). <article-title>Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome</article-title>. <source/>J. Neurosci.
<volume>30</volume>, <fpage>8769</fpage>–<lpage>8779</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0534-10.2010</pub-id><pub-id pub-id-type="pmid">20592198</pub-id></mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boada</surname><given-names>R.</given-names></name><name><surname>Hutaff-Lee</surname><given-names>C.</given-names></name><name><surname>Schrader</surname><given-names>A.</given-names></name><name><surname>Weitzenkamp</surname><given-names>D.</given-names></name><name><surname>Benke</surname><given-names>T. A.</given-names></name><name><surname>Goldson</surname><given-names>E. J.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial</article-title>. <source/>Transl. Psychiatry
<volume>2</volume>:<fpage>e141</fpage>. <pub-id pub-id-type="doi">10.1038/tp.2012.66</pub-id><pub-id pub-id-type="pmid">22806212</pub-id></mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Böhme</surname><given-names>I.</given-names></name><name><surname>Rabe</surname><given-names>H.</given-names></name><name><surname>Lüddens</surname><given-names>H.</given-names></name></person-group> (<year>2004</year>). <article-title>Four amino acids in the αsubunits determine the γ-aminobutyric acid sensitivities of GABA<sub>A</sub> receptor subtypes</article-title>. <source/>J. Biol. Chem.
<volume>279</volume>, <fpage>35193</fpage>–<lpage>35200</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.m405653200</pub-id><pub-id pub-id-type="pmid">15199051</pub-id></mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bony</surname><given-names>G.</given-names></name><name><surname>Szczurkowska</surname><given-names>J.</given-names></name><name><surname>Tamagno</surname><given-names>I.</given-names></name><name><surname>Shelly</surname><given-names>M.</given-names></name><name><surname>Contestabile</surname><given-names>A.</given-names></name><name><surname>Cancedda</surname><given-names>L.</given-names></name></person-group> (<year>2013</year>). <article-title>Non-hyperpolarizing GABA<sub>B</sub> receptor activation regulates neuronal migration and neurite growth and specification by cAMP/LKB1</article-title>. <source/>Nat. Commun.
<volume>4</volume>:<fpage>1800</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms2820</pub-id><pub-id pub-id-type="pmid">23653212</pub-id></mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braudeau</surname><given-names>J.</given-names></name><name><surname>Dauphinot</surname><given-names>L.</given-names></name><name><surname>Duchon</surname><given-names>A.</given-names></name><name><surname>Loistron</surname><given-names>A.</given-names></name><name><surname>Dodd</surname><given-names>R. H.</given-names></name><name><surname>Hérault</surname><given-names>Y.</given-names></name><etal></etal></person-group>. (<year>2011a</year>). <article-title>Chronic treatment with a promnesiant GABA-A α5-selective inverse agonist increases immediate early genes expression during memory processing in mice and rectifies their expression levels in a Down Syndrome mouse model</article-title>. <source/>Adv. Pharmacol. Sci.
<volume>2011</volume>:<fpage>153218</fpage>. <pub-id pub-id-type="doi">10.1155/2011/153218</pub-id><pub-id pub-id-type="pmid">22028705</pub-id></mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braudeau</surname><given-names>J.</given-names></name><name><surname>Delatour</surname><given-names>B.</given-names></name><name><surname>Duchon</surname><given-names>A.</given-names></name><name><surname>Pereira</surname><given-names>P. L.</given-names></name><name><surname>Dauphinot</surname><given-names>L.</given-names></name><name><surname>De Chaumont</surname><given-names>F.</given-names></name><etal></etal></person-group>. (<year>2011b</year>). <article-title>Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice</article-title>. <source/>J. Psychopharmacol.
<volume>25</volume>, <fpage>1030</fpage>–<lpage>1042</lpage>. <pub-id pub-id-type="doi">10.1177/0269881111405366</pub-id><pub-id pub-id-type="pmid">21693554</pub-id></mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breslin</surname><given-names>J. H.</given-names></name><name><surname>Edgin</surname><given-names>J. O.</given-names></name><name><surname>Bootzin</surname><given-names>R. R.</given-names></name><name><surname>Goodwin</surname><given-names>J. L.</given-names></name><name><surname>Nadel</surname><given-names>L.</given-names></name></person-group> (<year>2011</year>). <article-title>Parental report of sleep problems in Down syndrome</article-title>. <source/>J. Intellect. Disabil. Res.
<volume>55</volume>, <fpage>1086</fpage>–<lpage>1091</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2788.2011.01435.x</pub-id><pub-id pub-id-type="pmid">21726315</pub-id></mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caiati</surname><given-names>M. D.</given-names></name><name><surname>Cherubini</surname><given-names>E.</given-names></name></person-group> (<year>2013</year>). <article-title>Fluoxetine impairs GABAergic signaling in hippocampal slices from neonatal rats</article-title>. <source/>Front. Cell. Neurosci.
<volume>7</volume>:<fpage>63</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2013.00063</pub-id><pub-id pub-id-type="pmid">23641199</pub-id></mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caraiscos</surname><given-names>V. B.</given-names></name><name><surname>Elliott</surname><given-names>E. M.</given-names></name><name><surname>You-Ten</surname><given-names>K. E.</given-names></name><name><surname>Cheng</surname><given-names>V. Y.</given-names></name><name><surname>Belelli</surname><given-names>D.</given-names></name><name><surname>Newell</surname><given-names>J. G.</given-names></name><etal></etal></person-group>. (<year>2004</year>). <article-title>Tonic inhibition in mouse hippocampal CA1 pyramidal neurons is mediated by α5 subunit-containing γ-aminobutyric acid type A receptors</article-title>. <source/>Proc. Natl. Acad. Sci. U S A
<volume>101</volume>, <fpage>3662</fpage>–<lpage>3667</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0307231101</pub-id><pub-id pub-id-type="pmid">14993607</pub-id></mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>M.</given-names></name><name><surname>McCaughey</surname><given-names>E.</given-names></name><name><surname>Annaz</surname><given-names>D.</given-names></name><name><surname>Hill</surname><given-names>C. M.</given-names></name></person-group> (<year>2009</year>). <article-title>Sleep problems in a Down syndrome population</article-title>. <source/>Arch. Dis. Child.
<volume>94</volume>, <fpage>308</fpage>–<lpage>310</lpage>. <pub-id pub-id-type="doi">10.1136/adc.2008.146845</pub-id><pub-id pub-id-type="pmid">18786953</pub-id></mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catuara-Solarz</surname><given-names>S.</given-names></name><name><surname>Espinosa-Carrasco</surname><given-names>J.</given-names></name><name><surname>Erb</surname><given-names>I.</given-names></name><name><surname>Langohr</surname><given-names>K.</given-names></name><name><surname>Notredame</surname><given-names>C.</given-names></name><name><surname>Gonzalez</surname><given-names>J. R.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Principal component analysis of the effects of environmental enrichment and (-)-epigallocatechin-3-gallate on age-associated learning deficits in a mouse model of Down syndrome</article-title>. <source/>Front. Behav. Neurosci.
<volume>9</volume>:<fpage>330</fpage>. <pub-id pub-id-type="doi">10.3389/fnbeh.2015.00330</pub-id><pub-id pub-id-type="pmid">26696850</pub-id></mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cellot</surname><given-names>G.</given-names></name><name><surname>Cherubini</surname><given-names>E.</given-names></name></person-group> (<year>2013</year>). <article-title>Functional role of ambient GABA in refining neuronal circuits early in postnatal development</article-title>. <source/>Front. Neural Circuits
<volume>7</volume>:<fpage>136</fpage>. <pub-id pub-id-type="doi">10.3389/fncir.2013.00136</pub-id><pub-id pub-id-type="pmid">23964205</pub-id></mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cellot</surname><given-names>G.</given-names></name><name><surname>Cherubini</surname><given-names>E.</given-names></name></person-group> (<year>2014</year>). <article-title>GABAergic signaling as therapeutic target for autism spectrum disorders</article-title>. <source/>Front. Pediatr.
<volume>2</volume>:<fpage>70</fpage>. <pub-id pub-id-type="doi">10.3389/fped.2014.00070</pub-id><pub-id pub-id-type="pmid">25072038</pub-id></mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakrabarti</surname><given-names>L.</given-names></name><name><surname>Best</surname><given-names>T. K.</given-names></name><name><surname>Cramer</surname><given-names>N. P.</given-names></name><name><surname>Carney</surname><given-names>R. S. E.</given-names></name><name><surname>Isaac</surname><given-names>J. T. R.</given-names></name><name><surname>Galdzicki</surname><given-names>Z.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Olig1 and Olig2 triplication causes developmental brain defects in Down syndrome</article-title>. <source/>Nat. Neurosci.
<volume>13</volume>, <fpage>927</fpage>–<lpage>934</lpage>. <pub-id pub-id-type="doi">10.1038/nn.2600</pub-id><pub-id pub-id-type="pmid">20639873</pub-id></mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakrabarti</surname><given-names>L.</given-names></name><name><surname>Galdzicki</surname><given-names>Z.</given-names></name><name><surname>Haydar</surname><given-names>T. F.</given-names></name></person-group> (<year>2007</year>). <article-title>Defects in embryonic neurogenesis and initial synapse formation in the forebrain of the Ts65Dn mouse model of Down syndrome</article-title>. <source/>J. Neurosci.
<volume>27</volume>, <fpage>11483</fpage>–<lpage>11495</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3406-07.2007</pub-id><pub-id pub-id-type="pmid">17959791</pub-id></mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chalifoux</surname><given-names>J. R.</given-names></name><name><surname>Carter</surname><given-names>A. G.</given-names></name></person-group> (<year>2011</year>). <article-title>GABAB receptor modulation of voltage-sensitive calcium channels in spines and dendrites</article-title>. <source/>J. Neurosci.
<volume>31</volume>, <fpage>4221</fpage>–<lpage>4232</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.4561-10.2011</pub-id><pub-id pub-id-type="pmid">21411663</pub-id></mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chambers</surname><given-names>M. S.</given-names></name><name><surname>Atack</surname><given-names>J. R.</given-names></name><name><surname>Broughton</surname><given-names>H. B.</given-names></name><name><surname>Collinson</surname><given-names>N.</given-names></name><name><surname>Cook</surname><given-names>S.</given-names></name><name><surname>Dawson</surname><given-names>G. R.</given-names></name><etal></etal></person-group>. (<year>2003</year>). <article-title>Identification of a novel, selective GABA<sub>A</sub> α5 receptor inverse agonist which enhances cognition</article-title>. <source/>J. Med. Chem.
<volume>46</volume>, <fpage>2227</fpage>–<lpage>2240</lpage>. <pub-id pub-id-type="doi">10.1021/jm020582q</pub-id><pub-id pub-id-type="pmid">12747794</pub-id></mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>X. P.</given-names></name><name><surname>Sun</surname><given-names>H.</given-names></name><name><surname>Ye</surname><given-names>Z. Y.</given-names></name><name><surname>Zhou</surname><given-names>J. N.</given-names></name></person-group> (<year>2012</year>). <article-title>Melatonin modulates the GABAergic response in cultured rat hippocampal neurons</article-title>. <source/>J. Pharmacol. Sci.
<volume>119</volume>, <fpage>177</fpage>–<lpage>185</lpage>. <pub-id pub-id-type="doi">10.1254/jphs.11183fp</pub-id><pub-id pub-id-type="pmid">22673185</pub-id></mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherubini</surname><given-names>E.</given-names></name><name><surname>Rovira</surname><given-names>C.</given-names></name><name><surname>Gaiarsa</surname><given-names>J. L.</given-names></name><name><surname>Corradetti</surname><given-names>R.</given-names></name><name><surname>Ben-Ari</surname><given-names>Y.</given-names></name></person-group> (<year>1990</year>). <article-title>GABA mediated excitation in immature rat CA3 hippocampal neurons</article-title>. <source/>Int. J. Dev. Neurosci.
<volume>8</volume>, <fpage>481</fpage>–<lpage>490</lpage>. <pub-id pub-id-type="doi">10.1016/0736-5748(90)90080-l</pub-id><pub-id pub-id-type="pmid">2174638</pub-id></mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>P.-H.</given-names></name><name><surname>Wu</surname><given-names>P.-Y.</given-names></name><name><surname>Kuo</surname><given-names>T.-W.</given-names></name><name><surname>Liu</surname><given-names>Y.-C.</given-names></name><name><surname>Chan</surname><given-names>C.-F.</given-names></name><name><surname>Chien</surname><given-names>T.-C.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>GABA is depolarizing in hippocampal dentate granule cells of the adolescent and adult rats</article-title>. <source/>J. Neurosci.
<volume>32</volume>, <fpage>62</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3393-11.2012</pub-id><pub-id pub-id-type="pmid">22219270</pub-id></mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>H. J.</given-names></name><name><surname>Lee</surname><given-names>C. J.</given-names></name><name><surname>Schroeder</surname><given-names>A.</given-names></name><name><surname>Kim</surname><given-names>Y. S.</given-names></name><name><surname>Jung</surname><given-names>S. H.</given-names></name><name><surname>Kim</surname><given-names>J. S.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>Excitatory actions of GABA in the suprachiasmatic nucleus</article-title>. <source/>J. Neurosci.
<volume>28</volume>, <fpage>5450</fpage>–<lpage>5459</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.5750-07.2008</pub-id><pub-id pub-id-type="pmid">18495878</pub-id></mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciruela</surname><given-names>F.</given-names></name><name><surname>Fernández-Dueñas</surname><given-names>V.</given-names></name><name><surname>Sahlholm</surname><given-names>K.</given-names></name><name><surname>Fernández-Alacid</surname><given-names>L.</given-names></name><name><surname>Nicolau</surname><given-names>J. C.</given-names></name><name><surname>Watanabe</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Evidence for oligomerization between GABAB receptors and GIRK channels containing the GIRK1 and GIRK3 subunits</article-title>. <source/>Eur. J. Neurosci.
<volume>32</volume>, <fpage>1265</fpage>–<lpage>1277</lpage>. <pub-id pub-id-type="doi">10.1111/j.1460-9568.2010.07356.x</pub-id><pub-id pub-id-type="pmid">20846323</pub-id></mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>S.</given-names></name><name><surname>Schwalbe</surname><given-names>J.</given-names></name><name><surname>Stasko</surname><given-names>M. R.</given-names></name><name><surname>Yarowsky</surname><given-names>P. J.</given-names></name><name><surname>Costa</surname><given-names>A. C.</given-names></name></person-group> (<year>2006</year>). <article-title>Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome</article-title>. <source/>Exp. Neurol.
<volume>200</volume>, <fpage>256</fpage>–<lpage>261</lpage>. <pub-id pub-id-type="doi">10.1016/j.expneurol.2006.02.005</pub-id><pub-id pub-id-type="pmid">16624293</pub-id></mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colas</surname><given-names>D.</given-names></name><name><surname>Chuluun</surname><given-names>B.</given-names></name><name><surname>Warrier</surname><given-names>D.</given-names></name><name><surname>Blank</surname><given-names>M.</given-names></name><name><surname>Wetmore</surname><given-names>D. Z.</given-names></name><name><surname>Buckmaster</surname><given-names>P.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Short-term treatment with the GABA<sub>A</sub> receptor antagonist pentylenetetrazole produces a sustained pro-cognitive benefit in a mouse model of Down’s syndrome</article-title>. <source/>Br. J. Pharmacol.
<volume>169</volume>, <fpage>963</fpage>–<lpage>973</lpage>. <pub-id pub-id-type="doi">10.1111/bph.12169</pub-id><pub-id pub-id-type="pmid">23489250</pub-id></mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colas</surname><given-names>D.</given-names></name><name><surname>Valletta</surname><given-names>J. S.</given-names></name><name><surname>Takimoto-Kimura</surname><given-names>R.</given-names></name><name><surname>Nishino</surname><given-names>S.</given-names></name><name><surname>Fujiki</surname><given-names>N.</given-names></name><name><surname>Mobley</surname><given-names>W. C.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>Sleep and EEG features in genetic models of Down syndrome</article-title>. <source/>Neurobiol. Dis.
<volume>30</volume>, <fpage>1</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2007.07.014</pub-id><pub-id pub-id-type="pmid">18282758</pub-id></mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collinson</surname><given-names>N.</given-names></name><name><surname>Kuenzi</surname><given-names>F. M.</given-names></name><name><surname>Jarolimek</surname><given-names>W.</given-names></name><name><surname>Maubach</surname><given-names>K. A.</given-names></name><name><surname>Cothliff</surname><given-names>R.</given-names></name><name><surname>Sur</surname><given-names>C.</given-names></name><etal></etal></person-group>. (<year>2002</year>). <article-title>Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the α5 subunit of the GABA<sub>A</sub> receptor</article-title>. <source/>J. Neurosci.
<volume>22</volume>, <fpage>5572</fpage>–<lpage>5580</lpage>. <pub-id pub-id-type="pmid">12097508</pub-id></mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colon</surname><given-names>E. J.</given-names></name></person-group> (<year>1972</year>). <article-title>The structure of cerebral cortex in Down syndrome—A quantitative analysis</article-title>. <source/>Neuropediatrie
<volume>3</volume>, <fpage>362</fpage>–<lpage>376</lpage>. <pub-id pub-id-type="doi">10.1055/s-0028-1091775</pub-id></mixed-citation>
</ref>
<ref id="B53">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Contestabile</surname><given-names>A.</given-names></name><name><surname>Fila</surname><given-names>T.</given-names></name><name><surname>Bartesaghi</surname><given-names>R.</given-names></name><name><surname>Ciani</surname><given-names>E.</given-names></name></person-group> (<year>2009</year>). <article-title>Cell cycle elongation impairs proliferation of cerebellar granule cell precursors in the Ts65Dn Mouse, an animal model for Down syndrome</article-title>. <source/>Brain Pathol.
<volume>19</volume>, <fpage>224</fpage>–<lpage>237</lpage>. <pub-id pub-id-type="doi">10.1111/j.1750-3639.2008.00168.x</pub-id><pub-id pub-id-type="pmid">18482164</pub-id></mixed-citation>
</ref>
<ref id="B54">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Contestabile</surname><given-names>A.</given-names></name><name><surname>Fila</surname><given-names>T.</given-names></name><name><surname>Ceccarelli</surname><given-names>C.</given-names></name><name><surname>Bonasone</surname><given-names>P.</given-names></name><name><surname>Bonapace</surname><given-names>L.</given-names></name><name><surname>Santini</surname><given-names>D.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with Down syndrome and in Ts65Dn mice</article-title>. <source/>Hippocampus
<volume>17</volume>, <fpage>665</fpage>–<lpage>678</lpage>. <pub-id pub-id-type="doi">10.1002/hipo.20308</pub-id><pub-id pub-id-type="pmid">17546680</pub-id></mixed-citation>
</ref>
<ref id="B55">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Contestabile</surname><given-names>A.</given-names></name><name><surname>Greco</surname><given-names>B.</given-names></name><name><surname>Ghezzi</surname><given-names>D.</given-names></name><name><surname>Tucci</surname><given-names>V.</given-names></name><name><surname>Benfenati</surname><given-names>F.</given-names></name><name><surname>Gasparini</surname><given-names>L.</given-names></name></person-group> (<year>2013</year>). <article-title>Lithium rescues synaptic plasticity and memory in Down syndrome mice</article-title>. <source/>J. Clin. Invest.
<volume>123</volume>, <fpage>348</fpage>–<lpage>361</lpage>. <pub-id pub-id-type="doi">10.1172/JCI64650</pub-id><pub-id pub-id-type="pmid">23202733</pub-id></mixed-citation>
</ref>
<ref id="B56">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cornelisse</surname><given-names>L. N.</given-names></name><name><surname>van der Harst</surname><given-names>J. E.</given-names></name><name><surname>Lodder</surname><given-names>J. C.</given-names></name><name><surname>Baarendse</surname><given-names>P. J.</given-names></name><name><surname>Timmerman</surname><given-names>A. J.</given-names></name><name><surname>Mansvelder</surname><given-names>H. D.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>Reduced 5-HT1A- and GABAB receptor function in dorsal raphé neurons upon chronic fluoxetine treatment of socially stressed rats</article-title>. <source/>J. Neurophysiol.
<volume>98</volume>, <fpage>196</fpage>–<lpage>204</lpage>. <pub-id pub-id-type="doi">10.1152/jn.00109.2007</pub-id><pub-id pub-id-type="pmid">17460100</pub-id></mixed-citation>
</ref>
<ref id="B57">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corrales</surname><given-names>A.</given-names></name><name><surname>Vidal</surname><given-names>R.</given-names></name><name><surname>García</surname><given-names>S.</given-names></name><name><surname>Vidal</surname><given-names>V.</given-names></name><name><surname>Martínez</surname><given-names>P.</given-names></name><name><surname>García</surname><given-names>E.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Chronic melatonin treatment rescues electrophysiological and neuromorphological deficits in a mouse model of Down syndrome</article-title>. <source/>J. Pineal Res.
<volume>56</volume>, <fpage>51</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1111/jpi.12097</pub-id><pub-id pub-id-type="pmid">24147912</pub-id></mixed-citation>
</ref>
<ref id="B58">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortez</surname><given-names>M. A.</given-names></name><name><surname>Shen</surname><given-names>L.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Aleem</surname><given-names>I. S.</given-names></name><name><surname>Trepanier</surname><given-names>C. H.</given-names></name><name><surname>Sadeghnia</surname><given-names>H. R.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>Infantile spasms and Down syndrome: a new animal model</article-title>. <source/>Pediatr. Res.
<volume>65</volume>, <fpage>499</fpage>–<lpage>503</lpage>. <pub-id pub-id-type="doi">10.1203/PDR.0b013e31819d9076</pub-id><pub-id pub-id-type="pmid">19190545</pub-id></mixed-citation>
</ref>
<ref id="B59">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>A. C.</given-names></name></person-group> (<year>2014</year>). <article-title>The glutamatergic hypothesis for Down syndrome: the potential use of N-methyl-D-aspartate receptor antagonists to enhance cognition and decelerate neurodegeneration</article-title>. <source/>CNS Neurol. Disord. Drug Targets
<volume>13</volume>, <fpage>16</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.2174/18715273113126660183</pub-id><pub-id pub-id-type="pmid">24152324</pub-id></mixed-citation>
</ref>
<ref id="B60">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>A. C.</given-names></name><name><surname>Grybko</surname><given-names>M. J.</given-names></name></person-group> (<year>2005</year>). <article-title>Deficits in hippocampal CA1 LTP induced by TBS but not HFS in the Ts65Dn mouse: a model of Down syndrome</article-title>. <source/>Neurosci. Lett.
<volume>382</volume>, <fpage>317</fpage>–<lpage>322</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2005.03.031</pub-id><pub-id pub-id-type="pmid">15925111</pub-id></mixed-citation>
</ref>
<ref id="B62">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>C. S. A.</given-names></name><name><surname>Scott-McKean</surname><given-names>J. J.</given-names></name><name><surname>Stasko</surname><given-names>M. R.</given-names></name></person-group> (<year>2007</year>). <article-title>Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test</article-title>. <source/>Neuropsychopharmacology
<volume>33</volume>, <fpage>1624</fpage>–<lpage>1632</lpage>. <pub-id pub-id-type="doi">10.1038/sj.npp.1301535</pub-id><pub-id pub-id-type="pmid">17700645</pub-id></mixed-citation>
</ref>
<ref id="B61">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>A. C.</given-names></name><name><surname>Stasko</surname><given-names>M. R.</given-names></name><name><surname>Stoffel</surname><given-names>M.</given-names></name><name><surname>Scott-McKean</surname><given-names>J. J.</given-names></name></person-group> (<year>2005</year>). <article-title>G-protein-gated potassium (GIRK) channels containing the GIRK2 subunit are control hubs for pharmacologically induced hypothermic responses</article-title>. <source/>J. Neurosci.
<volume>25</volume>, <fpage>7801</fpage>–<lpage>7804</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1699-05.2005</pub-id><pub-id pub-id-type="pmid">16120781</pub-id></mixed-citation>
</ref>
<ref id="B63">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coyle</surname><given-names>J. T.</given-names></name><name><surname>Oster-Granite</surname><given-names>M. L.</given-names></name><name><surname>Gearhart</surname><given-names>J. D.</given-names></name></person-group> (<year>1986</year>). <article-title>The neurobiologie consequences of Down syndrome</article-title>. <source/>Brain Res. Bull.
<volume>16</volume>, <fpage>773</fpage>–<lpage>787</lpage>. <pub-id pub-id-type="doi">10.1016/0361-9230(86)90074-2</pub-id><pub-id pub-id-type="pmid">2875770</pub-id></mixed-citation>
</ref>
<ref id="B64">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cramer</surname><given-names>N. P.</given-names></name><name><surname>Xu</surname><given-names>X. F.</given-names></name><name><surname>Haydar</surname><given-names>T.</given-names></name><name><surname>Galdzicki</surname><given-names>Z.</given-names></name></person-group> (<year>2015</year>). <article-title>Altered intrinsic and network properties of neocortical neurons in the Ts65Dn mouse model of Down syndrome</article-title>. <source/>Physiol. Rep.
<volume>3</volume>:<fpage>e12655</fpage>. <pub-id pub-id-type="doi">10.14814/phy2.12655</pub-id><pub-id pub-id-type="pmid">26702072</pub-id></mixed-citation>
</ref>
<ref id="B65">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>I.</given-names></name><name><surname>Park</surname><given-names>J.-M.</given-names></name><name><surname>Shin</surname><given-names>J. H.</given-names></name><name><surname>Jeon</surname><given-names>S. K.</given-names></name><name><surname>Lorenzi</surname><given-names>H.</given-names></name><name><surname>Linden</surname><given-names>D. J.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Hedgehog agonist therapy corrects structural and cognitive deficits in a Down syndrome mouse model</article-title>. <source/>Sci. Transl. Med.
<volume>5</volume>:<fpage>201ra120</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.3005983</pub-id><pub-id pub-id-type="pmid">24005160</pub-id></mixed-citation>
</ref>
<ref id="B66">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>David</surname><given-names>M.</given-names></name><name><surname>Richer</surname><given-names>M.</given-names></name><name><surname>Mamarbachi</surname><given-names>A. M.</given-names></name><name><surname>Villeneuve</surname><given-names>L. R.</given-names></name><name><surname>Dupré</surname><given-names>D. J.</given-names></name><name><surname>Hebert</surname><given-names>T. E.</given-names></name></person-group> (<year>2006</year>). <article-title>Interactions between GABA-B<sub>1</sub> receptors and Kir 3 inwardly rectifying potassium channels</article-title>. <source/>Cell. Signal.
<volume>18</volume>, <fpage>2172</fpage>–<lpage>2181</lpage>. <pub-id pub-id-type="doi">10.1016/j.cellsig.2006.05.014</pub-id><pub-id pub-id-type="pmid">16809021</pub-id></mixed-citation>
</ref>
<ref id="B67">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>C. H.</given-names></name><name><surname>Starkey</surname><given-names>S. J.</given-names></name><name><surname>Pozza</surname><given-names>M. F.</given-names></name><name><surname>Collingridge</surname><given-names>G. L.</given-names></name></person-group> (<year>1991</year>). <article-title>GABA autoreceptors regulate the induction of LTP</article-title>. <source/>Nature
<volume>349</volume>, <fpage>609</fpage>–<lpage>611</lpage>. <pub-id pub-id-type="doi">10.1038/349609a0</pub-id><pub-id pub-id-type="pmid">1847993</pub-id></mixed-citation>
</ref>
<ref id="B70">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deidda</surname><given-names>G.</given-names></name><name><surname>Allegra</surname><given-names>M.</given-names></name><name><surname>Cerri</surname><given-names>C.</given-names></name><name><surname>Naskar</surname><given-names>S.</given-names></name><name><surname>Bony</surname><given-names>G.</given-names></name><name><surname>Zunino</surname><given-names>G.</given-names></name><etal></etal></person-group>. (<year>2015a</year>). <article-title>Early depolarizing GABA controls critical-period plasticity in the rat visual cortex</article-title>. <source/>Nat. Neurosci.
<volume>18</volume>, <fpage>87</fpage>–<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1038/nn.3890</pub-id><pub-id pub-id-type="pmid">25485756</pub-id></mixed-citation>
</ref>
<ref id="B72">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deidda</surname><given-names>G.</given-names></name><name><surname>Parrini</surname><given-names>M.</given-names></name><name><surname>Naskar</surname><given-names>S.</given-names></name><name><surname>Bozarth</surname><given-names>I. F.</given-names></name><name><surname>Contestabile</surname><given-names>A.</given-names></name><name><surname>Cancedda</surname><given-names>L.</given-names></name></person-group> (<year>2015b</year>). <article-title>Reversing excitatory GABA<sub>A</sub>R signaling restores synaptic plasticity and memory in a mouse model of Down syndrome</article-title>. <source/>Nat. Med.
<volume>21</volume>, <fpage>318</fpage>–<lpage>326</lpage>. <pub-id pub-id-type="doi">10.1038/nm.3827</pub-id><pub-id pub-id-type="pmid">25774849</pub-id></mixed-citation>
</ref>
<ref id="B71">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deidda</surname><given-names>G.</given-names></name><name><surname>Bozarth</surname><given-names>I. F.</given-names></name><name><surname>Cancedda</surname><given-names>L.</given-names></name></person-group> (<year>2014</year>). <article-title>Modulation of GABAergic transmission in development and neurodevelopmental disorders: investigating physiology and pathology to gain therapeutic perspectives</article-title>. <source/>Front. Cell. Neurosci.
<volume>8</volume>:<fpage>119</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2014.00119</pub-id><pub-id pub-id-type="pmid">24904277</pub-id></mixed-citation>
</ref>
<ref id="B73">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delabar</surname><given-names>J. M.</given-names></name><name><surname>Theophile</surname><given-names>D.</given-names></name><name><surname>Rahmani</surname><given-names>Z.</given-names></name><name><surname>Chettouh</surname><given-names>Z.</given-names></name><name><surname>Blouin</surname><given-names>J. L.</given-names></name><name><surname>Prieur</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>1993</year>). <article-title>Molecular mapping of twenty-four features of Down syndrome on chromosome 21</article-title>. <source/>Eur. J. Hum. Genet.
<volume>1</volume>, <fpage>114</fpage>–<lpage>124</lpage>. <pub-id pub-id-type="pmid">8055322</pub-id></mixed-citation>
</ref>
<ref id="B69">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de la Torre</surname><given-names>R.</given-names></name><name><surname>de Sola</surname><given-names>S.</given-names></name><name><surname>Hernandez</surname><given-names>G.</given-names></name><name><surname>Farré</surname><given-names>M.</given-names></name><name><surname>Pujol</surname><given-names>J.</given-names></name><name><surname>Rodriguez</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down’s syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial</article-title>. <source/>Lancet Neurol.
<volume>15</volume>, <fpage>801</fpage>–<lpage>810</lpage>. <pub-id pub-id-type="doi">10.1016/s1474-4422(16)30034-5</pub-id><pub-id pub-id-type="pmid">27302362</pub-id></mixed-citation>
</ref>
<ref id="B68">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De la Torre</surname><given-names>R.</given-names></name><name><surname>De Sol</surname><given-names>A. S.</given-names></name><name><surname>Pons</surname><given-names>M.</given-names></name><name><surname>Duchon</surname><given-names>A.</given-names></name><name><surname>de Lagran</surname><given-names>M. M.</given-names></name><name><surname>Farré</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans</article-title>. <source/>Mol. Nutr. Food Res.
<volume>58</volume>, <fpage>278</fpage>–<lpage>288</lpage>. <pub-id pub-id-type="doi">10.1002/mnfr.201300325</pub-id><pub-id pub-id-type="pmid">24039182</pub-id></mixed-citation>
</ref>
<ref id="B74">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dierssen</surname><given-names>M.</given-names></name></person-group> (<year>2012</year>). <article-title>Down syndrome: the brain in trisomic mode</article-title>. <source/>Nat. Rev. Neurosci.
<volume>13</volume>, <fpage>844</fpage>–<lpage>858</lpage>. <pub-id pub-id-type="doi">10.1038/nrn3314</pub-id><pub-id pub-id-type="pmid">23165261</pub-id></mixed-citation>
</ref>
<ref id="B75">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duchon</surname><given-names>A.</given-names></name><name><surname>Raveau</surname><given-names>M.</given-names></name><name><surname>Chevalier</surname><given-names>C.</given-names></name><name><surname>Nalesso</surname><given-names>V.</given-names></name><name><surname>Sharp</surname><given-names>A. J.</given-names></name><name><surname>Herault</surname><given-names>Y.</given-names></name></person-group> (<year>2011</year>). <article-title>Identification of the translocation breakpoints in the Ts65Dn and Ts1Cje mouse lines: relevance for modeling Down syndrome</article-title>. <source/>Mamm. Genome
<volume>22</volume>, <fpage>674</fpage>–<lpage>684</lpage>. <pub-id pub-id-type="doi">10.1007/s00335-011-9356-0</pub-id><pub-id pub-id-type="pmid">21953411</pub-id></mixed-citation>
</ref>
<ref id="B76">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edgin</surname><given-names>J. O.</given-names></name><name><surname>Tooley</surname><given-names>U.</given-names></name><name><surname>Demara</surname><given-names>B.</given-names></name><name><surname>Nyhuis</surname><given-names>C.</given-names></name><name><surname>Anand</surname><given-names>P.</given-names></name><name><surname>Spanò</surname><given-names>G.</given-names></name></person-group> (<year>2015</year>). <article-title>Sleep disturbance and expressive language development in preschool-age children with Down syndrome</article-title>. <source/>Child Dev.
<volume>86</volume>, <fpage>1984</fpage>–<lpage>1998</lpage>. <pub-id pub-id-type="doi">10.1111/cdev.12443</pub-id><pub-id pub-id-type="pmid">26435268</pub-id></mixed-citation>
</ref>
<ref id="B77">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escorihuela</surname><given-names>R. M.</given-names></name><name><surname>Fernández-Teruel</surname><given-names>A.</given-names></name><name><surname>Vallina</surname><given-names>I. F.</given-names></name><name><surname>Baamonde</surname><given-names>C.</given-names></name><name><surname>Lumbreras</surname><given-names>M. A.</given-names></name><name><surname>Dierssen</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>1995</year>). <article-title>A behavioral assessment of Ts65Dn mice: a putative Down syndrome model</article-title>. <source/>Neurosci. Lett.
<volume>199</volume>, <fpage>143</fpage>–<lpage>146</lpage>. <pub-id pub-id-type="doi">10.1016/0304-3940(95)12052-6</pub-id><pub-id pub-id-type="pmid">8584244</pub-id></mixed-citation>
</ref>
<ref id="B78">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farrant</surname><given-names>M.</given-names></name><name><surname>Nusser</surname><given-names>Z.</given-names></name></person-group> (<year>2005</year>). <article-title>Variations on an inhibitory theme: phasic and tonic activation of GABA<sub>A</sub> receptors</article-title>. <source/>Nat. Rev. Neurosci.
<volume>6</volume>, <fpage>215</fpage>–<lpage>229</lpage>. <pub-id pub-id-type="doi">10.1038/nrn1625</pub-id><pub-id pub-id-type="pmid">15738957</pub-id></mixed-citation>
</ref>
<ref id="B79">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>F.</given-names></name><name><surname>Edgin</surname><given-names>J. O.</given-names></name></person-group> (<year>2016</year>). <article-title>Pharmacotherapy in Down’s syndrome: which way forward?</article-title>
<source/>Lancet Neurol.
<volume>15</volume>, <fpage>776</fpage>–<lpage>777</lpage>. <pub-id pub-id-type="doi">10.1016/s1474-4422(16)30056-4</pub-id><pub-id pub-id-type="pmid">27302343</pub-id></mixed-citation>
</ref>
<ref id="B80">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>F.</given-names></name><name><surname>Garner</surname><given-names>C. C.</given-names></name></person-group> (<year>2007</year>). <article-title>Object recognition memory is conserved in Ts1Cje, a mouse model of Down syndrome</article-title>. <source/>Neurosci. Lett.
<volume>421</volume>, <fpage>137</fpage>–<lpage>141</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2007.04.075</pub-id><pub-id pub-id-type="pmid">17566652</pub-id></mixed-citation>
</ref>
<ref id="B81">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>F.</given-names></name><name><surname>Morishita</surname><given-names>W.</given-names></name><name><surname>Zuniga</surname><given-names>E.</given-names></name><name><surname>Nguyen</surname><given-names>J.</given-names></name><name><surname>Blank</surname><given-names>M.</given-names></name><name><surname>Malenka</surname><given-names>R. C.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome</article-title>. <source/>Nat. Neurosci.
<volume>10</volume>, <fpage>411</fpage>–<lpage>413</lpage>. <pub-id pub-id-type="doi">10.1038/nn1860</pub-id><pub-id pub-id-type="pmid">17322876</pub-id></mixed-citation>
</ref>
<ref id="B82">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiorentino</surname><given-names>H.</given-names></name><name><surname>Kuczewski</surname><given-names>N.</given-names></name><name><surname>Diabira</surname><given-names>D.</given-names></name><name><surname>Ferrand</surname><given-names>N.</given-names></name><name><surname>Pangalos</surname><given-names>M. N.</given-names></name><name><surname>Porcher</surname><given-names>C.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>GABA<sub>B</sub> receptor activation triggers BDNF release and promotes the maturation of GABAergic synapses</article-title>. <source/>J. Neurosci.
<volume>29</volume>, <fpage>11650</fpage>–<lpage>11661</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3587-09.2009</pub-id><pub-id pub-id-type="pmid">19759312</pub-id></mixed-citation>
</ref>
<ref id="B83">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiumelli</surname><given-names>H.</given-names></name><name><surname>Cancedda</surname><given-names>L.</given-names></name><name><surname>Poo</surname><given-names>M. M.</given-names></name></person-group> (<year>2005</year>). <article-title>Modulation of GABAergic transmission by activity via postsynaptic Ca<sup>2+</sup>-dependent regulation of KCC2 function</article-title>. <source/>Neuron
<volume>48</volume>, <fpage>773</fpage>–<lpage>786</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2005.10.025</pub-id><pub-id pub-id-type="pmid">16337915</pub-id></mixed-citation>
</ref>
<ref id="B84">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fowler</surname><given-names>C. E.</given-names></name><name><surname>Aryal</surname><given-names>P.</given-names></name><name><surname>Suen</surname><given-names>K. F.</given-names></name><name><surname>Slesinger</surname><given-names>P. A.</given-names></name></person-group> (<year>2007</year>). <article-title>Evidence for association of GABA<sub>B</sub> receptors with Kir3 channels and regulators of G protein signalling (RGS4) proteins</article-title>. <source/>J. Physiol.
<volume>580</volume>, <fpage>51</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1113/jphysiol.2006.123216</pub-id><pub-id pub-id-type="pmid">17185339</pub-id></mixed-citation>
</ref>
<ref id="B85">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frazer</surname><given-names>S.</given-names></name><name><surname>Otomo</surname><given-names>K.</given-names></name><name><surname>Dayer</surname><given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>Early-life serotonin dysregulation affects the migration and positioning of cortical interneuron subtypes</article-title>. <source/>Transl. Psychiatry
<volume>5</volume>:<fpage>e644</fpage>. <pub-id pub-id-type="doi">10.1038/tp.2015.147</pub-id><pub-id pub-id-type="pmid">26393490</pub-id></mixed-citation>
</ref>
<ref id="B86">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fritschy</surname><given-names>J. M.</given-names></name><name><surname>Panzanelli</surname><given-names>P.</given-names></name></person-group> (<year>2014</year>). <article-title>GABA<sub>A</sub> receptors and plasticity of inhibitory neurotransmission in the central nervous system</article-title>. <source/>Eur. J. Neurosci.
<volume>39</volume>, <fpage>1845</fpage>–<lpage>1865</lpage>. <pub-id pub-id-type="doi">10.1111/ejn.12534</pub-id><pub-id pub-id-type="pmid">24628861</pub-id></mixed-citation>
</ref>
<ref id="B87">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukuda</surname><given-names>A.</given-names></name><name><surname>Mody</surname><given-names>I.</given-names></name><name><surname>Prince</surname><given-names>D. A.</given-names></name></person-group> (<year>1993</year>). <article-title>Differential ontogenesis of presynaptic and postsynaptic GABA<sub>B</sub> inhibition in rat somatosensory cortex</article-title>. <source/>J. Neurophysiol.
<volume>70</volume>, <fpage>448</fpage>–<lpage>452</lpage>. <pub-id pub-id-type="pmid">8395587</pub-id></mixed-citation>
</ref>
<ref id="B88">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaiarsa</surname><given-names>J.-L.</given-names></name><name><surname>Porcher</surname><given-names>C.</given-names></name></person-group> (<year>2013</year>). <article-title>Emerging neurotrophic role of GABAB receptors in neuronal circuit development</article-title>. <source/>Front. Cell. Neurosci.
<volume>7</volume>:<fpage>206</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2013.00206</pub-id><pub-id pub-id-type="pmid">24282395</pub-id></mixed-citation>
</ref>
<ref id="B89">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaiarsa</surname><given-names>J. L.</given-names></name><name><surname>Tseeb</surname><given-names>V.</given-names></name><name><surname>Ben-Ari</surname><given-names>Y.</given-names></name></person-group> (<year>1995</year>). <article-title>Postnatal development of pre- and postsynaptic GABAB-mediated inhibitions in the CA3 hippocampal region of the rat</article-title>. <source/>J. Neurophysiol.
<volume>73</volume>, <fpage>246</fpage>–<lpage>255</lpage>. <pub-id pub-id-type="pmid">7714569</pub-id></mixed-citation>
</ref>
<ref id="B90">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>García-Cerro</surname><given-names>S.</given-names></name><name><surname>Martínez</surname><given-names>P.</given-names></name><name><surname>Vidal</surname><given-names>V.</given-names></name><name><surname>Corrales</surname><given-names>A.</given-names></name><name><surname>Flórez</surname><given-names>J.</given-names></name><name><surname>Vidal</surname><given-names>R.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and neuromorphological alterations found in a mouse model of Down syndrome</article-title>. <source/>PLoS One
<volume>9</volume>:<fpage>e106572</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0106572</pub-id><pub-id pub-id-type="pmid">25188425</pub-id></mixed-citation>
</ref>
<ref id="B92">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gardiner</surname><given-names>K. J.</given-names></name></person-group> (<year>2010</year>). <article-title>Molecular basis of pharmacotherapies for cognition in Down syndrome</article-title>. <source/>Trends Pharmacol. Sci.
<volume>31</volume>, <fpage>66</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2009.10.010</pub-id><pub-id pub-id-type="pmid">19963286</pub-id></mixed-citation>
</ref>
<ref id="B93">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gardiner</surname><given-names>K. J.</given-names></name></person-group> (<year>2014</year>). <article-title>Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations</article-title>. <source/>Drug Des. Devel. Ther.
<volume>9</volume>, <fpage>103</fpage>–<lpage>125</lpage>. <pub-id pub-id-type="doi">10.2147/DDDT.S51476</pub-id><pub-id pub-id-type="pmid">25552901</pub-id></mixed-citation>
</ref>
<ref id="B91">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gardiner</surname><given-names>K.</given-names></name><name><surname>Fortna</surname><given-names>A.</given-names></name><name><surname>Bechtel</surname><given-names>L.</given-names></name><name><surname>Davisson</surname><given-names>M. T.</given-names></name></person-group> (<year>2003</year>). <article-title>Mouse models of Down syndrome: how useful can they be? Comparison of the gene content of human chromosome 21 with orthologous mouse genomic regions</article-title>. <source/>Gene
<volume>318</volume>, <fpage>137</fpage>–<lpage>147</lpage>. <pub-id pub-id-type="doi">10.1016/s0378-1119(03)00769-8</pub-id><pub-id pub-id-type="pmid">14585506</pub-id></mixed-citation>
</ref>
<ref id="B94">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gassmann</surname><given-names>M.</given-names></name><name><surname>Bettler</surname><given-names>B.</given-names></name></person-group> (<year>2012</year>). <article-title>Regulation of neuronal GABA<sub>B</sub> receptor functions by subunit composition</article-title>. <source/>Nat. Rev. Neurosci.
<volume>13</volume>, <fpage>380</fpage>–<lpage>394</lpage>. <pub-id pub-id-type="doi">10.1038/nrn3249</pub-id><pub-id pub-id-type="pmid">22595784</pub-id></mixed-citation>
</ref>
<ref id="B95">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grover</surname><given-names>L. M.</given-names></name><name><surname>Yan</surname><given-names>C.</given-names></name></person-group> (<year>1999</year>). <article-title>Blockade of GABA<sub>A</sub> receptors facilitates induction of NMDA receptor-independent long-term potentiation</article-title>. <source/>J. Neurophysiol.
<volume>81</volume>, <fpage>2814</fpage>–<lpage>2822</lpage>. <pub-id pub-id-type="pmid">10368399</pub-id></mixed-citation>
</ref>
<ref id="B96">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guidi</surname><given-names>S.</given-names></name><name><surname>Bonasoni</surname><given-names>P.</given-names></name><name><surname>Caccarelli</surname><given-names>C.</given-names></name><name><surname>Santini</surname><given-names>D.</given-names></name><name><surname>Gualtieri</surname><given-names>F.</given-names></name><name><surname>Ciani</surname><given-names>E.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>Neurogenesis impairment and increased cell death reduce total neuron number in the hippocampal region of fetuses with Down syndrome</article-title>. <source/>Brain Pathol.
<volume>18</volume>, <fpage>180</fpage>–<lpage>197</lpage>. <pub-id pub-id-type="doi">10.1111/j.1750-3639.2007.00113.x</pub-id><pub-id pub-id-type="pmid">18093248</pub-id></mixed-citation>
</ref>
<ref id="B97">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guidi</surname><given-names>S.</given-names></name><name><surname>Stagni</surname><given-names>F.</given-names></name><name><surname>Bianchi</surname><given-names>P.</given-names></name><name><surname>Ciani</surname><given-names>E.</given-names></name><name><surname>Giacomini</surname><given-names>A.</given-names></name><name><surname>De Franceschi</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Prenatal pharmacotherapy rescues brain development in a Down’s syndrome mouse model</article-title>. <source/>Brain
<volume>137</volume>, <fpage>380</fpage>–<lpage>401</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awt340</pub-id><pub-id pub-id-type="pmid">24334313</pub-id></mixed-citation>
</ref>
<ref id="B98">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guidi</surname><given-names>S.</given-names></name><name><surname>Stagni</surname><given-names>F.</given-names></name><name><surname>Bianchi</surname><given-names>P.</given-names></name><name><surname>Ciani</surname><given-names>E.</given-names></name><name><surname>Ragazzi</surname><given-names>E.</given-names></name><name><surname>Trazzi</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Early pharmacotherapy with fluoxetine rescues dendritic pathology in the Ts65Dn mouse model of Down syndrome</article-title>. <source/>Brain Pathol.
<volume>23</volume>, <fpage>129</fpage>–<lpage>143</lpage>. <pub-id pub-id-type="doi">10.1111/j.1750-3639.2012.00624.x</pub-id><pub-id pub-id-type="pmid">22817700</pub-id></mixed-citation>
</ref>
<ref id="B99">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gulledge</surname><given-names>A. T.</given-names></name><name><surname>Stuart</surname><given-names>G. J.</given-names></name></person-group> (<year>2003</year>). <article-title>Excitatory actions of GABA in the cortex</article-title>. <source/>Neuron
<volume>37</volume>, <fpage>299</fpage>–<lpage>309</lpage>. <pub-id pub-id-type="doi">10.1016/s0896-6273(02)01146-7</pub-id><pub-id pub-id-type="pmid">12546824</pub-id></mixed-citation>
</ref>
<ref id="B100">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>M.</given-names></name><name><surname>Dhanasekaran</surname><given-names>A. R.</given-names></name><name><surname>Gardiner</surname><given-names>K. J.</given-names></name></person-group> (<year>2016</year>). <article-title>Mouse models of Down syndrome: gene content and consequences</article-title>. <source/>Mamm. Genome
<volume>27</volume>, <fpage>538</fpage>–<lpage>555</lpage>. <pub-id pub-id-type="doi">10.1007/s00335-016-9661-8</pub-id><pub-id pub-id-type="pmid">27538963</pub-id></mixed-citation>
</ref>
<ref id="B101">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanney</surname><given-names>M.</given-names></name><name><surname>Prasher</surname><given-names>V.</given-names></name><name><surname>Williams</surname><given-names>N.</given-names></name><name><surname>Jones</surname><given-names>E. L.</given-names></name><name><surname>Aarsland</surname><given-names>D.</given-names></name><name><surname>Corbett</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Memantine for dementia in adults older than 40 years with Down’s syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial</article-title>. <source/>Lancet
<volume>379</volume>, <fpage>528</fpage>–<lpage>536</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(11)61676-0</pub-id><pub-id pub-id-type="pmid">22236802</pub-id></mixed-citation>
</ref>
<ref id="B102">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanson</surname><given-names>J. E.</given-names></name><name><surname>Blank</surname><given-names>M.</given-names></name><name><surname>Valenzuela</surname><given-names>R. A.</given-names></name><name><surname>Garner</surname><given-names>C. C.</given-names></name><name><surname>Madison</surname><given-names>D. V.</given-names></name></person-group> (<year>2007</year>). <article-title>The functional nature of synaptic circuitry is altered in area CA3 of the hippocampus in a mouse model of Down’s syndrome</article-title>. <source/>J. Physiol.
<volume>579</volume>, <fpage>53</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1113/jphysiol.2006.114868</pub-id><pub-id pub-id-type="pmid">17158177</pub-id></mixed-citation>
</ref>
<ref id="B103">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanson</surname><given-names>J. E.</given-names></name><name><surname>Weber</surname><given-names>M.</given-names></name><name><surname>Meilandt</surname><given-names>W. J.</given-names></name><name><surname>Wu</surname><given-names>T.</given-names></name><name><surname>Luu</surname><given-names>T.</given-names></name><name><surname>Deng</surname><given-names>L.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>GluN2B antagonism affects interneurons and leads to immediate and persistent changes in synaptic plasticity, oscillations, and behavior</article-title>. <source/>Neuropsychopharmacology
<volume>38</volume>, <fpage>1221</fpage>–<lpage>1233</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2013.19</pub-id><pub-id pub-id-type="pmid">23340518</pub-id></mixed-citation>
</ref>
<ref id="B104">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harashima</surname><given-names>C.</given-names></name><name><surname>Jacobowitz</surname><given-names>D. M.</given-names></name><name><surname>Witta</surname><given-names>J.</given-names></name><name><surname>Borke</surname><given-names>R. C.</given-names></name><name><surname>Best</surname><given-names>T. K.</given-names></name><name><surname>Siarey</surname><given-names>R. J.</given-names></name><etal></etal></person-group>. (<year>2006</year>). <article-title>Abnormal expression of the G-protein-activated inwardly rectifying potassium channel 2 (GIRK2) in hippocampus, frontal cortex and substantia nigra of Ts65Dn mouse: a model of Down syndrome</article-title>. <source/>J. Comp. Neurol.
<volume>494</volume>, <fpage>815</fpage>–<lpage>833</lpage>. <pub-id pub-id-type="doi">10.1002/cne.20844</pub-id><pub-id pub-id-type="pmid">16374808</pub-id></mixed-citation>
</ref>
<ref id="B105">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hattori</surname><given-names>M.</given-names></name><name><surname>Fujiyama</surname><given-names>A.</given-names></name><name><surname>Taylor</surname><given-names>T. D.</given-names></name><name><surname>Watanabe</surname><given-names>H.</given-names></name><name><surname>Yada</surname><given-names>T.</given-names></name><name><surname>Park</surname><given-names>H. S.</given-names></name><etal></etal></person-group>. (<year>2000</year>). <article-title>The DNA sequence of human chromosome 21</article-title>. <source/>Nature
<volume>405</volume>, <fpage>311</fpage>–<lpage>319</lpage>. <pub-id pub-id-type="doi">10.1038/35012518</pub-id><pub-id pub-id-type="pmid">10830953</pub-id></mixed-citation>
</ref>
<ref id="B106">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haw</surname><given-names>C. M.</given-names></name><name><surname>Barnes</surname><given-names>T. R.</given-names></name><name><surname>Clark</surname><given-names>K.</given-names></name><name><surname>Crichton</surname><given-names>P.</given-names></name><name><surname>Kohen</surname><given-names>D.</given-names></name></person-group> (<year>1996</year>). <article-title>Movement disorder in Down’s syndrome: a possible marker of the severity of mental handicap</article-title>. <source/>Mov. Disord.
<volume>11</volume>, <fpage>395</fpage>–<lpage>403</lpage>. <pub-id pub-id-type="doi">10.1002/mds.870110408</pub-id><pub-id pub-id-type="pmid">8813219</pub-id></mixed-citation>
</ref>
<ref id="B107">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Q.</given-names></name><name><surname>Nomura</surname><given-names>T.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Contractor</surname><given-names>A.</given-names></name></person-group> (<year>2014</year>). <article-title>The developmental switch in GABA polarity is delayed in fragile X mice</article-title>. <source/>J. Neurosci.
<volume>34</volume>, <fpage>446</fpage>–<lpage>450</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.4447-13.2014</pub-id><pub-id pub-id-type="pmid">24403144</pub-id></mixed-citation>
</ref>
<ref id="B108">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernández</surname><given-names>S.</given-names></name><name><surname>Gilabert-Juan</surname><given-names>J.</given-names></name><name><surname>Blasco-Ibáñez</surname><given-names>J. M.</given-names></name><name><surname>Crespo</surname><given-names>C.</given-names></name><name><surname>Nácher</surname><given-names>J.</given-names></name><name><surname>Varea</surname><given-names>E.</given-names></name></person-group> (<year>2012</year>). <article-title>Altered expression of neuropeptides in the primary somatosensory cortex of the Down syndrome model Ts65Dn</article-title>. <source/>Neuropeptides
<volume>46</volume>, <fpage>29</fpage>–<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1016/j.npep.2011.10.002</pub-id><pub-id pub-id-type="pmid">22078870</pub-id></mixed-citation>
</ref>
<ref id="B109">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernández-González</surname><given-names>S.</given-names></name><name><surname>Ballestin</surname><given-names>R.</given-names></name><name><surname>López-Hidalgo</surname><given-names>R.</given-names></name><name><surname>Gilabert-Juan</surname><given-names>J.</given-names></name><name><surname>Blasco-Ibáñez</surname><given-names>J. M.</given-names></name><name><surname>Crespo</surname><given-names>C.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Altered distribution of hippocampal interneurons in the murine Down syndrome model Ts65Dn</article-title>. <source/>Neurochem. Res.
<volume>40</volume>, <fpage>151</fpage>–<lpage>164</lpage>. <pub-id pub-id-type="doi">10.1007/s11064-014-1479-8</pub-id><pub-id pub-id-type="pmid">25399236</pub-id></mixed-citation>
</ref>
<ref id="B110">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hibaoui</surname><given-names>Y.</given-names></name><name><surname>Grad</surname><given-names>I.</given-names></name><name><surname>Letourneau</surname><given-names>A.</given-names></name><name><surname>Sailani</surname><given-names>M. R.</given-names></name><name><surname>Dahoun</surname><given-names>S.</given-names></name><name><surname>Santoni</surname><given-names>F. A.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Modelling and rescuing neurodevelopmental defect of Down syndrome using induced pluripotent stem cells from monozygotic twins discordant for trisomy 21</article-title>. <source/>EMBO Mol. Med.
<volume>6</volume>, <fpage>259</fpage>–<lpage>277</lpage>. <pub-id pub-id-type="doi">10.1002/emmm.201302848</pub-id><pub-id pub-id-type="pmid">24375627</pub-id></mixed-citation>
</ref>
<ref id="B111">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnston</surname><given-names>A.</given-names></name><name><surname>McBain</surname><given-names>C. J.</given-names></name><name><surname>Fisahn</surname><given-names>A.</given-names></name></person-group> (<year>2014</year>). <article-title>5-Hydroxytryptamine1A receptor-activation hyperpolarizes pyramidal cells and suppresses hippocampal gamma oscillations via Kir3 channel activation</article-title>. <source/>J. Physiol.
<volume>592</volume>, <fpage>4187</fpage>–<lpage>4199</lpage>. <pub-id pub-id-type="doi">10.1113/jphysiol.2014.279083</pub-id><pub-id pub-id-type="pmid">25107925</pub-id></mixed-citation>
</ref>
<ref id="B112">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonas</surname><given-names>P.</given-names></name><name><surname>Buzsaki</surname><given-names>G.</given-names></name></person-group> (<year>2007</year>). <article-title>Neural inhibition</article-title>. <source/>Scholarpedia
<volume>2</volume>:<fpage>3286</fpage>
<pub-id pub-id-type="doi">10.4249/scholarpedia.3286</pub-id></mixed-citation>
</ref>
<ref id="B113">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joshi</surname><given-names>K.</given-names></name><name><surname>Shen</surname><given-names>L.</given-names></name><name><surname>Michaeli</surname><given-names>A.</given-names></name><name><surname>Salter</surname><given-names>M.</given-names></name><name><surname>Thibault-Messier</surname><given-names>G.</given-names></name><name><surname>Hashmi</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>Infantile spasms in down syndrome: rescue by knockdown of the GIRK2 channel</article-title>. <source/>Ann. Neurol.
<volume>80</volume>, <fpage>511</fpage>–<lpage>521</lpage>. <pub-id pub-id-type="doi">10.1002/ana.24749</pub-id><pub-id pub-id-type="pmid">27462820</pub-id></mixed-citation>
</ref>
<ref id="B114">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaila</surname><given-names>K.</given-names></name><name><surname>Price</surname><given-names>T. J.</given-names></name><name><surname>Payne</surname><given-names>J. A.</given-names></name><name><surname>Puskarjov</surname><given-names>M.</given-names></name><name><surname>Voipio</surname><given-names>J.</given-names></name></person-group> (<year>2014a</year>). <article-title>Cation-chloride cotransporters in neuronal development, plasticity and disease</article-title>. <source/>Nat. Rev. Neurosci.
<volume>15</volume>, <fpage>637</fpage>–<lpage>654</lpage>. <pub-id pub-id-type="doi">10.1038/nrn3819</pub-id><pub-id pub-id-type="pmid">25234263</pub-id></mixed-citation>
</ref>
<ref id="B115">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaila</surname><given-names>K.</given-names></name><name><surname>Ruusuvuori</surname><given-names>E.</given-names></name><name><surname>Seja</surname><given-names>P.</given-names></name><name><surname>Voipio</surname><given-names>J.</given-names></name><name><surname>Puskarjov</surname><given-names>M.</given-names></name></person-group> (<year>2014b</year>). <article-title>GABA actions and ionic plasticity in epilepsy</article-title>. <source/>Curr. Opin. Neurobiol.
<volume>26</volume>, <fpage>34</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/j.conb.2013.11.004</pub-id><pub-id pub-id-type="pmid">24650502</pub-id></mixed-citation>
</ref>
<ref id="B116">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katona</surname><given-names>I.</given-names></name><name><surname>Sperlágh</surname><given-names>B.</given-names></name><name><surname>Sík</surname><given-names>A.</given-names></name><name><surname>Käfalvi</surname><given-names>A.</given-names></name><name><surname>Vizi</surname><given-names>E. S.</given-names></name><name><surname>Mackie</surname><given-names>K.</given-names></name><etal></etal></person-group>. (<year>1999</year>). <article-title>Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons</article-title>. <source/>J. Neurosci.
<volume>19</volume>, <fpage>4544</fpage>–<lpage>4558</lpage>. <pub-id pub-id-type="pmid">10341254</pub-id></mixed-citation>
</ref>
<ref id="B117">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kesslak</surname><given-names>J. P.</given-names></name><name><surname>Nagata</surname><given-names>S. F.</given-names></name><name><surname>Lott</surname><given-names>I.</given-names></name><name><surname>Nalciouglu</surname><given-names>O.</given-names></name></person-group> (<year>1994</year>). <article-title>Magnetic resonance imaging analysis of age-related changes in the brains of individuals with Down’s syndrome</article-title>. <source/>Neurology
<volume>44</volume>, <fpage>1039</fpage>–<lpage>1045</lpage>. <pub-id pub-id-type="doi">10.1212/wnl.44.6.1039</pub-id><pub-id pub-id-type="pmid">8208396</pub-id></mixed-citation>
</ref>
<ref id="B118">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khazipov</surname><given-names>R.</given-names></name><name><surname>Valeeva</surname><given-names>G.</given-names></name><name><surname>Khalilov</surname><given-names>I.</given-names></name></person-group> (<year>2015</year>). <article-title>Depolarizing GABA and developmental epilepsies</article-title>. <source/>CNS Neurosci. Ther.
<volume>21</volume>, <fpage>83</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1111/cns.12353</pub-id><pub-id pub-id-type="pmid">25438879</pub-id></mixed-citation>
</ref>
<ref id="B119">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khirug</surname><given-names>S.</given-names></name><name><surname>Yamada</surname><given-names>J.</given-names></name><name><surname>Afzalov</surname><given-names>R.</given-names></name><name><surname>Voipio</surname><given-names>J.</given-names></name><name><surname>Khiroug</surname><given-names>L.</given-names></name><name><surname>Kaila</surname><given-names>K.</given-names></name></person-group> (<year>2008</year>). <article-title>GABAergic depolarization of the axon initial segment in cortical principal neurons is caused by the Na-K-2Cl cotransporter NKCC1</article-title>. <source/>J. Neurosci.
<volume>28</volume>, <fpage>4635</fpage>–<lpage>4639</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0908-08.2008</pub-id><pub-id pub-id-type="pmid">18448640</pub-id></mixed-citation>
</ref>
<ref id="B120">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kilb</surname><given-names>W.</given-names></name><name><surname>Kirischuk</surname><given-names>S.</given-names></name><name><surname>Luhmann</surname><given-names>H. J.</given-names></name></person-group> (<year>2013</year>). <article-title>Role of tonic GABAergic currents during pre- and early postnatal rodent development</article-title>. <source/>Front. Neural Circuits
<volume>7</volume>:<fpage>139</fpage>. <pub-id pub-id-type="doi">10.3389/fncir.2013.00139</pub-id><pub-id pub-id-type="pmid">24027498</pub-id></mixed-citation>
</ref>
<ref id="B121">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiryanova</surname><given-names>V.</given-names></name><name><surname>McAllister</surname><given-names>B. B.</given-names></name><name><surname>Dyck</surname><given-names>R. H.</given-names></name></person-group> (<year>2013</year>). <article-title>Long-term outcomes of developmental exposure to fluoxetine: a review of the animal literature</article-title>. <source/>Dev. Neurosci.
<volume>35</volume>, <fpage>437</fpage>–<lpage>439</lpage>. <pub-id pub-id-type="doi">10.1159/000355709</pub-id><pub-id pub-id-type="pmid">24247012</pub-id></mixed-citation>
</ref>
<ref id="B122">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleschevnikov</surname><given-names>A. M.</given-names></name><name><surname>Belichenko</surname><given-names>P. V.</given-names></name><name><surname>Faizi</surname><given-names>M.</given-names></name><name><surname>Jacobs</surname><given-names>L. F.</given-names></name><name><surname>Htun</surname><given-names>K.</given-names></name><name><surname>Shamloo</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2012a</year>). <article-title>Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABA<sub>B</sub> receptor antagonists</article-title>. <source/>J. Neurosci.
<volume>32</volume>, <fpage>9217</fpage>–<lpage>9227</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1673-12.2012</pub-id><pub-id pub-id-type="pmid">22764230</pub-id></mixed-citation>
</ref>
<ref id="B123">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleschevnikov</surname><given-names>A. M.</given-names></name><name><surname>Belichenko</surname><given-names>P. V.</given-names></name><name><surname>Gall</surname><given-names>J.</given-names></name><name><surname>George</surname><given-names>L.</given-names></name><name><surname>Nosheny</surname><given-names>R.</given-names></name><name><surname>Maloney</surname><given-names>M. T.</given-names></name><etal></etal></person-group>. (<year>2012b</year>). <article-title>Increased efficiency of the GABA<sub>A</sub> and GABA<sub>B</sub> receptor-mediated neurotransmission in the Ts65Dn mouse model of Down syndrome</article-title>. <source/>Neurobiol. Dis.
<volume>45</volume>, <fpage>683</fpage>–<lpage>691</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2011.10.009</pub-id><pub-id pub-id-type="pmid">22062771</pub-id></mixed-citation>
</ref>
<ref id="B124">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleschevnikov</surname><given-names>A. M.</given-names></name><name><surname>Belichenko</surname><given-names>P. V.</given-names></name><name><surname>Villar</surname><given-names>A. J.</given-names></name><name><surname>Epstein</surname><given-names>C. J.</given-names></name><name><surname>Malenka</surname><given-names>R. C.</given-names></name><name><surname>Mobley</surname><given-names>W. C.</given-names></name></person-group> (<year>2004</year>). <article-title>Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome</article-title>. <source/>J. Neurosci.
<volume>24</volume>, <fpage>8153</fpage>–<lpage>8160</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.1766-04.2004</pub-id><pub-id pub-id-type="pmid">15371516</pub-id></mixed-citation>
</ref>
<ref id="B125">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>M. C.</given-names></name><name><surname>Lee</surname><given-names>L. J.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Lee</surname><given-names>L. J.</given-names></name></person-group> (<year>2014</year>). <article-title>Long-term consequences of neonatal fluoxetine exposure in adult rats</article-title>. <source/>Dev. Neurobiol.
<volume>74</volume>, <fpage>1038</fpage>–<lpage>1051</lpage>. <pub-id pub-id-type="doi">10.1002/dneu.22185</pub-id><pub-id pub-id-type="pmid">24771683</pub-id></mixed-citation>
</ref>
<ref id="B126">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>K.</given-names></name><name><surname>Emson</surname><given-names>P. C.</given-names></name><name><surname>Mountjoy</surname><given-names>C. Q.</given-names></name><name><surname>Thornton</surname><given-names>S. N.</given-names></name><name><surname>Lawson</surname><given-names>D. E.</given-names></name><name><surname>Mann</surname><given-names>D. M.</given-names></name></person-group> (<year>1990</year>). <article-title>Cerebral cortical calbindin D28K and parvalbumin neurones in Down’s syndrome</article-title>. <source/>Neurosci. Lett.
<volume>113</volume>, <fpage>17</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/0304-3940(90)90487-t</pub-id><pub-id pub-id-type="pmid">2142259</pub-id></mixed-citation>
</ref>
<ref id="B127">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>T.</given-names></name><name><surname>Washiyama</surname><given-names>K.</given-names></name><name><surname>Ikeda</surname><given-names>K.</given-names></name></person-group> (<year>2003</year>). <article-title>Inhibition of G protein-activated inwardly rectifying K<sup>+</sup> channels by fluoxetine (Prozac)</article-title>. <source/>Br. J. Pharmacol.
<volume>138</volume>, <fpage>1119</fpage>–<lpage>1128</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjp.0705172</pub-id><pub-id pub-id-type="pmid">12684268</pub-id></mixed-citation>
</ref>
<ref id="B128">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohl</surname><given-names>M. M.</given-names></name><name><surname>Paulsen</surname><given-names>O.</given-names></name></person-group> (<year>2010</year>). <article-title>The roles of GABAB receptors in cortical network activity</article-title>. <source/>Adv. Pharmacol.
<volume>58</volume>, <fpage>205</fpage>–<lpage>229</lpage>. <pub-id pub-id-type="doi">10.1016/S1054-3589(10)58009-8</pub-id><pub-id pub-id-type="pmid">20655484</pub-id></mixed-citation>
</ref>
<ref id="B129">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konstantinopoulou</surname><given-names>S.</given-names></name><name><surname>Tapia</surname><given-names>I. E.</given-names></name><name><surname>Kim</surname><given-names>J. Y.</given-names></name><name><surname>Xanthopoulos</surname><given-names>M. S.</given-names></name><name><surname>Radcliffe</surname><given-names>J.</given-names></name><name><surname>Cohen</surname><given-names>M. S.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>Relationship between obstructive sleep apnea cardiac complications and sleepiness in children with Down syndrome</article-title>. <source/>Sleep Med.
<volume>17</volume>, <fpage>18</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1016/j.sleep.2015.09.014</pub-id><pub-id pub-id-type="pmid">26847969</pub-id></mixed-citation>
</ref>
<ref id="B130">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korenberg</surname><given-names>J. R.</given-names></name><name><surname>Chen</surname><given-names>X. N.</given-names></name><name><surname>Schipper</surname><given-names>R.</given-names></name><name><surname>Sun</surname><given-names>Z.</given-names></name><name><surname>Gonsky</surname><given-names>R.</given-names></name><name><surname>Gerwehr</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>1994</year>). <article-title>Down syndrome phenotypes: the consequences of chromosomal imbalance</article-title>. <source/>Proc. Natl. Acad. Sci. U S A
<volume>91</volume>, <fpage>4997</fpage>–<lpage>5001</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.91.11.4997</pub-id><pub-id pub-id-type="pmid">8197171</pub-id></mixed-citation>
</ref>
<ref id="B131">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koyrakh</surname><given-names>L.</given-names></name><name><surname>Luján</surname><given-names>R.</given-names></name><name><surname>Colón</surname><given-names>J.</given-names></name><name><surname>Karschin</surname><given-names>C.</given-names></name><name><surname>Kurachi</surname><given-names>Y.</given-names></name><name><surname>Karschin</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2005</year>). <article-title>Molecular and cellular diversity of neuronal G-protein-gated potassium channels</article-title>. <source/>J. Neurosci.
<volume>25</volume>, <fpage>11468</fpage>–<lpage>11478</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3484-05.2005</pub-id><pub-id pub-id-type="pmid">16339040</pub-id></mixed-citation>
</ref>
<ref id="B133">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurt</surname><given-names>M. A.</given-names></name><name><surname>Davies</surname><given-names>D. C.</given-names></name><name><surname>Kidd</surname><given-names>M.</given-names></name><name><surname>Dierssen</surname><given-names>M.</given-names></name><name><surname>Florez</surname><given-names>J.</given-names></name></person-group> (<year>2000</year>). <article-title>Synaptic deficit in the temporal cortex of partial trisomy 16 (Ts65Dn) mice</article-title>. <source/>Brain Res.
<volume>858</volume>, <fpage>191</fpage>–<lpage>197</lpage>. <pub-id pub-id-type="doi">10.1016/s0006-8993(00)01984-3</pub-id><pub-id pub-id-type="pmid">10700614</pub-id></mixed-citation>
</ref>
<ref id="B132">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurt</surname><given-names>A. M.</given-names></name><name><surname>Kafa</surname><given-names>I. M.</given-names></name><name><surname>Dierssen</surname><given-names>M.</given-names></name><name><surname>Davies</surname><given-names>C. D.</given-names></name></person-group> (<year>2004</year>). <article-title>Deficits of neuronal density in CA1 and synaptic density in the dentate gyrus, CA3 and CA1, in a mouse model of Down syndrome</article-title>. <source/>Brain Res.
<volume>1022</volume>, <fpage>101</fpage>–<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2004.06.075</pub-id><pub-id pub-id-type="pmid">15353219</pub-id></mixed-citation>
</ref>
<ref id="B134">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamsa</surname><given-names>K.</given-names></name><name><surname>Taira</surname><given-names>T.</given-names></name></person-group> (<year>2003</year>). <article-title>Use-dependent shift from inhibitory to excitatory GABAA receptor action in SP-O interneurons in the rat hippocampal CA3 area</article-title>. <source/>J. Neurophysiol.
<volume>90</volume>, <fpage>1983</fpage>–<lpage>1995</lpage>. <pub-id pub-id-type="doi">10.1152/jn.00060.2003</pub-id><pub-id pub-id-type="pmid">12750426</pub-id></mixed-citation>
</ref>
<ref id="B135">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsen</surname><given-names>K. B.</given-names></name><name><surname>Laursen</surname><given-names>H.</given-names></name><name><surname>Græmb</surname><given-names>N.</given-names></name><name><surname>Samuelsena</surname><given-names>G. B.</given-names></name><name><surname>Bogdanovicc</surname><given-names>N.</given-names></name><name><surname>Pakkenberga</surname><given-names>B.</given-names></name></person-group> (<year>2008</year>). <article-title>Reduced cell number in the neocortical part of the human fetal brain in Down syndrome</article-title>. <source/>Ann. Anat.
<volume>190</volume>, <fpage>421</fpage>–<lpage>427</lpage>. <pub-id pub-id-type="doi">10.1016/j.aanat.2008.05.007</pub-id><pub-id pub-id-type="pmid">18722098</pub-id></mixed-citation>
</ref>
<ref id="B137">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S. H.</given-names></name><name><surname>Ledri</surname><given-names>M.</given-names></name><name><surname>Tóth</surname><given-names>B.</given-names></name><name><surname>Marchionni</surname><given-names>I.</given-names></name><name><surname>Henstridge</surname><given-names>C. M.</given-names></name><name><surname>Dudok</surname><given-names>B.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Multiple forms of Endocannabinoid and endovanilloid signaling regulate the tonic control of GABA release</article-title>. <source/>J. Neurosci.
<volume>35</volume>, <fpage>10039</fpage>–<lpage>10057</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.4112-14.2015</pub-id><pub-id pub-id-type="pmid">26157003</pub-id></mixed-citation>
</ref>
<ref id="B138">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leinekugel</surname><given-names>X.</given-names></name><name><surname>Medina</surname><given-names>I.</given-names></name><name><surname>Khalilov</surname><given-names>I.</given-names></name><name><surname>Ben-Ari</surname><given-names>Y.</given-names></name><name><surname>Khazipov</surname><given-names>R.</given-names></name></person-group> (<year>1997</year>). <article-title>Ca<sup>2+</sup> oscillations mediated by the synergistic excitatory actions of GABA<sub>A</sub> and NMDA receptors in the neonatal hippocampus</article-title>. <source/>Neuron
<volume>18</volume>, <fpage>243</fpage>–<lpage>255</lpage>. <pub-id pub-id-type="doi">10.1016/s0896-6273(00)80265-2</pub-id><pub-id pub-id-type="pmid">9052795</pub-id></mixed-citation>
</ref>
<ref id="B139">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leinekugel</surname><given-names>X.</given-names></name><name><surname>Tseeb</surname><given-names>V.</given-names></name><name><surname>Ben-Ari</surname><given-names>Y.</given-names></name><name><surname>Bregestovski</surname><given-names>P.</given-names></name></person-group> (<year>1995</year>). <article-title>Synaptic GABAA activation induces Ca<sup>2+</sup> rise in pyramidal cells and interneurons from rat neonatal hippocampal slices</article-title>. <source/>J. Physiol.
<volume>487</volume>, <fpage>319</fpage>–<lpage>329</lpage>. <pub-id pub-id-type="doi">10.1113/jphysiol.1995.sp020882</pub-id><pub-id pub-id-type="pmid">8558466</pub-id></mixed-citation>
</ref>
<ref id="B136">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Magueresse</surname><given-names>C.</given-names></name><name><surname>Monyer</surname><given-names>H.</given-names></name></person-group> (<year>2013</year>). <article-title>GABAergic interneurons shape the functional maturation of the cortex</article-title>. <source/>Neuron
<volume>77</volume>, <fpage>388</fpage>–<lpage>405</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2013.01.011</pub-id><pub-id pub-id-type="pmid">23395369</pub-id></mixed-citation>
</ref>
<ref id="B140">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>L. S.</given-names></name><name><surname>Peloquin</surname><given-names>P.</given-names></name></person-group> (<year>2006</year>). <article-title>GABA<sub>B</sub> receptors inhibit backpropagating dendritic spikes in hippocampal CA1 pyramidal cells <italic>in vivo</italic></article-title>. <source/>Hippocampus
<volume>16</volume>, <fpage>388</fpage>–<lpage>407</lpage>. <pub-id pub-id-type="doi">10.1002/hipo.20168</pub-id><pub-id pub-id-type="pmid">16411229</pub-id></mixed-citation>
</ref>
<ref id="B141">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levelt</surname><given-names>C. N.</given-names></name><name><surname>Hübener</surname><given-names>M.</given-names></name></person-group> (<year>2012</year>). <article-title>Critical-period plasticity in the visual cortex</article-title>. <source/>Annu. Rev. Neurosci.
<volume>35</volume>, <fpage>309</fpage>–<lpage>330</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-neuro-061010-113813</pub-id><pub-id pub-id-type="pmid">22462544</pub-id></mixed-citation>
</ref>
<ref id="B142">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leverenz</surname><given-names>J. B.</given-names></name><name><surname>Raskind</surname><given-names>M. A.</given-names></name></person-group> (<year>1998</year>). <article-title>Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis</article-title>. <source/>Exp. Neurol.
<volume>150</volume>, <fpage>296</fpage>–<lpage>304</lpage>. <pub-id pub-id-type="doi">10.1006/exnr.1997.6777</pub-id><pub-id pub-id-type="pmid">9527899</pub-id></mixed-citation>
</ref>
<ref id="B143">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Bu</surname><given-names>G.</given-names></name><name><surname>Zheng</surname><given-names>H.</given-names></name></person-group> (<year>2016</year>). <article-title>Implications of GABAergic neurotransmission in Alzheimer’s disease</article-title>. <source/>Front. Aging Neurosci.
<volume>8</volume>:<fpage>31</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2016.00031</pub-id><pub-id pub-id-type="pmid">26941642</pub-id></mixed-citation>
</ref>
<ref id="B144">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Morishima</surname><given-names>M.</given-names></name><name><surname>Pao</surname><given-names>A.</given-names></name><name><surname>Laduca</surname><given-names>J.</given-names></name><name><surname>Conroy</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>Duplication of the entire 22.9 Mb human chromosome 21 syntenic region on mouse chromosome 16 causes cardiovascular and gastrointestinal abnormalities</article-title>. <source/>Hum. Mol. Genet.
<volume>16</volume>, <fpage>1359</fpage>–<lpage>1366</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddm086</pub-id><pub-id pub-id-type="pmid">17412756</pub-id></mixed-citation>
</ref>
<ref id="B145">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llamosas</surname><given-names>N.</given-names></name><name><surname>Bruzos-Cidón</surname><given-names>C.</given-names></name><name><surname>Rodríguez</surname><given-names>J. J.</given-names></name><name><surname>Ugedo</surname><given-names>L.</given-names></name><name><surname>Torrecilla</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>Deletion of GIRK2 Subunit of GIRK channels alters the 5-HT1A receptor-mediated signaling and results in a depression-resistant behavior</article-title>. <source/>Int. J. Neuropsychopharmacol.
<volume>18</volume>:<fpage>pyv051</fpage>. <pub-id pub-id-type="doi">10.1093/ijnp/pyv051</pub-id><pub-id pub-id-type="pmid">25956878</pub-id></mixed-citation>
</ref>
<ref id="B146">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lockrow</surname><given-names>J.</given-names></name><name><surname>Bogera</surname><given-names>H.</given-names></name><name><surname>Bimonte-Nelson</surname><given-names>H.</given-names></name><name><surname>Granholm</surname><given-names>A. C.</given-names></name></person-group> (<year>2011</year>). <article-title>Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome</article-title>. <source/>Behav. Brain Res.
<volume>221</volume>, <fpage>610</fpage>–<lpage>622</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2010.03.036</pub-id><pub-id pub-id-type="pmid">20363261</pub-id></mixed-citation>
</ref>
<ref id="B147">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>López-Bendito</surname><given-names>G.</given-names></name><name><surname>Luján</surname><given-names>R.</given-names></name><name><surname>Shigemoto</surname><given-names>R.</given-names></name><name><surname>Ganter</surname><given-names>P.</given-names></name><name><surname>Paulsen</surname><given-names>O.</given-names></name><name><surname>Molnár</surname><given-names>Z.</given-names></name></person-group> (<year>2003</year>). <article-title>Blockade of GABA<sub>B</sub> receptors alters the tangential migration of cortical neurons</article-title>. <source/>Cereb. Cortex
<volume>13</volume>, <fpage>932</fpage>–<lpage>942</lpage>. <pub-id pub-id-type="doi">10.1093/cercor/13.9.932</pub-id><pub-id pub-id-type="pmid">12902392</pub-id></mixed-citation>
</ref>
<ref id="B148">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorenzi</surname><given-names>H. A.</given-names></name><name><surname>Reeves</surname><given-names>R. H.</given-names></name></person-group> (<year>2006</year>). <article-title>Hippocampal hypocellularity in the Ts65Dn mouse originates early in development</article-title>. <source/>Brain Res.
<volume>1104</volume>, <fpage>153</fpage>–<lpage>159</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2006.05.022</pub-id><pub-id pub-id-type="pmid">16828061</pub-id></mixed-citation>
</ref>
<ref id="B150">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lott</surname><given-names>I. T.</given-names></name></person-group> (<year>2012</year>). <article-title>Neurological phenotypes for Down syndrome across the life span</article-title>. <source/>Prog. Brain Res.
<volume>197</volume>, <fpage>101</fpage>–<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1016/b978-0-444-54299-1.00006-6</pub-id><pub-id pub-id-type="pmid">22541290</pub-id></mixed-citation>
</ref>
<ref id="B149">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lott</surname><given-names>I.</given-names></name><name><surname>Dierssen</surname><given-names>M.</given-names></name></person-group> (<year>2010</year>). <article-title>Cognitive deficits and associated neurological complications in individuals with Down’s syndrome</article-title>. <source/>Lancet Neurol.
<volume>9</volume>, <fpage>623</fpage>–<lpage>633</lpage>. <pub-id pub-id-type="doi">10.1016/s1474-4422(10)70112-5</pub-id><pub-id pub-id-type="pmid">20494326</pub-id></mixed-citation>
</ref>
<ref id="B151">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luhmann</surname><given-names>H. J.</given-names></name><name><surname>Fukuda</surname><given-names>A.</given-names></name><name><surname>Kilb</surname><given-names>W.</given-names></name></person-group> (<year>2015</year>). <article-title>Control of cortical neuronal migration by glutamate and GABA</article-title>. <source/>Front. Cell. Neurosci.
<volume>9</volume>:<fpage>4</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2015.00004</pub-id><pub-id pub-id-type="pmid">25688185</pub-id></mixed-citation>
</ref>
<ref id="B152">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lüscher</surname><given-names>C.</given-names></name><name><surname>Jan</surname><given-names>L. Y.</given-names></name><name><surname>Stoffel</surname><given-names>M.</given-names></name><name><surname>Malenka</surname><given-names>R. C.</given-names></name><name><surname>Nicoll</surname><given-names>R. A.</given-names></name></person-group> (<year>1997</year>). <article-title>G protein-coupled inwardly rectifying K<sup>+</sup> channels (GIRKs) mediate postsynaptic but not presynaptic transmitter actions in hippocampal neurons</article-title>. <source/>Neuron
<volume>19</volume>, <fpage>687</fpage>–<lpage>695</lpage>. <pub-id pub-id-type="doi">10.1016/s0896-6273(00)80381-5</pub-id><pub-id pub-id-type="pmid">9331358</pub-id></mixed-citation>
</ref>
<ref id="B153">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>M. A.</given-names></name></person-group> (<year>2004</year>). <article-title>Long-term potentiation and memory</article-title>. <source/>Physiol. Rev.
<volume>84</volume>, <fpage>87</fpage>–<lpage>136</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00014.2003</pub-id><pub-id pub-id-type="pmid">14715912</pub-id></mixed-citation>
</ref>
<ref id="B154">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lysenko</surname><given-names>L. V.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Henry</surname><given-names>C.</given-names></name><name><surname>Tyrtyshnaia</surname><given-names>A.</given-names></name><name><surname>Kohnz</surname><given-names>R. A.</given-names></name><name><surname>Madamba</surname><given-names>F.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Monoacylglycerol lipase inhibitor JZL184 improves behavior and neural properties in Ts65Dn mice, a model of down syndrome</article-title>. <source/>PLoS One
<volume>9</volume>:<fpage>e114521</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0114521</pub-id><pub-id pub-id-type="pmid">25474204</pub-id></mixed-citation>
</ref>
<ref id="B155">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mann</surname><given-names>D. M.</given-names></name><name><surname>Esiri</surname><given-names>M. M.</given-names></name></person-group> (<year>1989</year>). <article-title>The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down’s syndrome</article-title>. <source/>J. Neurol. Sci.
<volume>89</volume>, <fpage>169</fpage>–<lpage>179</lpage>. <pub-id pub-id-type="doi">10.1016/0022-510x(89)90019-1</pub-id><pub-id pub-id-type="pmid">2522541</pub-id></mixed-citation>
</ref>
<ref id="B157">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mann</surname><given-names>E. O.</given-names></name><name><surname>Kohl</surname><given-names>M. M.</given-names></name><name><surname>Paulsen</surname><given-names>O.</given-names></name></person-group> (<year>2009</year>). <article-title>Distinct roles of GABA<sub>A</sub> and GABA<sub>B</sub> receptors in balancing and terminating persistent cortical activity</article-title>. <source/>J. Neurosci.
<volume>29</volume>, <fpage>7513</fpage>–<lpage>7518</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.6162-08.2009</pub-id><pub-id pub-id-type="pmid">19515919</pub-id></mixed-citation>
</ref>
<ref id="B156">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mann</surname><given-names>E. O.</given-names></name><name><surname>Mody</surname><given-names>I.</given-names></name></person-group> (<year>2010</year>). <article-title>Control of hippocampal gamma oscillation frequency by tonic inhibition and excitation of interneurons</article-title>. <source/>Nat. Neurosci.
<volume>13</volume>, <fpage>205</fpage>–<lpage>212</lpage>. <pub-id pub-id-type="doi">10.1038/nn.2464</pub-id><pub-id pub-id-type="pmid">20023655</pub-id></mixed-citation>
</ref>
<ref id="B158">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcott</surname><given-names>P. F.</given-names></name><name><surname>Mamaligas</surname><given-names>A. A.</given-names></name><name><surname>Ford</surname><given-names>C. P.</given-names></name></person-group> (<year>2014</year>). <article-title>Phasic dopamine release drives rapid activation of striatal D2-receptors</article-title>. <source/>Neuron
<volume>84</volume>, <fpage>164</fpage>–<lpage>176</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2014.08.058</pub-id><pub-id pub-id-type="pmid">25242218</pub-id></mixed-citation>
</ref>
<ref id="B159">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marín</surname><given-names>O.</given-names></name><name><surname>Müller</surname><given-names>U.</given-names></name></person-group> (<year>2014</year>). <article-title>Lineage origins of GABAergic versus glutamatergic neurons in the neocortex</article-title>. <source/>Curr. Opin. Neurobiol.
<volume>26</volume>, <fpage>132</fpage>–<lpage>141</lpage>. <pub-id pub-id-type="doi">10.1016/j.conb.2014.01.015</pub-id><pub-id pub-id-type="pmid">24549207</pub-id></mixed-citation>
</ref>
<ref id="B160">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maris</surname><given-names>M.</given-names></name><name><surname>Verhulst</surname><given-names>S.</given-names></name><name><surname>Wojciechowski</surname><given-names>M.</given-names></name><name><surname>Van De Heyning</surname><given-names>P.</given-names></name><name><surname>Boudewyns</surname><given-names>A.</given-names></name></person-group> (<year>2016</year>). <article-title>Prevalence of obstructive sleep apnea in children with down syndrome</article-title>. <source/>Sleep
<volume>39</volume>, <fpage>699</fpage>–<lpage>704</lpage>. <pub-id pub-id-type="doi">10.5665/sleep.5554</pub-id><pub-id pub-id-type="pmid">26612391</pub-id></mixed-citation>
</ref>
<ref id="B161">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martínez-Cué</surname><given-names>C.</given-names></name><name><surname>Martínez</surname><given-names>P.</given-names></name><name><surname>Rueda</surname><given-names>N.</given-names></name><name><surname>Vidal</surname><given-names>R.</given-names></name><name><surname>García</surname><given-names>S.</given-names></name><name><surname>Vidal</surname><given-names>V.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Reducing GABA<sub>A</sub> α5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of down syndrome</article-title>. <source/>J. Neurosci.
<volume>33</volume>, <fpage>3953</fpage>–<lpage>3966</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1203-12.2013</pub-id><pub-id pub-id-type="pmid">23447605</pub-id></mixed-citation>
</ref>
<ref id="B162">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuyama</surname><given-names>S.</given-names></name><name><surname>Taniguchi</surname><given-names>T.</given-names></name><name><surname>Kadoyama</surname><given-names>K.</given-names></name><name><surname>Matsumoto</surname><given-names>A.</given-names></name></person-group> (<year>2008</year>). <article-title>Long-term potentiation-like facilitation through GABA<sub>A</sub> receptor blockade in the mouse dentate gyrus <italic>in vivo</italic></article-title>. <source/>Neuroreport
<volume>19</volume>, <fpage>1809</fpage>–<lpage>1813</lpage>. <pub-id pub-id-type="doi">10.1097/WNR.0b013e328319ab94</pub-id><pub-id pub-id-type="pmid">18971795</pub-id></mixed-citation>
</ref>
<ref id="B163">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maya Vetencourt</surname><given-names>J. F.</given-names></name><name><surname>Sale</surname><given-names>A.</given-names></name><name><surname>Viegi</surname><given-names>A.</given-names></name><name><surname>Baroncelli</surname><given-names>L.</given-names></name><name><surname>De Pasquale</surname><given-names>R.</given-names></name><name><surname>O’Leary</surname><given-names>O. F.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>The antidepressant fluoxetine restores plasticity in the adult visual cortex</article-title>. <source/>Science
<volume>320</volume>, <fpage>385</fpage>–<lpage>388</lpage>. <pub-id pub-id-type="doi">10.1126/science.1150516</pub-id><pub-id pub-id-type="pmid">18420937</pub-id></mixed-citation>
</ref>
<ref id="B164">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLean</surname><given-names>H. A.</given-names></name><name><surname>Caillard</surname><given-names>O.</given-names></name><name><surname>Khazipov</surname><given-names>R.</given-names></name><name><surname>Ben-Ari</surname><given-names>Y.</given-names></name><name><surname>Gaiarsa</surname><given-names>J. L.</given-names></name></person-group> (<year>1996</year>). <article-title>Spontaneous release of GABA activates GABA<sub>B</sub> receptors and controls network activity in the neonatal rat hippocampus</article-title>. <source/>J. Neurophysiol.
<volume>76</volume>, <fpage>1036</fpage>–<lpage>1046</lpage>. <pub-id pub-id-type="pmid">8871218</pub-id></mixed-citation>
</ref>
<ref id="B165">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Megías</surname><given-names>M.</given-names></name><name><surname>Emri</surname><given-names>Z.</given-names></name><name><surname>Freund</surname><given-names>T. F.</given-names></name><name><surname>Gulyás</surname><given-names>A. I.</given-names></name></person-group> (<year>2001</year>). <article-title>Total number and distribution of inhibitory and excitatory synapses on hippocampal CA1 pyramidal cells</article-title>. <source/>Neuroscience
<volume>102</volume>, <fpage>527</fpage>–<lpage>540</lpage>. <pub-id pub-id-type="doi">10.1016/s0306-4522(00)00496-6</pub-id><pub-id pub-id-type="pmid">11226691</pub-id></mixed-citation>
</ref>
<ref id="B166">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Méndez</surname><given-names>P.</given-names></name><name><surname>Pazienti</surname><given-names>A.</given-names></name><name><surname>Szabó</surname><given-names>G.</given-names></name><name><surname>Bacci</surname><given-names>A.</given-names></name></person-group> (<year>2012</year>). <article-title>Direct alteration of a specific inhibitory circuit of the hippocampus by antidepressants</article-title>. <source/>J. Neurosci.
<volume>32</volume>, <fpage>16616</fpage>–<lpage>16628</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1720-12.2012</pub-id><pub-id pub-id-type="pmid">23175817</pub-id></mixed-citation>
</ref>
<ref id="B167">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitra</surname><given-names>A.</given-names></name><name><surname>Blank</surname><given-names>M.</given-names></name><name><surname>Madison</surname><given-names>D. V.</given-names></name></person-group> (<year>2012</year>). <article-title>Developmentally altered inhibition in Ts65Dn, a mouse model of Down syndrome</article-title>. <source/>Brain Res.
<volume>1440</volume>, <fpage>1</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2011.12.034</pub-id><pub-id pub-id-type="pmid">22284618</pub-id></mixed-citation>
</ref>
<ref id="B168">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Möhler</surname><given-names>H.</given-names></name></person-group> (<year>2012</year>). <article-title>The GABA system in anxiety and depression and its therapeutic potential</article-title>. <source/>Neuropharmacology
<volume>62</volume>, <fpage>42</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2011.08.040</pub-id><pub-id pub-id-type="pmid">21889518</pub-id></mixed-citation>
</ref>
<ref id="B169">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mojabi</surname><given-names>F. S.</given-names></name><name><surname>Fahimi</surname><given-names>A.</given-names></name><name><surname>Moghadam</surname><given-names>S.</given-names></name><name><surname>Moghadam</surname><given-names>S.</given-names></name><name><surname>Windy McNerneny</surname><given-names>M. W.</given-names></name><name><surname>Ponnusamy</surname><given-names>R.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>GABAergic hyperinnervation of dentate granule cells in the Ts65Dn mouse model of down syndrome exploring the role of app</article-title>. <source/>Hippocampus
<volume>26</volume>, <fpage>1641</fpage>–<lpage>1654</lpage>. <pub-id pub-id-type="doi">10.1002/hipo.22664</pub-id><pub-id pub-id-type="pmid">27701794</pub-id></mixed-citation>
</ref>
<ref id="B170">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mombereau</surname><given-names>C.</given-names></name><name><surname>Kaupmann</surname><given-names>K.</given-names></name><name><surname>Gassmann</surname><given-names>M.</given-names></name><name><surname>Bettler</surname><given-names>B.</given-names></name><name><surname>van der Putten</surname><given-names>H.</given-names></name><name><surname>Cryan</surname><given-names>J. F.</given-names></name></person-group> (<year>2005</year>). <article-title>Altered anxiety and depression-related behaviour in mice lacking GABAB<sub>2</sub> receptor subunits</article-title>. <source/>Neuroreport
<volume>16</volume>, <fpage>307</fpage>–<lpage>310</lpage>. <pub-id pub-id-type="doi">10.1097/00001756-200502280-00021</pub-id><pub-id pub-id-type="pmid">15706241</pub-id></mixed-citation>
</ref>
<ref id="B171">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montalbano</surname><given-names>A.</given-names></name><name><surname>Corradetti</surname><given-names>R.</given-names></name><name><surname>Mlinar</surname><given-names>B.</given-names></name></person-group> (<year>2015</year>). <article-title>Pharmacological characterization of 5-HT1A autoreceptor-coupled GIRK channels in rat dorsal raphe 5-HT neurons</article-title>. <source/>PLoS One
<volume>10</volume>:<fpage>e0140369</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0140369</pub-id><pub-id pub-id-type="pmid">26460748</pub-id></mixed-citation>
</ref>
<ref id="B172">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Gandhy</surname><given-names>S. U.</given-names></name><name><surname>Strawderman</surname><given-names>M.</given-names></name><name><surname>Levitsky</surname><given-names>D. A.</given-names></name><name><surname>Maclean</surname><given-names>K. N.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Perinatal choline supplementation improves cognitive functioning and emotion regulation in the Ts65Dn mouse model of Down syndrome</article-title>. <source/>Behav. Neurosci.
<volume>124</volume>, <fpage>346</fpage>–<lpage>361</lpage>. <pub-id pub-id-type="doi">10.1037/a0019590</pub-id><pub-id pub-id-type="pmid">20528079</pub-id></mixed-citation>
</ref>
<ref id="B173">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nabavi</surname><given-names>S.</given-names></name><name><surname>Fox</surname><given-names>R.</given-names></name><name><surname>Proulx</surname><given-names>C. D.</given-names></name><name><surname>Lin</surname><given-names>J. Y.</given-names></name><name><surname>Tsien</surname><given-names>R. Y.</given-names></name><name><surname>Malinow</surname><given-names>R.</given-names></name></person-group> (<year>2014</year>). <article-title>Engineering a memory with LTD and LTP</article-title>. <source/>Nature
<volume>511</volume>, <fpage>348</fpage>–<lpage>352</lpage>. <pub-id pub-id-type="doi">10.1038/nature13294</pub-id><pub-id pub-id-type="pmid">24896183</pub-id></mixed-citation>
</ref>
<ref id="B174">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nadel</surname><given-names>L.</given-names></name></person-group> (<year>2003</year>). <article-title>Down’s syndrome: a genetic disorder in biobehavioral perspective</article-title>. <source/>Genes Brain Behav.
<volume>2</volume>, <fpage>156</fpage>–<lpage>166</lpage>. <pub-id pub-id-type="doi">10.1034/j.1601-183x.2003.00026.x</pub-id><pub-id pub-id-type="pmid">12931789</pub-id></mixed-citation>
</ref>
<ref id="B175">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicoll</surname><given-names>R. A.</given-names></name></person-group> (<year>2004</year>). <article-title>My close encounter with GABA<sub>B</sub> receptors</article-title>. <source/>Biochem. Pharmacol.
<volume>68</volume>, <fpage>1667</fpage>–<lpage>1674</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2004.07.024</pub-id><pub-id pub-id-type="pmid">15451410</pub-id></mixed-citation>
</ref>
<ref id="B176">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nuss</surname><given-names>P.</given-names></name></person-group> (<year>2015</year>). <article-title>Anxiety disorders and GABA neurotransmission: a disturbance of modulation</article-title>. <source/>Neuropsychiatr. Dis. Treat.
<volume>11</volume>, <fpage>165</fpage>–<lpage>175</lpage>. <pub-id pub-id-type="doi">10.2147/NDT.s58841</pub-id><pub-id pub-id-type="pmid">25653526</pub-id></mixed-citation>
</ref>
<ref id="B177">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohira</surname><given-names>M.</given-names></name><name><surname>Seki</surname><given-names>N.</given-names></name><name><surname>Nagase</surname><given-names>T.</given-names></name><name><surname>Suzuki</surname><given-names>E.</given-names></name><name><surname>Nomura</surname><given-names>N.</given-names></name><name><surname>Ohara</surname><given-names>O.</given-names></name><etal></etal></person-group>. (<year>1997</year>). <article-title>Gene identification in 1.6-Mb region of the Down syndrome region on chromosome 21</article-title>. <source/>Genome Res.
<volume>7</volume>, <fpage>47</fpage>–<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1101/gr.7.1.47</pub-id><pub-id pub-id-type="pmid">9037601</pub-id></mixed-citation>
</ref>
<ref id="B178">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olsen</surname><given-names>R. W.</given-names></name><name><surname>Sieghart</surname><given-names>W.</given-names></name></person-group> (<year>2008</year>). <article-title>International union of pharmacology. LXX. Subtypes of γ-aminobutyric acid<sub>A</sub> receptors: classification on the basis of subunit composition, pharmacology and function. Update</article-title>. <source/>Pharmacol. Rev.
<volume>60</volume>, <fpage>243</fpage>–<lpage>260</lpage>. <pub-id pub-id-type="doi">10.1124/pr.108.00505</pub-id><pub-id pub-id-type="pmid">18790874</pub-id></mixed-citation>
</ref>
<ref id="B179">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olson</surname><given-names>L. E.</given-names></name><name><surname>Richtsmeier</surname><given-names>J. T.</given-names></name><name><surname>Leszl</surname><given-names>J.</given-names></name><name><surname>Reeves</surname><given-names>R. H.</given-names></name></person-group> (<year>2004</year>). <article-title>A chromosome 21 critical region does not cause specific down syndrome phenotypes</article-title>. <source/>Science
<volume>306</volume>, <fpage>687</fpage>–<lpage>690</lpage>. <pub-id pub-id-type="doi">10.1126/science.1098992</pub-id><pub-id pub-id-type="pmid">15499018</pub-id></mixed-citation>
</ref>
<ref id="B180">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olson</surname><given-names>L. E.</given-names></name><name><surname>Roper</surname><given-names>R. J.</given-names></name><name><surname>Sengstaken</surname><given-names>C. L.</given-names></name><name><surname>Peterson</surname><given-names>E. A.</given-names></name><name><surname>Aquino</surname><given-names>V.</given-names></name><name><surname>Galdzicki</surname><given-names>Z.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>Trisomy for the Down syndrome ‘critical region’ is necessary but not sufficient for brain phenotypes of trisomic mice</article-title>. <source/>Hum. Mol. Genet.
<volume>16</volume>, <fpage>774</fpage>–<lpage>782</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddm022</pub-id><pub-id pub-id-type="pmid">17339268</pub-id></mixed-citation>
</ref>
<ref id="B181">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Padgett</surname><given-names>C. L.</given-names></name><name><surname>Slesinger</surname><given-names>P. A.</given-names></name></person-group> (<year>2010</year>). <article-title>GABAB receptor coupling to G-proteins and ion channels</article-title>. <source/>Adv. Pharmacol.
<volume>58</volume>, <fpage>123</fpage>–<lpage>147</lpage>. <pub-id pub-id-type="doi">10.1016/S1054-3589(10)58006-2</pub-id><pub-id pub-id-type="pmid">20655481</pub-id></mixed-citation>
</ref>
<ref id="B182">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pallotto</surname><given-names>M.</given-names></name><name><surname>Deprez</surname><given-names>F.</given-names></name></person-group> (<year>2014</year>). <article-title>Regulation of adult neurogenesis by GABAergic transmission: signaling beyond GABA<sub>A</sub>-receptors</article-title>. <source/>Front. Cell. Neurosci.
<volume>8</volume>:<fpage>166</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2014.00166</pub-id><pub-id pub-id-type="pmid">24999317</pub-id></mixed-citation>
</ref>
<ref id="B183">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>I.</given-names></name><name><surname>Arora</surname><given-names>N.</given-names></name><name><surname>Huo</surname><given-names>H.</given-names></name><name><surname>Maherali</surname><given-names>N.</given-names></name><name><surname>Ahfeldt</surname><given-names>T.</given-names></name><name><surname>Shimamura</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>Disease-specific induced pluripotent stem cells</article-title>. <source/>Cell
<volume>134</volume>, <fpage>877</fpage>–<lpage>886</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2008.07.041</pub-id><pub-id pub-id-type="pmid">18691744</pub-id></mixed-citation>
</ref>
<ref id="B184">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>K. S.</given-names></name><name><surname>Han</surname><given-names>J. Y.</given-names></name><name><surname>Moon</surname><given-names>D. C.</given-names></name><name><surname>Hong</surname><given-names>J. T.</given-names></name><name><surname>Oh</surname><given-names>K. W.</given-names></name></person-group> (<year>2011</year>). <article-title>(-)-Epigallocatechin-3-<italic>O</italic>-gallate augments pentobarbital-induced sleeping behaviors through Cl<sup>−</sup> channel activation</article-title>. <source/>J. Med. Food
<volume>14</volume>, <fpage>1456</fpage>–<lpage>1462</lpage>. <pub-id pub-id-type="doi">10.1089/jmf.2010.1529</pub-id><pub-id pub-id-type="pmid">21883003</pub-id></mixed-citation>
</ref>
<ref id="B185">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pennington</surname><given-names>B. F.</given-names></name><name><surname>Moon</surname><given-names>J.</given-names></name><name><surname>Edgin</surname><given-names>J.</given-names></name><name><surname>Stedron</surname><given-names>J.</given-names></name><name><surname>Nadel</surname><given-names>L.</given-names></name></person-group> (<year>2003</year>). <article-title>The neuropsychology of Down syndrome: evidence for hippocampal dysfunction</article-title>. <source/>Child Dev.
<volume>74</volume>, <fpage>75</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1111/1467-8624.00522</pub-id><pub-id pub-id-type="pmid">12625437</pub-id></mixed-citation>
</ref>
<ref id="B186">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez</surname><given-names>M. F.</given-names></name><name><surname>White</surname><given-names>F. J.</given-names></name><name><surname>Hu</surname><given-names>X. T.</given-names></name></person-group> (<year>2006</year>). <article-title>Dopamine D<sub>2</sub> receptor modulation of K<sup>+</sup> channel activity regulates excitability of nucleus accumbens neurons at different membrane potentials</article-title>. <source/>J. Neurophysiol.
<volume>96</volume>, <fpage>2217</fpage>–<lpage>2228</lpage>. <pub-id pub-id-type="doi">10.1152/jn.00254.2006</pub-id><pub-id pub-id-type="pmid">16885524</pub-id></mixed-citation>
</ref>
<ref id="B187">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pérez-Cremades</surname><given-names>D.</given-names></name><name><surname>Hernández</surname><given-names>S.</given-names></name><name><surname>Blasco-Ibáñez</surname><given-names>J. M.</given-names></name><name><surname>Crespo</surname><given-names>C.</given-names></name><name><surname>Nacher</surname><given-names>J.</given-names></name><name><surname>Varea</surname><given-names>E.</given-names></name></person-group> (<year>2010</year>). <article-title>Alteration of inhibitory circuits in the somatosensory cortex of Ts65Dn mice, a model for Down’s syndrome</article-title>. <source/>J. Neural Transm. (Vienna)
<volume>117</volume>, <fpage>445</fpage>–<lpage>455</lpage>. <pub-id pub-id-type="doi">10.1007/s00702-010-0376-9</pub-id><pub-id pub-id-type="pmid">20157742</pub-id></mixed-citation>
</ref>
<ref id="B188">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinter</surname><given-names>J. D.</given-names></name><name><surname>Eliez</surname><given-names>S.</given-names></name><name><surname>Schmitt</surname><given-names>J. E.</given-names></name><name><surname>Capone</surname><given-names>G. T.</given-names></name><name><surname>Reiss</surname><given-names>A. L.</given-names></name></person-group> (<year>2001</year>). <article-title>Neuroanatomy of Down’s syndrome: a high-resolution MRI study</article-title>. <source/>Am. J. Psychiatry
<volume>158</volume>, <fpage>1659</fpage>–<lpage>1665</lpage>. <pub-id pub-id-type="doi">10.1176/appi.ajp.158.10.1659</pub-id><pub-id pub-id-type="pmid">11578999</pub-id></mixed-citation>
</ref>
<ref id="B189">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pisani</surname><given-names>F.</given-names></name><name><surname>Spina</surname><given-names>E.</given-names></name><name><surname>Oteri</surname><given-names>G.</given-names></name></person-group> (<year>1999</year>). <article-title>Antidepressant drugs and seizure susceptibility: from <italic>in vitro</italic> data to clinical practice</article-title>. <source/>Epilepsia
<volume>10</volume>, <fpage>S48</fpage>–<lpage>S56</lpage>. <pub-id pub-id-type="doi">10.1111/j.1528-1157.1999.tb00885.x</pub-id><pub-id pub-id-type="pmid">10609604</pub-id></mixed-citation>
</ref>
<ref id="B190">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Podda</surname><given-names>M. V.</given-names></name><name><surname>Riccardi</surname><given-names>E.</given-names></name><name><surname>D’Ascenzo</surname><given-names>M.</given-names></name><name><surname>Azzena</surname><given-names>G. B.</given-names></name><name><surname>Grassi</surname><given-names>C.</given-names></name></person-group> (<year>2010</year>). <article-title>Dopamine D1-like receptor activation depolarizes medium spiny neurons of the mouse nucleus accumbens by inhibiting inwardly rectifying K<sup>+</sup> currents through a cAMP-dependent protein kinase A-independent mechanism</article-title>. <source/>Neuroscience
<volume>167</volume>, <fpage>678</fpage>–<lpage>690</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2010.02.075</pub-id><pub-id pub-id-type="pmid">20211700</pub-id></mixed-citation>
</ref>
<ref id="B191">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pontes</surname><given-names>A.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>W.</given-names></name></person-group> (<year>2013</year>). <article-title>Novel functions of GABA signaling in adult neurogenesis</article-title>. <source/>Front. Biol.
<volume>8</volume>, <fpage>496</fpage>–<lpage>507</lpage>. <pub-id pub-id-type="doi">10.1007/s11515-013-1270-2</pub-id><pub-id pub-id-type="pmid">24285940</pub-id></mixed-citation>
</ref>
<ref id="B192">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pouille</surname><given-names>F.</given-names></name><name><surname>Scanziani</surname><given-names>M.</given-names></name></person-group> (<year>2001</year>). <article-title>Enforcement of temporal fidelity in pyramidal cells by somatic feed-forward inhibition</article-title>. <source/>Science
<volume>293</volume>, <fpage>1159</fpage>–<lpage>1163</lpage>. <pub-id pub-id-type="doi">10.1126/science.1060342</pub-id><pub-id pub-id-type="pmid">11498596</pub-id></mixed-citation>
</ref>
<ref id="B193">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pravetoni</surname><given-names>M.</given-names></name><name><surname>Wickman</surname><given-names>K.</given-names></name></person-group> (<year>2008</year>). <article-title>Behavioral characterization of mice lacking GIRK/Kir3 channel subunits</article-title>. <source/>Genes Brain Behav.
<volume>7</volume>, <fpage>523</fpage>–<lpage>531</lpage>. <pub-id pub-id-type="doi">10.1111/j.1601-183x.2008.00388.x</pub-id><pub-id pub-id-type="pmid">18194467</pub-id></mixed-citation>
</ref>
<ref id="B194">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pressler</surname><given-names>R. M.</given-names></name><name><surname>Boylan</surname><given-names>G. B.</given-names></name><name><surname>Marlow</surname><given-names>N.</given-names></name><name><surname>Blennow</surname><given-names>M.</given-names></name><name><surname>Chiron</surname><given-names>C.</given-names></name><name><surname>Cross</surname><given-names>J. H.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding and feasibility phase 1/2 trial</article-title>. <source/>Lancet Neurol.
<volume>14</volume>, <fpage>469</fpage>–<lpage>477</lpage>. <pub-id pub-id-type="doi">10.1016/s1474-4422(14)70303-5</pub-id><pub-id pub-id-type="pmid">25765333</pub-id></mixed-citation>
</ref>
<ref id="B195">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pueschel</surname><given-names>S. M.</given-names></name><name><surname>Bernier</surname><given-names>J. C.</given-names></name><name><surname>Pezzullo</surname><given-names>J. C.</given-names></name></person-group> (<year>1991</year>). <article-title>Behavioural observations in children with Down’s syndrome</article-title>. <source/>J. Ment. Defic. Res.
<volume>35</volume>, <fpage>502</fpage>–<lpage>511</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2788.1991.tb00447.x</pub-id><pub-id pub-id-type="pmid">1839314</pub-id></mixed-citation>
</ref>
<ref id="B196">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raccuglia</surname><given-names>D.</given-names></name><name><surname>Mueller</surname><given-names>U.</given-names></name></person-group> (<year>2013</year>). <article-title>Focal uncaging of GABA reveals a temporally defined role for GABAergic inhibition during appetitive associative olfactory conditioning in honeybees</article-title>. <source/>Learn. Mem.
<volume>20</volume>, <fpage>410</fpage>–<lpage>416</lpage>. <pub-id pub-id-type="doi">10.1101/lm.030205.112</pub-id><pub-id pub-id-type="pmid">23860600</pub-id></mixed-citation>
</ref>
<ref id="B197">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramamoorthi</surname><given-names>K.</given-names></name><name><surname>Lin</surname><given-names>Y.</given-names></name></person-group> (<year>2011</year>). <article-title>The contribution of GABAergic dysfunction to neurodevelopmental disorders</article-title>. <source/>Trends Mol. Med.
<volume>17</volume>, <fpage>452</fpage>–<lpage>462</lpage>. <pub-id pub-id-type="doi">10.1016/j.molmed.2011.03.003</pub-id><pub-id pub-id-type="pmid">21514225</pub-id></mixed-citation>
</ref>
<ref id="B198">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raz</surname><given-names>N.</given-names></name><name><surname>Torres</surname><given-names>I. J.</given-names></name><name><surname>Briggs</surname><given-names>S. D.</given-names></name><name><surname>Spencer</surname><given-names>W. D.</given-names></name><name><surname>Thornton</surname><given-names>A. E.</given-names></name><name><surname>Loken</surname><given-names>W. J.</given-names></name><etal></etal></person-group>. (<year>1995</year>). <article-title>Selective neuroanatomic abnormalities in Down’s syndrome and their cognitive correlates: evidence from MRI morphometry</article-title>. <source/>Neurology
<volume>45</volume>, <fpage>356</fpage>–<lpage>366</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.45.2.356</pub-id><pub-id pub-id-type="pmid">7854539</pub-id></mixed-citation>
</ref>
<ref id="B199">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reefhuis</surname><given-names>J.</given-names></name><name><surname>Devine</surname><given-names>O.</given-names></name><name><surname>Friedman</surname><given-names>J. M.</given-names></name><name><surname>Louik</surname><given-names>C.</given-names></name><name><surname>Honein</surname><given-names>M. A.</given-names></name><collab>National Birth Defects Prevention Study</collab></person-group>. (<year>2015</year>). <article-title>Specific SSRIs and birth defects: bayesian analysis to interpret new data in the context of previous reports</article-title>. <source/>BMJ
<volume>351</volume>:<fpage>h3190</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.h3190</pub-id><pub-id pub-id-type="pmid">26156519</pub-id></mixed-citation>
</ref>
<ref id="B200">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reeves</surname><given-names>R. H.</given-names></name><name><surname>Irving</surname><given-names>N. G.</given-names></name><name><surname>Moran</surname><given-names>T. H.</given-names></name><name><surname>Wohn</surname><given-names>A.</given-names></name><name><surname>Kitt</surname><given-names>C.</given-names></name><name><surname>Sisodia</surname><given-names>S. S.</given-names></name><etal></etal></person-group>. (<year>1995</year>). <article-title>A mouse model for Down syndrome exhibits learning and behaviour deficits</article-title>. <source/>Nat. Genet.
<volume>11</volume>, <fpage>177</fpage>–<lpage>184</lpage>. <pub-id pub-id-type="doi">10.1038/ng1095-177</pub-id><pub-id pub-id-type="pmid">7550346</pub-id></mixed-citation>
</ref>
<ref id="B201">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reinholdt</surname><given-names>L. G.</given-names></name><name><surname>Czechanski</surname><given-names>A.</given-names></name><name><surname>Kamdar</surname><given-names>S.</given-names></name><name><surname>King</surname><given-names>B. L.</given-names></name><name><surname>Sun</surname><given-names>F.</given-names></name><name><surname>Handel</surname><given-names>M. A.</given-names></name></person-group> (<year>2009</year>). <article-title>Meiotic behavior of aneuploid chromatin in mouse models of Down syndrome</article-title>. <source/>Chromosoma
<volume>118</volume>, <fpage>723</fpage>–<lpage>736</lpage>. <pub-id pub-id-type="doi">10.1007/s00412-009-0230-8</pub-id><pub-id pub-id-type="pmid">19639331</pub-id></mixed-citation>
</ref>
<ref id="B202">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reynolds</surname><given-names>G. P.</given-names></name><name><surname>Warner</surname><given-names>C. E.</given-names></name></person-group> (<year>1988</year>). <article-title>Amino acid neurotransmitter deficits in adult Down’s syndrome brain tissue</article-title>. <source/>Neurosci. Lett.
<volume>94</volume>, <fpage>224</fpage>–<lpage>227</lpage>. <pub-id pub-id-type="doi">10.1016/0304-3940(88)90299-6</pub-id><pub-id pub-id-type="pmid">2907377</pub-id></mixed-citation>
</ref>
<ref id="B203">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rissman</surname><given-names>R. A.</given-names></name><name><surname>Mobley</surname><given-names>W. C.</given-names></name></person-group> (<year>2011</year>). <article-title>Implications for treatment: GABA<sub>A</sub> receptors in aging, Down syndrome and Alzheimer’s disease</article-title>. <source/>J. Neurochem.
<volume>117</volume>, <fpage>613</fpage>–<lpage>622</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2011.07237.x</pub-id><pub-id pub-id-type="pmid">21388375</pub-id></mixed-citation>
</ref>
<ref id="B204">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivera</surname><given-names>C.</given-names></name><name><surname>Voipio</surname><given-names>J.</given-names></name><name><surname>Payne</surname><given-names>J. A.</given-names></name><name><surname>Ruusuvuori</surname><given-names>E.</given-names></name><name><surname>Lahtinen</surname><given-names>H.</given-names></name><name><surname>Lamsa</surname><given-names>K.</given-names></name><etal></etal></person-group>. (<year>1999</year>). <article-title>The K<sup>+</sup>/Cl<sup>−</sup> co-transporter KCC2 renders GABA Hyperpolarizing during neuronal maturation</article-title>. <source/>Nature
<volume>397</volume>, <fpage>251</fpage>–<lpage>255</lpage>. <pub-id pub-id-type="doi">10.1038/16697</pub-id><pub-id pub-id-type="pmid">9930699</pub-id></mixed-citation>
</ref>
<ref id="B205">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>J.</given-names></name><name><surname>Hatton</surname><given-names>C.</given-names></name><name><surname>Emerson</surname><given-names>E.</given-names></name><name><surname>Baines</surname><given-names>S.</given-names></name></person-group> (<year>2015</year>). <article-title>Prevalence of epilepsy among people with intellectual disabilities: a systematic review</article-title>. <source/>Seizure
<volume>29</volume>, <fpage>46</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.seizure.2015.03.016</pub-id><pub-id pub-id-type="pmid">26076844</pub-id></mixed-citation>
</ref>
<ref id="B206">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roper</surname><given-names>R. J.</given-names></name><name><surname>Baxter</surname><given-names>L. L.</given-names></name><name><surname>Saran</surname><given-names>N. G.</given-names></name><name><surname>Klinedinst</surname><given-names>D. K.</given-names></name><name><surname>Beachy</surname><given-names>P. A.</given-names></name><name><surname>Reeves</surname><given-names>R. H.</given-names></name></person-group> (<year>2006</year>). <article-title>Defective cerebellar response to mitogenic Hedgehog signaling in Down syndrome mice</article-title>. <source/>Proc. Natl. Acad. Sci. U S A
<volume>103</volume>, <fpage>1452</fpage>–<lpage>1456</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0601630103</pub-id><pub-id pub-id-type="pmid">16432181</pub-id></mixed-citation>
</ref>
<ref id="B207">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>M. H.</given-names></name><name><surname>Galaburda</surname><given-names>A. M.</given-names></name><name><surname>Kemper</surname><given-names>T. L.</given-names></name></person-group> (<year>1984</year>). <article-title>Down’s syndrome: is there a decreased population of neurons?</article-title>
<source/>Neurology
<volume>34</volume>, <fpage>909</fpage>–<lpage>916</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.34.7.909</pub-id><pub-id pub-id-type="pmid">6234479</pub-id></mixed-citation>
</ref>
<ref id="B208">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rost</surname><given-names>B. R.</given-names></name><name><surname>Nicholson</surname><given-names>P.</given-names></name><name><surname>Ahnert-Hilger</surname><given-names>G.</given-names></name><name><surname>Rummel</surname><given-names>A.</given-names></name><name><surname>Rosenmund</surname><given-names>C.</given-names></name><name><surname>Breustedt</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Activation of metabotropic GABA receptors increases the energy barrier for vesicle fusion</article-title>. <source/>J. Cell Sci.
<volume>124</volume>, <fpage>3066</fpage>–<lpage>3073</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.074963</pub-id><pub-id pub-id-type="pmid">21852427</pub-id></mixed-citation>
</ref>
<ref id="B209">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>T.</given-names></name><name><surname>Roehrs</surname><given-names>T.</given-names></name><name><surname>Wittig</surname><given-names>R.</given-names></name><name><surname>Zorick</surname><given-names>F.</given-names></name></person-group> (<year>1984</year>). <article-title>Benzodiazepines and memory</article-title>. <source/>Br. J. Clin. Pharmacol.
<volume>18</volume>, <fpage>45S</fpage>–<lpage>49S</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2125.1984.tb02581.x</pub-id><pub-id pub-id-type="pmid">6151849</pub-id></mixed-citation>
</ref>
<ref id="B210">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruby</surname><given-names>N. F.</given-names></name><name><surname>Fernandez</surname><given-names>F.</given-names></name><name><surname>Garrett</surname><given-names>A.</given-names></name><name><surname>Klima</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name><name><surname>Sapolsky</surname><given-names>R.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Spatial memory and long-term object recognition are impaired by circadian arrhythmia and restored by the GABA<sub>A</sub> antagonist pentylenetetrazole</article-title>. <source/>PLoS One
<volume>8</volume>:<fpage>e72433</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0072433</pub-id><pub-id pub-id-type="pmid">24009680</pub-id></mixed-citation>
</ref>
<ref id="B211">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruby</surname><given-names>N. F.</given-names></name><name><surname>Fernandez</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name><name><surname>Klima</surname><given-names>J.</given-names></name><name><surname>Heller</surname><given-names>H. C.</given-names></name><name><surname>Garner</surname><given-names>C. C.</given-names></name></person-group> (<year>2010</year>). <article-title>Circadian locomotor rhythms are normal in Ts65Dn “Down syndrome” mice and unaffected by pentylenetetrazole</article-title>. <source/>J. Biol. Rhythms
<volume>25</volume>, <fpage>63</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1177/0748730409356202</pub-id><pub-id pub-id-type="pmid">20075302</pub-id></mixed-citation>
</ref>
<ref id="B212">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruby</surname><given-names>N. F.</given-names></name><name><surname>Hwang</surname><given-names>C. E.</given-names></name><name><surname>Wessells</surname><given-names>C.</given-names></name><name><surname>Fernandez</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name><name><surname>Sapolsky</surname><given-names>R.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>Hippocampal-dependent learning requires a functional circadian system</article-title>. <source/>Proc. Natl. Acad. Sci. U S A
<volume>105</volume>, <fpage>15593</fpage>–<lpage>15598</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0808259105</pub-id><pub-id pub-id-type="pmid">18832172</pub-id></mixed-citation>
</ref>
<ref id="B213">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudolph</surname><given-names>U.</given-names></name><name><surname>Knoflach</surname><given-names>F.</given-names></name></person-group> (<year>2011</year>). <article-title>Beyond classical benzodiazepines: novel therapeutic potential of GABA<sub>A</sub> receptor subtypes</article-title>. <source/>Nat. Rev. Drug Discov.
<volume>10</volume>, <fpage>685</fpage>–<lpage>697</lpage>. <pub-id pub-id-type="doi">10.1038/nrd3502</pub-id><pub-id pub-id-type="pmid">21799515</pub-id></mixed-citation>
</ref>
<ref id="B214">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rueda</surname><given-names>N.</given-names></name><name><surname>Flórez</surname><given-names>J.</given-names></name><name><surname>Martínez-Cué</surname><given-names>C.</given-names></name></person-group> (<year>2008</year>). <article-title>Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome</article-title>. <source/>Neurosci. Lett.
<volume>433</volume>, <fpage>22</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2007.12.039</pub-id><pub-id pub-id-type="pmid">18226451</pub-id></mixed-citation>
</ref>
<ref id="B215">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rueda</surname><given-names>N.</given-names></name><name><surname>Flórez</surname><given-names>J.</given-names></name><name><surname>Martínez-Cué</surname><given-names>C.</given-names></name></person-group> (<year>2012</year>). <article-title>Mouse models of down syndrome as a tool to unravel the causes of mental disabilities</article-title>. <source/>Neural Plast.
<volume>2012</volume>:<fpage>584071</fpage>. <pub-id pub-id-type="doi">10.1155/2012/584071</pub-id><pub-id pub-id-type="pmid">22685678</pub-id></mixed-citation>
</ref>
<ref id="B216">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rueda</surname><given-names>N.</given-names></name><name><surname>Llorens-Martín</surname><given-names>M.</given-names></name><name><surname>Flórez</surname><given-names>J.</given-names></name><name><surname>Valdizán</surname><given-names>E.</given-names></name><name><surname>Banerjee</surname><given-names>P.</given-names></name><name><surname>Trejo</surname><given-names>J. L.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome</article-title>. <source/>J. Alzheimers Dis.
<volume>21</volume>, <fpage>277</fpage>–<lpage>290</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-2010-100240</pub-id><pub-id pub-id-type="pmid">20421694</pub-id></mixed-citation>
</ref>
<ref id="B217">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruusuvuori</surname><given-names>E.</given-names></name><name><surname>Huebner</surname><given-names>A. K.</given-names></name><name><surname>Kirilkin</surname><given-names>I.</given-names></name><name><surname>Yukin</surname><given-names>A. Y.</given-names></name><name><surname>Blaesse</surname><given-names>P.</given-names></name><name><surname>Helmy</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Neuronal carbonic anhydrase VII provides GABAergic excitatory drive to exacerbate febrile seizures</article-title>. <source/>EMBO J.
<volume>32</volume>, <fpage>2275</fpage>–<lpage>2286</lpage>. <pub-id pub-id-type="doi">10.1038/emboj.2013.160</pub-id><pub-id pub-id-type="pmid">23881097</pub-id></mixed-citation>
</ref>
<ref id="B218">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sago</surname><given-names>H.</given-names></name><name><surname>Carlson</surname><given-names>E. J.</given-names></name><name><surname>Smith</surname><given-names>D. J.</given-names></name><name><surname>Kilbridge</surname><given-names>J.</given-names></name><name><surname>Rubin</surname><given-names>E. M.</given-names></name><name><surname>Mobley</surname><given-names>W. C.</given-names></name><etal></etal></person-group>. (<year>1998</year>). <article-title>Ts1Cje, a partial trisomy 16 mouse model for Down syndrome, exhibits learning and behavioral abnormalities</article-title>. <source/>Proc. Natl. Acad. Sci. U S A
<volume>95</volume>, <fpage>6256</fpage>–<lpage>6261</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.95.11.6256</pub-id><pub-id pub-id-type="pmid">9600952</pub-id></mixed-citation>
</ref>
<ref id="B219">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sago</surname><given-names>H.</given-names></name><name><surname>Carlson</surname><given-names>E. J.</given-names></name><name><surname>Smith</surname><given-names>D. J.</given-names></name><name><surname>Rubin</surname><given-names>E. M.</given-names></name><name><surname>Crnic</surname><given-names>L. S.</given-names></name><name><surname>Huang</surname><given-names>T. T.</given-names></name><etal></etal></person-group>. (<year>2000</year>). <article-title>Genetic dissection of region associated with behavioral abnormalities in mouse models for Down syndrome</article-title>. <source/>Pediatr. Res.
<volume>48</volume>, <fpage>606</fpage>–<lpage>613</lpage>. <pub-id pub-id-type="doi">10.1203/00006450-200011000-00009</pub-id><pub-id pub-id-type="pmid">11044479</pub-id></mixed-citation>
</ref>
<ref id="B220">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santin</surname><given-names>M. D.</given-names></name><name><surname>Valabrèguea</surname><given-names>R.</given-names></name><name><surname>Rivalsc</surname><given-names>I.</given-names></name><name><surname>Pénagera</surname><given-names>R.</given-names></name><name><surname>Paquina</surname><given-names>R.</given-names></name><name><surname>Dauphinota</surname><given-names>L.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title><italic>In vivo</italic>
<sup>1</sup>H MRS study in microlitre voxels in the hippocampus of a mouse model of Down syndrome at 11.7 T</article-title>. <source/>NMR Biomed.
<volume>27</volume>, <fpage>1143</fpage>–<lpage>1150</lpage>. <pub-id pub-id-type="doi">10.1002/nbm.3155</pub-id><pub-id pub-id-type="pmid">25088227</pub-id></mixed-citation>
</ref>
<ref id="B221">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scanziani</surname><given-names>M.</given-names></name></person-group> (<year>2000</year>). <article-title>GABA spillover activates postsynaptic GABA<sub>B</sub> receptors to control rhythmic hippocampal activity</article-title>. <source/>Neuron
<volume>25</volume>, <fpage>673</fpage>–<lpage>681</lpage>. <pub-id pub-id-type="doi">10.1016/s0896-6273(00)81069-7</pub-id><pub-id pub-id-type="pmid">10774734</pub-id></mixed-citation>
</ref>
<ref id="B222">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt-Sidor</surname><given-names>B.</given-names></name><name><surname>Wisniewski</surname><given-names>K. E.</given-names></name><name><surname>Shepard</surname><given-names>T. H.</given-names></name><name><surname>Sersen</surname><given-names>E. A.</given-names></name></person-group> (<year>1990</year>). <article-title>Brain growth in Down syndrome subjects 15 to 22 weeks of gestational age and birth to 60 months</article-title>. <source/>Clin. Neuropathol.
<volume>9</volume>, <fpage>181</fpage>–<lpage>190</lpage>. <pub-id pub-id-type="pmid">2146054</pub-id></mixed-citation>
</ref>
<ref id="B223">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>F. F.</given-names></name><name><surname>Belle</surname><given-names>M. D.</given-names></name><name><surname>Delagrange</surname><given-names>P.</given-names></name><name><surname>Piggins</surname><given-names>H. D.</given-names></name></person-group> (<year>2010</year>). <article-title>Electrophysiological effects of melatonin on mouse Per1 and non-Per1 suprachiasmatic nuclei neurones <italic>in vitro</italic></article-title>. <source/>J. Neuroendocrinol.
<volume>22</volume>, <fpage>1148</fpage>–<lpage>1156</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2826.2010.02063.x</pub-id><pub-id pub-id-type="pmid">20819119</pub-id></mixed-citation>
</ref>
<ref id="B225">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott-McKean</surname><given-names>J. J.</given-names></name><name><surname>Chang</surname><given-names>B.</given-names></name><name><surname>Hurd</surname><given-names>R. E.</given-names></name><name><surname>Nusinowitz</surname><given-names>S.</given-names></name><name><surname>Schmidt</surname><given-names>C.</given-names></name><name><surname>Davisson</surname><given-names>M. T.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>The mouse model of Down syndrome Ts65Dn presents visual deficits as assessed by pattern visual evoked potentials</article-title>. <source/>Invest. Ophthalmol. Vis. Sci.
<volume>51</volume>, <fpage>3300</fpage>–<lpage>3308</lpage>. <pub-id pub-id-type="doi">10.1167/iovs.09-4465</pub-id><pub-id pub-id-type="pmid">20130276</pub-id></mixed-citation>
</ref>
<ref id="B224">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott-McKean</surname><given-names>J. J.</given-names></name><name><surname>Costa</surname><given-names>A. C.</given-names></name></person-group> (<year>2011</year>). <article-title>Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine</article-title>. <source/>Learn. Mem.
<volume>18</volume>, <fpage>774</fpage>–<lpage>778</lpage>. <pub-id pub-id-type="doi">10.1101/lm.024182.111</pub-id><pub-id pub-id-type="pmid">22101180</pub-id></mixed-citation>
</ref>
<ref id="B226">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seidl</surname><given-names>R.</given-names></name><name><surname>Cairns</surname><given-names>N.</given-names></name><name><surname>Singewald</surname><given-names>N.</given-names></name><name><surname>Kaehler</surname><given-names>S. T.</given-names></name><name><surname>Lubec</surname><given-names>G.</given-names></name></person-group> (<year>2001</year>). <article-title>Differences between GABA levels in Alzheimer’s disease and Down syndrome with Alzheimer-like neuropathology</article-title>. <source/>Naunyn Schmiedebergs Arch. Pharmacol.
<volume>363</volume>, <fpage>139</fpage>–<lpage>145</lpage>. <pub-id pub-id-type="doi">10.1007/s002100000346</pub-id><pub-id pub-id-type="pmid">11218066</pub-id></mixed-citation>
</ref>
<ref id="B227">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>B. L.</given-names></name></person-group> (<year>2001</year>). <article-title>Developmental instability of the cerebellum and its relevance to Down syndrome</article-title>. <source/>J. Neural Transm. Suppl.
<volume>61</volume>, <fpage>11</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-7091-6262-0_2</pub-id><pub-id pub-id-type="pmid">11771737</pub-id></mixed-citation>
</ref>
<ref id="B229">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siarey</surname><given-names>R. J.</given-names></name><name><surname>Carlson</surname><given-names>E. J.</given-names></name><name><surname>Epstein</surname><given-names>C. J.</given-names></name><name><surname>Balbo</surname><given-names>A.</given-names></name><name><surname>Rapoport</surname><given-names>S. I.</given-names></name><name><surname>Galdzicki</surname><given-names>Z.</given-names></name></person-group> (<year>1999</year>). <article-title>Increased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down syndrome</article-title>. <source/>Neuropharmacology
<volume>38</volume>, <fpage>1917</fpage>–<lpage>1920</lpage>. <pub-id pub-id-type="doi">10.1016/s0028-3908(99)00083-0</pub-id><pub-id pub-id-type="pmid">10608287</pub-id></mixed-citation>
</ref>
<ref id="B228">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siarey</surname><given-names>R. J.</given-names></name><name><surname>Kline-Burgess</surname><given-names>A.</given-names></name><name><surname>Cho</surname><given-names>M.</given-names></name><name><surname>Balbo</surname><given-names>A.</given-names></name><name><surname>Best</surname><given-names>T. K.</given-names></name><name><surname>Harashima</surname><given-names>C.</given-names></name><etal></etal></person-group>. (<year>2006</year>). <article-title>Altered signaling pathways underlying abnormal hippocampal synaptic plasticity in the Ts65Dn mouse model of Down syndrome</article-title>. <source/>J. Neurochem.
<volume>98</volume>, <fpage>1266</fpage>–<lpage>1277</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2006.03971.x</pub-id><pub-id pub-id-type="pmid">16895585</pub-id></mixed-citation>
</ref>
<ref id="B230">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siarey</surname><given-names>R. J.</given-names></name><name><surname>Stoll</surname><given-names>J.</given-names></name><name><surname>Rapoport</surname><given-names>S. I.</given-names></name><name><surname>Galdzicki</surname><given-names>Z.</given-names></name></person-group> (<year>1997</year>). <article-title>Altered long-term potentiation in the young and old Ts65Dn mouse, a model for Down syndrome</article-title>. <source/>Neuropharmacology
<volume>36</volume>, <fpage>1549</fpage>–<lpage>1554</lpage>. <pub-id pub-id-type="doi">10.1016/s0028-3908(97)00157-3</pub-id><pub-id pub-id-type="pmid">9517425</pub-id></mixed-citation>
</ref>
<ref id="B231">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siarey</surname><given-names>R. J.</given-names></name><name><surname>Villar</surname><given-names>A. J.</given-names></name><name><surname>Epstein</surname><given-names>C. J.</given-names></name><name><surname>Galdzicki</surname><given-names>Z.</given-names></name></person-group> (<year>2005</year>). <article-title>Abnormal synaptic plasticity in the Ts1Cje segmental trisomy 16 mouse model of Down syndrome</article-title>. <source/>Neuropharmacology
<volume>49</volume>, <fpage>122</fpage>–<lpage>128</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2005.02.012</pub-id><pub-id pub-id-type="pmid">15992587</pub-id></mixed-citation>
</ref>
<ref id="B232">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silver</surname><given-names>R. A.</given-names></name></person-group> (<year>2010</year>). <article-title>Neuronal arithmetic</article-title>. <source/>Nat. Rev. Neurosci.
<volume>11</volume>, <fpage>474</fpage>–<lpage>489</lpage>. <pub-id pub-id-type="doi">10.1038/nrn2864</pub-id><pub-id pub-id-type="pmid">20531421</pub-id></mixed-citation>
</ref>
<ref id="B233">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sim</surname><given-names>H. R.</given-names></name><name><surname>Choi</surname><given-names>T. Y.</given-names></name><name><surname>Lee</surname><given-names>H. J.</given-names></name><name><surname>Kang</surname><given-names>E. Y.</given-names></name><name><surname>Yoon</surname><given-names>S.</given-names></name><name><surname>Han</surname><given-names>P. L.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Role of dopamine D2 receptors in plasticity of stress-induced addictive behaviours</article-title>. <source/>Nat. Commun.
<volume>4</volume>:<fpage>1579</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms2598</pub-id><pub-id pub-id-type="pmid">23481387</pub-id></mixed-citation>
</ref>
<ref id="B235">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Śmigielska-Kuzia</surname><given-names>J.</given-names></name><name><surname>Bockowski</surname><given-names>L.</given-names></name><name><surname>Sobaniec</surname><given-names>W.</given-names></name><name><surname>Kułak</surname><given-names>W.</given-names></name><name><surname>Sendrowski</surname><given-names>K.</given-names></name></person-group> (<year>2010</year>). <article-title>Amino acid metabolic processes in the temporal lobes assessed by proton magnetic resonance spectroscopy (1H MRS) in children with Down syndrome</article-title>. <source/>Pharmacol. Rep.
<volume>62</volume>, <fpage>1070</fpage>–<lpage>1077</lpage>. <pub-id pub-id-type="doi">10.1016/s1734-1140(10)70369-8</pub-id><pub-id pub-id-type="pmid">21273664</pub-id></mixed-citation>
</ref>
<ref id="B234">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Śmigielska-Kuzia</surname><given-names>J.</given-names></name><name><surname>Sobaniec</surname><given-names>W.</given-names></name></person-group> (<year>2007</year>). <article-title>Brain metabolic profile obtained by proton magnetic resonance spectroscopy HMRS in children with Down syndrome</article-title>. <source/>Adv. Med. Sci.
<volume>52</volume>, <fpage>183</fpage>–<lpage>187</lpage>. <pub-id pub-id-type="pmid">18229661</pub-id></mixed-citation>
</ref>
<ref id="B236">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>J.</given-names></name><name><surname>Zhong</surname><given-names>C.</given-names></name><name><surname>Bonaguidi</surname><given-names>M. A.</given-names></name><name><surname>Sun</surname><given-names>G. J.</given-names></name><name><surname>Hsu</surname><given-names>D.</given-names></name><name><surname>Gu</surname><given-names>Y.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Neuronal circuitry mechanism regulating adult quiescent neural stem-cell fate decision</article-title>. <source/>Nature
<volume>489</volume>, <fpage>150</fpage>–<lpage>154</lpage>. <pub-id pub-id-type="doi">10.1038/nature11306</pub-id><pub-id pub-id-type="pmid">22842902</pub-id></mixed-citation>
</ref>
<ref id="B237">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Souchet</surname><given-names>B.</given-names></name><name><surname>Guedj</surname><given-names>F.</given-names></name><name><surname>Penke-Verdier</surname><given-names>Z.</given-names></name><name><surname>Daubigney</surname><given-names>F.</given-names></name><name><surname>Duchon</surname><given-names>A.</given-names></name><name><surname>Herault</surname><given-names>Y.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Pharmacological correction of excitation/inhibition imbalance in Down syndrome mouse models</article-title>. <source/>Front. Behav. Neurosci.
<volume>9</volume>:<fpage>267</fpage>. <pub-id pub-id-type="doi">10.3389/fnbeh.2015.00267</pub-id><pub-id pub-id-type="pmid">26539088</pub-id></mixed-citation>
</ref>
<ref id="B238">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stafstrom</surname><given-names>C. E.</given-names></name><name><surname>Patxot</surname><given-names>O. F.</given-names></name><name><surname>Gilmore</surname><given-names>H. E.</given-names></name><name><surname>Wisniewski</surname><given-names>K. E.</given-names></name></person-group> (<year>1991</year>). <article-title>Seizures in children with Down syndrome: etiology, characteristics and outcome</article-title>. <source/>Dev. Med. Child Neurol.
<volume>33</volume>, <fpage>191</fpage>–<lpage>200</lpage>. <pub-id pub-id-type="doi">10.1111/j.1469-8749.1991.tb05108.x</pub-id><pub-id pub-id-type="pmid">1827417</pub-id></mixed-citation>
</ref>
<ref id="B239">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stagni</surname><given-names>F.</given-names></name><name><surname>Magistretti</surname><given-names>J.</given-names></name><name><surname>Guidi</surname><given-names>S.</given-names></name><name><surname>Ciani</surname><given-names>E.</given-names></name><name><surname>Mangano</surname><given-names>C.</given-names></name><name><surname>Calzà</surname><given-names>L.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Pharmacotherapy with fluoxetine restores functional connectivity from the dentate gyrus to field CA3 in the Ts65Dn mouse model of down syndrome</article-title>. <source/>PLoS One
<volume>8</volume>:<fpage>e61689</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0061689</pub-id><pub-id pub-id-type="pmid">23620781</pub-id></mixed-citation>
</ref>
<ref id="B240">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staley</surname><given-names>K. J.</given-names></name><name><surname>Soldo</surname><given-names>B. L.</given-names></name><name><surname>Proctor</surname><given-names>W. R.</given-names></name></person-group> (<year>1995</year>). <article-title>Ionic mechanisms of neuronal excitation by inhibitory GABA<sub>A</sub> receptors</article-title>. <source/>Science
<volume>269</volume>, <fpage>977</fpage>–<lpage>981</lpage>. <pub-id pub-id-type="doi">10.1126/science.7638623</pub-id><pub-id pub-id-type="pmid">7638623</pub-id></mixed-citation>
</ref>
<ref id="B241">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stasko</surname><given-names>M. R.</given-names></name><name><surname>Scott-McKean</surname><given-names>J. J.</given-names></name><name><surname>Costa</surname><given-names>A. C.</given-names></name></person-group> (<year>2006</year>). <article-title>Hypothermic responses to 8-OH-DPAT in the Ts65Dn mouse model of Down syndrome</article-title>. <source/>Neuroreport
<volume>17</volume>, <fpage>837</fpage>–<lpage>841</lpage>. <pub-id pub-id-type="doi">10.1097/01.WNR.0000220129.78726.bb</pub-id><pub-id pub-id-type="pmid">16708025</pub-id></mixed-citation>
</ref>
<ref id="B242">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stäubli</surname><given-names>U.</given-names></name><name><surname>Scafidi</surname><given-names>J.</given-names></name><name><surname>Chun</surname><given-names>D.</given-names></name></person-group> (<year>1999</year>). <article-title>GABAB receptor antagonism: facilitatory effects on memory parallel those on LTP induced by TBS but not HFS</article-title>. <source/>J. Neurosci.
<volume>19</volume>, <fpage>4609</fpage>–<lpage>4615</lpage>. <pub-id pub-id-type="pmid">10341258</pub-id></mixed-citation>
</ref>
<ref id="B243">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steele</surname><given-names>P. M.</given-names></name><name><surname>Mauk</surname><given-names>M. D.</given-names></name></person-group> (<year>1999</year>). <article-title>Inhibitory control of LTP and LTD: stability of synapse strength</article-title>. <source/>J. Neurophysiol.
<volume>81</volume>, <fpage>1559</fpage>–<lpage>1566</lpage>. <pub-id pub-id-type="pmid">10200191</pub-id></mixed-citation>
</ref>
<ref id="B244">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stern</surname><given-names>S.</given-names></name><name><surname>Segal</surname><given-names>M.</given-names></name><name><surname>Moses</surname><given-names>E.</given-names></name></person-group> (<year>2015</year>). <article-title>Involvement of potassium and cation channels in hippocampal abnormalities of embryonic Ts65Dn and Tc1 trisomic mice</article-title>. <source/>EBioMedicine
<volume>2</volume>, <fpage>1048</fpage>–<lpage>1062</lpage>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2015.07.038</pub-id><pub-id pub-id-type="pmid">26501103</pub-id></mixed-citation>
</ref>
<ref id="B245">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>L. S.</given-names></name><name><surname>Persinger</surname><given-names>M. A.</given-names></name><name><surname>Cortez</surname><given-names>M. A.</given-names></name><name><surname>Snead</surname><given-names>O. C.</given-names><suffix>III</suffix></name></person-group>. (<year>2007</year>). <article-title>Chronobiometry of behavioral activity in the Ts65Dn model of Down syndrome</article-title>. <source/>Behav. Genet.
<volume>37</volume>, <fpage>388</fpage>–<lpage>398</lpage>. <pub-id pub-id-type="doi">10.1007/s10519-006-9119-y</pub-id><pub-id pub-id-type="pmid">17146725</pub-id></mixed-citation>
</ref>
<ref id="B246">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Succol</surname><given-names>F.</given-names></name><name><surname>Fiumelli</surname><given-names>H.</given-names></name><name><surname>Benfenati</surname><given-names>F.</given-names></name><name><surname>Cancedda</surname><given-names>L.</given-names></name><name><surname>Barberis</surname><given-names>A.</given-names></name></person-group> (<year>2012</year>). <article-title>Intracellular chloride concentration influences the GABA<sub>A</sub> receptor subunit composition</article-title>. <source/>Nat. Commun.
<volume>3</volume>:<fpage>738</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms1744</pub-id><pub-id pub-id-type="pmid">22415829</pub-id></mixed-citation>
</ref>
<ref id="B247">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svirsky</surname><given-names>N.</given-names></name><name><surname>Levy</surname><given-names>S.</given-names></name><name><surname>Avitsur</surname><given-names>R.</given-names></name></person-group> (<year>2016</year>). <article-title>Prenatal exposure to selective serotonin reuptake inhibitors (SSRI) increases aggression and modulates maternal behavior in offspring mice</article-title>. <source/>Dev. Psychobiol.
<volume>58</volume>, <fpage>71</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1002/dev.21356</pub-id><pub-id pub-id-type="pmid">26336834</pub-id></mixed-citation>
</ref>
<ref id="B248">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sylvester</surname><given-names>P. E.</given-names></name></person-group> (<year>1983</year>). <article-title>The hippocampus in Down’s syndrome</article-title>. <source/>J. Ment. Defic. Res.
<volume>27</volume>, <fpage>227</fpage>–<lpage>236</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2788.1983.tb00294.x</pub-id><pub-id pub-id-type="pmid">6226801</pub-id></mixed-citation>
</ref>
<ref id="B249">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szabadics</surname><given-names>J.</given-names></name><name><surname>Varga</surname><given-names>C.</given-names></name><name><surname>Molnár</surname><given-names>G.</given-names></name><name><surname>Oláh</surname><given-names>S.</given-names></name><name><surname>Barzó</surname><given-names>P.</given-names></name><name><surname>Tamás</surname><given-names>G.</given-names></name></person-group> (<year>2006</year>). <article-title>Excitatory effect of GABAergic axo-axonic cells in cortical microcircuits</article-title>. <source/>Science
<volume>311</volume>, <fpage>233</fpage>–<lpage>235</lpage>. <pub-id pub-id-type="doi">10.1126/science.1121325</pub-id><pub-id pub-id-type="pmid">16410524</pub-id></mixed-citation>
</ref>
<ref id="B250">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szemes</surname><given-names>M.</given-names></name><name><surname>Davies</surname><given-names>R. L.</given-names></name><name><surname>Garden</surname><given-names>C. L. P.</given-names></name><name><surname>Usowicz</surname><given-names>M. M.</given-names></name></person-group> (<year>2013</year>). <article-title>Weaker control of the electrical properties of cerebellar granule cells by tonically active GABA<sub>A</sub> receptors in the Ts65Dn mouse model of Down’s syndrome</article-title>. <source/>Mol. Brain
<volume>6</volume>:<fpage>33</fpage>. <pub-id pub-id-type="doi">10.1186/1756-6606-6-33</pub-id><pub-id pub-id-type="pmid">23870245</pub-id></mixed-citation>
</ref>
<ref id="B251">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>K.</given-names></name><name><surname>Tanabe</surname><given-names>K.</given-names></name><name><surname>Ohnuki</surname><given-names>M.</given-names></name><name><surname>Narita</surname><given-names>M.</given-names></name><name><surname>Ichisaka</surname><given-names>T.</given-names></name><name><surname>Tomoda</surname><given-names>K.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>Induction of pluripotent stem cells from adult human fibroblasts by defined factors</article-title>. <source/>Cell
<volume>131</volume>, <fpage>861</fpage>–<lpage>872</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2007.11.019</pub-id><pub-id pub-id-type="pmid">18035408</pub-id></mixed-citation>
</ref>
<ref id="B252">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teipel</surname><given-names>S. J.</given-names></name><name><surname>Hampel</surname><given-names>H.</given-names></name></person-group> (<year>2006</year>). <article-title>Neuroanatomy of down syndrome <italic>in vivo</italic>: a model of preclinical Alzheimer’s disease</article-title>. <source/>Behav. Genet.
<volume>36</volume>, <fpage>405</fpage>–<lpage>415</lpage>. <pub-id pub-id-type="doi">10.1007/s10519-006-9047-x</pub-id><pub-id pub-id-type="pmid">16485178</pub-id></mixed-citation>
</ref>
<ref id="B253">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teipel</surname><given-names>S. J.</given-names></name><name><surname>Schapiro</surname><given-names>M. B.</given-names></name><name><surname>Alexander</surname><given-names>G. E.</given-names></name><name><surname>Krasuski</surname><given-names>J. S.</given-names></name><name><surname>Horwitz</surname><given-names>B.</given-names></name><name><surname>Hoehne</surname><given-names>C.</given-names></name><etal></etal></person-group>. (<year>2003</year>). <article-title>Relation of corpus callosum and hippocampal size to age in nondemented adults with Down’s syndrome</article-title>. <source/>Am. J. Psychiatry
<volume>160</volume>, <fpage>1870</fpage>–<lpage>1878</lpage>. <pub-id pub-id-type="doi">10.1176/appi.ajp.160.10.1870</pub-id><pub-id pub-id-type="pmid">14514503</pub-id></mixed-citation>
</ref>
<ref id="B254">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tyler</surname><given-names>W. A.</given-names></name><name><surname>Haydar</surname><given-names>T. F.</given-names></name></person-group> (<year>2013</year>). <article-title>Multiplex genetic fate mapping reveals a novel route of neocortical neurogenesis, which is altered in the Ts65Dn mouse model of Down syndrome</article-title>. <source/>J. Neurosci.
<volume>33</volume>, <fpage>5106</fpage>–<lpage>5119</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.5380-12.2013</pub-id><pub-id pub-id-type="pmid">23516277</pub-id></mixed-citation>
</ref>
<ref id="B255">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Usowicz</surname><given-names>M. M.</given-names></name><name><surname>Garden</surname><given-names>C. L.</given-names></name></person-group> (<year>2012</year>). <article-title>Increased excitability and altered action potential waveform in cerebellar granule neurons of the Ts65Dn mouse model of Down syndrome</article-title>. <source/>Brain Res.
<volume>1465</volume>, <fpage>10</fpage>–<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2012.05.027</pub-id><pub-id pub-id-type="pmid">22627164</pub-id></mixed-citation>
</ref>
<ref id="B256">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velazquez</surname><given-names>R.</given-names></name><name><surname>Ash</surname><given-names>J. A.</given-names></name><name><surname>Powers</surname><given-names>B. E.</given-names></name><name><surname>Kelley</surname><given-names>C. M.</given-names></name><name><surname>Strawderman</surname><given-names>M.</given-names></name><name><surname>Luscher</surname><given-names>Z. I.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Maternal choline supplementation improves spatial learning and adult hippocampal neurogenesis in the Ts65Dn mouse model of Down syndrome</article-title>. <source/>Neurobiol. Dis.
<volume>58</volume>, <fpage>92</fpage>–<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2013.04.016</pub-id><pub-id pub-id-type="pmid">23643842</pub-id></mixed-citation>
</ref>
<ref id="B257">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venzi</surname><given-names>M.</given-names></name><name><surname>Di Giovanni</surname><given-names>G.</given-names></name><name><surname>Crunelli</surname><given-names>V.</given-names></name></person-group> (<year>2015</year>). <article-title>A critical evaluation of the γ-hydroxybutyrate (GHB) model of absence seizures</article-title>. <source/>CNS Neurosci. Ther.
<volume>21</volume>, <fpage>123</fpage>–<lpage>140</lpage>. <pub-id pub-id-type="doi">10.1111/cns.12337</pub-id><pub-id pub-id-type="pmid">25403866</pub-id></mixed-citation>
</ref>
<ref id="B258">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vicari</surname><given-names>S.</given-names></name></person-group> (<year>2004</year>). <article-title>Memory development and intellectual disabilities</article-title>. <source/>Acta Paediatr. Suppl.
<volume>93</volume>, <fpage>60</fpage>–<lpage>63</lpage>; discussion <fpage>63</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1111/j.1651-2227.2004.tb03059.x</pub-id><pub-id pub-id-type="pmid">15176723</pub-id></mixed-citation>
</ref>
<ref id="B259">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vicari</surname><given-names>S.</given-names></name><name><surname>Bellucci</surname><given-names>S.</given-names></name><name><surname>Carlesimo</surname><given-names>G. A.</given-names></name></person-group> (<year>2000</year>). <article-title>Implicit and explicit memory: a functional dissociation in persons with Down syndrome</article-title>. <source/>Neuropsychologia
<volume>38</volume>, <fpage>240</fpage>–<lpage>251</lpage>. <pub-id pub-id-type="doi">10.1016/s0028-3932(99)00081-0</pub-id><pub-id pub-id-type="pmid">10678691</pub-id></mixed-citation>
</ref>
<ref id="B260">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vicari</surname><given-names>S.</given-names></name><name><surname>Bellucci</surname><given-names>S.</given-names></name><name><surname>Carlesimo</surname><given-names>G. A.</given-names></name></person-group> (<year>2005</year>). <article-title>Visual and spatial long-term memory: differential pattern of impairments in Williams and Down syndromes</article-title>. <source/>Dev. Med. Child Neurol.
<volume>47</volume>, <fpage>305</fpage>–<lpage>311</lpage>. <pub-id pub-id-type="doi">10.1017/s0012162205000599</pub-id><pub-id pub-id-type="pmid">15892372</pub-id></mixed-citation>
</ref>
<ref id="B261">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vicari</surname><given-names>S.</given-names></name><name><surname>Pontillo</surname><given-names>M.</given-names></name><name><surname>Armando</surname><given-names>M.</given-names></name></person-group> (<year>2013</year>). <article-title>Neurodevelopmental and psychiatric issues in Down’s syndrome: assessment and intervention</article-title>. <source/>Psychiatr. Genet.
<volume>23</volume>, <fpage>95</fpage>–<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1097/YPG.0b013e32835fe426</pub-id><pub-id pub-id-type="pmid">23492931</pub-id></mixed-citation>
</ref>
<ref id="B262">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vignes</surname><given-names>M.</given-names></name><name><surname>Maurice</surname><given-names>T.</given-names></name><name><surname>Lanté</surname><given-names>F.</given-names></name><name><surname>Nedjar</surname><given-names>M.</given-names></name><name><surname>Thethi</surname><given-names>K.</given-names></name><name><surname>Guiramand</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2006</year>). <article-title>Anxiolytic properties of green tea polyphenol (-)-epigallocatechin gallate (EGCG)</article-title>. <source/>Brain Res.
<volume>1110</volume>, <fpage>102</fpage>–<lpage>115</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2006.06.062</pub-id><pub-id pub-id-type="pmid">16859659</pub-id></mixed-citation>
</ref>
<ref id="B263">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viitanen</surname><given-names>T.</given-names></name><name><surname>Ruusuvuori</surname><given-names>E.</given-names></name><name><surname>Kaila</surname><given-names>K.</given-names></name><name><surname>Voipio</surname><given-names>J.</given-names></name></person-group> (<year>2010</year>). <article-title>The K<sup>+</sup>-Cl<sup>−</sup> cotransporter KCC2 promotes GABAergic excitation in the mature rat hippocampus</article-title>. <source/>J. Physiol.
<volume>588</volume>, <fpage>1527</fpage>–<lpage>1540</lpage>. <pub-id pub-id-type="doi">10.1113/jphysiol.2009.181826</pub-id><pub-id pub-id-type="pmid">20211979</pub-id></mixed-citation>
</ref>
<ref id="B264">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>S.</given-names></name><name><surname>Castel</surname><given-names>M.</given-names></name><name><surname>Gainer</surname><given-names>H.</given-names></name><name><surname>Yarom</surname><given-names>Y.</given-names></name></person-group> (<year>1997</year>). <article-title>GABA in the mammalian suprachiasmatic nucleus and its role in diurnal rhythmicity</article-title>. <source/>Nature
<volume>387</volume>, <fpage>598</fpage>–<lpage>603</lpage>. <pub-id pub-id-type="doi">10.1038/42468</pub-id><pub-id pub-id-type="pmid">9177347</pub-id></mixed-citation>
</ref>
<ref id="B267">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X. J.</given-names></name><name><surname>Buzsáki</surname><given-names>G.</given-names></name></person-group> (<year>1996</year>). <article-title>γ oscillation by synaptic inhibition in a hippocampal interneuronal network model</article-title>. <source/>J. Neurosci.
<volume>16</volume>, <fpage>6402</fpage>–<lpage>6413</lpage>. <pub-id pub-id-type="pmid">8815919</pub-id></mixed-citation>
</ref>
<ref id="B265">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D. D.</given-names></name><name><surname>Kriegstein</surname><given-names>A. R.</given-names></name></person-group> (<year>2009</year>). <article-title>Defining the role of GABA in cortical development</article-title>. <source/>J. Physiol.
<volume>587</volume>, <fpage>1873</fpage>–<lpage>1879</lpage>. <pub-id pub-id-type="doi">10.1113/jphysiol.2008.167635</pub-id><pub-id pub-id-type="pmid">19153158</pub-id></mixed-citation>
</ref>
<ref id="B266">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>F.</given-names></name><name><surname>Zhao</surname><given-names>Q.</given-names></name></person-group> (<year>2003</year>). <article-title>The GABA<sub>A</sub> receptor mediates the hypnotic activity of melatonin in rats</article-title>. <source/>Pharmacol. Biochem. Behav.
<volume>74</volume>, <fpage>573</fpage>–<lpage>578</lpage>. <pub-id pub-id-type="doi">10.1016/s0091-3057(02)01045-6</pub-id><pub-id pub-id-type="pmid">12543221</pub-id></mixed-citation>
</ref>
<ref id="B268">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waseem</surname><given-names>T.</given-names></name><name><surname>Mukhtarov</surname><given-names>M.</given-names></name><name><surname>Buldakova</surname><given-names>S.</given-names></name><name><surname>Medina</surname><given-names>I.</given-names></name><name><surname>Bregestovski</surname><given-names>P.</given-names></name></person-group> (<year>2010</year>). <article-title>Genetically encoded Cl-Sensor as a tool for monitoring of Cl-dependent processes in small neuronal compartments</article-title>. <source/>J. Neurosci. Methods
<volume>193</volume>, <fpage>14</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneumeth.2010.08.002</pub-id><pub-id pub-id-type="pmid">20705097</pub-id></mixed-citation>
</ref>
<ref id="B269">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weick</surname><given-names>J. P.</given-names></name><name><surname>Held</surname><given-names>D. L.</given-names></name><name><surname>Bonadurer</surname><given-names>G. F.</given-names></name><name><surname>Doers</surname><given-names>M. E.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Maguire</surname><given-names>C.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Deficits in human trisomy 21 iPSCs and neurons</article-title>. <source/>Proc. Natl. Acad. Sci. U S A
<volume>110</volume>, <fpage>9962</fpage>–<lpage>9967</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1216575110</pub-id><pub-id pub-id-type="pmid">23716668</pub-id></mixed-citation>
</ref>
<ref id="B270">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westmark</surname><given-names>C. J.</given-names></name><name><surname>Westmark</surname><given-names>P. R.</given-names></name><name><surname>Malter</surname><given-names>J. S.</given-names></name></person-group> (<year>2010</year>). <article-title>Alzheimer’s disease and down syndrome rodent models exhibit audiogenic seizures</article-title>. <source/>J. Alzheimers Dis.
<volume>20</volume>, <fpage>1009</fpage>–<lpage>1013</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-2010-100087</pub-id><pub-id pub-id-type="pmid">20413855</pub-id></mixed-citation>
</ref>
<ref id="B271">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitlock</surname><given-names>J. R.</given-names></name><name><surname>Heynen</surname><given-names>A. J.</given-names></name><name><surname>Shuler</surname><given-names>M. G.</given-names></name><name><surname>Bear</surname><given-names>M. F.</given-names></name></person-group> (<year>2006</year>). <article-title>Learning induces long-term potentiation in the hippocampus</article-title>. <source/>Science
<volume>313</volume>, <fpage>1093</fpage>–<lpage>1097</lpage>. <pub-id pub-id-type="doi">10.1126/science.1128134</pub-id><pub-id pub-id-type="pmid">16931756</pub-id></mixed-citation>
</ref>
<ref id="B272">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whittle</surname><given-names>N.</given-names></name><name><surname>Sartori</surname><given-names>S. B.</given-names></name><name><surname>Dierssen</surname><given-names>M.</given-names></name><name><surname>Lubec</surname><given-names>G.</given-names></name><name><surname>Singewald</surname><given-names>N.</given-names></name></person-group> (<year>2007</year>). <article-title>Fetal Down syndrome brains exhibit aberrant levels of neurotransmitters critical for normal brain development</article-title>. <source/>Pediatrics
<volume>120</volume>, <fpage>e1465</fpage>–<lpage>e1471</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2006-3448</pub-id><pub-id pub-id-type="pmid">17998315</pub-id></mixed-citation>
</ref>
<ref id="B273">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wigström</surname><given-names>H.</given-names></name><name><surname>Gustafsson</surname><given-names>B.</given-names></name></person-group> (<year>1986</year>). <article-title>Postsynaptic control of hippocampal long-term potentiation</article-title>. <source/>J. Physiol.
<volume>81</volume>, <fpage>228</fpage>–<lpage>236</lpage>. <pub-id pub-id-type="pmid">2883309</pub-id></mixed-citation>
</ref>
<ref id="B274">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>J. T.</given-names></name><name><surname>Colmers</surname><given-names>W. F.</given-names></name><name><surname>Pan</surname><given-names>Z. Z.</given-names></name></person-group> (<year>1988</year>). <article-title>Voltage- and ligand-activated inwardly rectifying currents in dorsal raphe neurons <italic>in vitro</italic></article-title>. <source/>J. Neurosci.
<volume>8</volume>, <fpage>3499</fpage>–<lpage>3506</lpage>. <pub-id pub-id-type="pmid">3171686</pub-id></mixed-citation>
</ref>
<ref id="B275">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winter</surname><given-names>T. C.</given-names></name><name><surname>Ostrovsky</surname><given-names>A. A.</given-names></name><name><surname>Komarniski</surname><given-names>C. A.</given-names></name><name><surname>Uhrich</surname><given-names>S. B.</given-names></name></person-group> (<year>2000</year>). <article-title>Cerebellar and frontal lobe hypoplasia in fetuses with trisomy 21: usefulness as combined US markers</article-title>. <source/>Radiology
<volume>214</volume>, <fpage>533</fpage>–<lpage>538</lpage>. <pub-id pub-id-type="doi">10.1148/radiology.214.2.r00fe40533</pub-id><pub-id pub-id-type="pmid">10671607</pub-id></mixed-citation>
</ref>
<ref id="B276">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wisden</surname><given-names>W.</given-names></name><name><surname>Laurie</surname><given-names>D. J.</given-names></name><name><surname>Monyer</surname><given-names>H.</given-names></name><name><surname>Seeburg</surname><given-names>P. H.</given-names></name></person-group> (<year>1992</year>). <article-title>The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon</article-title>. <source/>J. Neurosci.
<volume>12</volume>, <fpage>1040</fpage>–<lpage>1062</lpage>. <pub-id pub-id-type="pmid">1312131</pub-id></mixed-citation>
</ref>
<ref id="B277">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wisniewski</surname><given-names>K. E.</given-names></name></person-group> (<year>1990</year>). <article-title>Down syndrome children often have brain with maturation delay, retardation of growth and cortical dysgenesis</article-title>. <source/>Am. J. Med. Genet. Suppl.
<volume>7</volume>, <fpage>274</fpage>–<lpage>281</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.1320370755</pub-id><pub-id pub-id-type="pmid">2149962</pub-id></mixed-citation>
</ref>
<ref id="B280">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wisniewski</surname><given-names>K. E.</given-names></name><name><surname>Dalton</surname><given-names>A. J.</given-names></name><name><surname>McLachlan</surname><given-names>C.</given-names></name><name><surname>Wen</surname><given-names>G. Y.</given-names></name><name><surname>Wisniewski</surname><given-names>H. M.</given-names></name></person-group> (<year>1985</year>). <article-title>Alzheimer’s disease in Down’s syndrome: clinicopathologic studies</article-title>. <source/>Neurology
<volume>35</volume>, <fpage>957</fpage>–<lpage>961</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.35.7.957</pub-id><pub-id pub-id-type="pmid">3159974</pub-id></mixed-citation>
</ref>
<ref id="B278">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wisniewski</surname><given-names>K. E.</given-names></name><name><surname>Kida</surname><given-names>E.</given-names></name></person-group> (<year>1994</year>). <article-title>Abnormal neurogenesis and synaptogenesis in Down syndrome</article-title>. <source/>Dev. Brain Dysfunction
<volume>7</volume>, <fpage>289</fpage>–<lpage>301</lpage>.</mixed-citation>
</ref>
<ref id="B281">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wisniewski</surname><given-names>K. E.</given-names></name><name><surname>Laure-Kamionowska</surname><given-names>M.</given-names></name><name><surname>Wisniewski</surname><given-names>H. M.</given-names></name></person-group> (<year>1984</year>). <article-title>Evidence of arrest of neurogenesis and synaptogensis in brains of patients with Down’s syndrome</article-title>. <source/>N. Engl. J. Med.
<volume>311</volume>, <fpage>1187</fpage>–<lpage>1188</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM198411013111819</pub-id><pub-id pub-id-type="pmid">6237262</pub-id></mixed-citation>
</ref>
<ref id="B279">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wisniewski</surname><given-names>K. E.</given-names></name><name><surname>Schmidt-Sidor</surname><given-names>B.</given-names></name></person-group> (<year>1989</year>). <article-title>Postnatal delay of myelin formation in brains from Down syndrome infants and children</article-title>. <source/>Clin. Neuropathol.
<volume>8</volume>, <fpage>55</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="pmid">2524302</pub-id></mixed-citation>
</ref>
<ref id="B282">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>W.</given-names></name><name><surname>Ramakrishna</surname><given-names>N.</given-names></name><name><surname>Wieraszko</surname><given-names>A.</given-names></name><name><surname>Hwang</surname><given-names>Y. W.</given-names></name></person-group> (<year>2008</year>). <article-title>Promotion of neuronal plasticity by (−)-epigallocatechin-3-gallate</article-title>. <source/>Neurochem. Res.
<volume>33</volume>, <fpage>776</fpage>–<lpage>783</lpage>. <pub-id pub-id-type="doi">10.1007/s11064-007-9494-7</pub-id><pub-id pub-id-type="pmid">17943438</pub-id></mixed-citation>
</ref>
<ref id="B283">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Jia</surname><given-names>Z.</given-names></name><name><surname>Clapcote</surname><given-names>S. J.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2010a</year>). <article-title>A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions</article-title>. <source/>Hum. Mol. Genet.
<volume>19</volume>, <fpage>2780</fpage>–<lpage>2791</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddQ199</pub-id><pub-id pub-id-type="pmid">20442137</pub-id></mixed-citation>
</ref>
<ref id="B284">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Belichenko</surname><given-names>P.</given-names></name><name><surname>Clapcote</surname><given-names>S. J.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Pao</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2010b</year>). <article-title>Effects of individual segmental trisomies of human chromosome 21 syntenic regions on hippocampal long-term potentiation and cognitive behaviors in mice</article-title>. <source/>Brain Res.
<volume>1366</volume>, <fpage>162</fpage>–<lpage>171</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2010.09.107</pub-id><pub-id pub-id-type="pmid">20932954</pub-id></mixed-citation>
</ref>
<ref id="B285">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zarrindast</surname><given-names>M. R.</given-names></name><name><surname>Bakhsha</surname><given-names>A.</given-names></name><name><surname>Rostami</surname><given-names>P.</given-names></name><name><surname>Shafaghi</surname><given-names>B.</given-names></name></person-group> (<year>2002</year>). <article-title>Effects of intrahippocampal injection of GABAergic drugs on memory retention of passive avoidance learning in rats</article-title>. <source/>J. Psychopharmacol.
<volume>16</volume>, <fpage>313</fpage>–<lpage>319</lpage>. <pub-id pub-id-type="doi">10.1177/026988110201600405</pub-id><pub-id pub-id-type="pmid">12503830</pub-id></mixed-citation>
</ref>
<ref id="B286">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S. Y.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Miao</surname><given-names>Q. L.</given-names></name><name><surname>Poo</surname><given-names>M. M.</given-names></name><name><surname>Zhang</surname><given-names>X. H.</given-names></name></person-group> (<year>2009</year>). <article-title>Endocannabinoid-dependent homeostatic regulation of inhibitory synapses by miniature excitatory synaptic activities</article-title>. <source/>J. Neurosci.
<volume>29</volume>, <fpage>13222</fpage>–<lpage>13231</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1710-09.2009</pub-id><pub-id pub-id-type="pmid">19846710</pub-id></mixed-citation>
</ref>
<ref id="B287">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>B.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Dai</surname><given-names>D.</given-names></name><name><surname>Xing</surname><given-names>J.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Fu</surname><given-names>Z.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>Differential dopaminergic regulation of inwardly rectifying potassium channel mediated subthreshold dynamics in striatal medium spiny neurons</article-title>. <source/>Neuropharmacology
<volume>107</volume>, <fpage>396</fpage>–<lpage>410</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2016.03.037</pub-id><pub-id pub-id-type="pmid">27018450</pub-id></mixed-citation>
</ref>
<ref id="B288">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheleznova</surname><given-names>N. N.</given-names></name><name><surname>Sedelnikova</surname><given-names>A.</given-names></name><name><surname>Weiss</surname><given-names>D. S.</given-names></name></person-group> (<year>2009</year>). <article-title>Function and modulation of δ-containing GABA<sub>A</sub> receptors</article-title>. <source/>Psychoneuroendocrinology
<volume>34</volume>, <fpage>S67</fpage>–<lpage>S73</lpage>. <pub-id pub-id-type="doi">10.1016/j.psyneuen.2009.08.010</pub-id><pub-id pub-id-type="pmid">19766404</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>